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Abstract 
Background. Pulmonary arterial hypertension (PAH), a rare condition of raised blood 
pressure in the lungs, is a debilitating disease with considerable morbidity and 
mortality. Clinical diagnosis is through an assessment of pulmonary artery pressures. 
The condition is treatable, but medications are expensive and not always practical, thus 
echocardiographic evidence of treatment response is used to rationalise ongoing 
therapy. However, outcome studies have now shown that invasive and 
echocardiographic pressures do not strongly associate with outcome.  
Aims. The thesis proposes that a variety of echocardiographic markers, including those 
of right ventricular (RV) systolic function, are more indicative of patients’ clinical 
status than currently used methods for assessing pressures, and six-minute walk 
(6MW) distance. Assessment of myocardial deformation (strain) is now accessible at 
the bedside using echocardiographic speckle tracking. I seek to determine how to use 
this measure throughout the treatment course, and how RV free wall strain relates to 
outcome in a clinical setting. The goal of this thesis is to determine where and how 
strain (especially RV strain) fits in the clinical decision process.  
Methods. A review of echocardiographic methods in regards to RV assessment with 
echocardiography was undertaken. Following ethics clearance, the majority of 
patient recruitment was from the Tasmanian Pulmonary Hypertension Registry 
(Hobart, Australia) Tasmanian Scleroderma Database (Hobart, Australia), and the 
Princess Alexandra Hospital (Brisbane, Australia). All echocardiographic 
measurements were performed in accordance with recommended echocardiographic 
guidelines. Statistical analysis was performed primarily with SPSS (version 21, IBM, 
Abstract v 
Chicago, IL) and MedCalc software version 16.8.4 (MedCalc Software bvba, Ostend, 
Belgium). 
Results. First, in PAH, baseline RV function (RVFWS) is a strong predictor of 
outcome, independent of PASP. Changes throughout therapy appear minimal, and 
the prognostic value of change appears limited. Second, Afterload changes should be 
taken into account in the evaluation of RVFWS during PAH follow-up, with the 
relationship to PASP likely to be linear. Third, RVFWS is more predictive than 
RVEDA and less variable than FAC in distinguishing acute from chronic RV 
pressure overload. RVFWS adds incremental and independent information to 
standard measures of RV function in assessing the acuity of PH. Fourth, RVFWS is 
strongly associated with exercise capacity in PAH and ise a useful adjunct to the 
assessment of treatment response. Fifth, RV dysfunction was associated with 
adverse outcome, independent of and incremental to clinical and LV deformation 
parameters in SSc. Subclinical LV dysfunction appears to have less prognostic 
relevance than RV dysfunction. Sixth, the detection of post-capillary PH appears to 
be better predicted with LV markers than recently recommended algorithms for 
detecting raised PCWP. Seventh, right atrial strain was significantly different 
between those with normal versus raised pressure, but it did not identify those with 
an incorrect echocardiographic assessment of RAP. Eighth, LV markers were 
associated with changes in PCWP after fluid loading. RV function showed a weak 
association with raises in PAPm. Myocardial deformation was not associated with a 
rise in filling pressure after fluid loading.  Ninth, microvascular disease appears to be 
related to be related to RV function in PAH. Macrovascular disease appears to relate 
to traditional heart disease factors such as LV mass. Endothelial function markers do 
not appear to be interchangeable in assessing patient outcome. 
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Conclusions: 
New echocardiographic markers of RV systolic function offer a significant increment 
of prognostic information in PAH. The measurement of RV free wall strain aids in 
clinical decision-making and integration daily clinical practice is needed.  We have 
found that in a group with a high rate of PAH, current guidelines do not offer strong 
guidance on the differentiation of LV and pulmonary vascular aetiologies for PH. 
Although RA speckle tracking is associated with RAP, it did not appear to add in the 
correction of pressure assessment. Speckle tracking imaging also shows potential in 
systemic CTD, exposing unique fibrosis patterns in the LV. Vascular function had 
associations with echocardiographic LV and RV parameters, but heterogeneity in this 
population hinder its use as a robust discriminative marker.  Speckle tracking 
echocardiography does not appear to detect elevations of invasive PCWP. This work 
shows that RV free wall strain is now ready for prime time and integration into the 
clinical decision-making process.  
  





This research was kindly supported by the National Heart Foundation of Australia, 
through their Health Professional Scholarship. I would also like to thank the 
American Society of Echocardiography, Cardiac Society of Australia and New 
Zealand and Professionals in Cardiac Science for awards, which have helped me to 
fund conference travel.  
This thesis has had the help of many different departments and organisations. 
Initially, the University of Queensland Centre for Cardiac Imaging, where I initially 
trained in echocardiography and research skills, and the Princess Alexandra 
Echocardiography Department for their assistance in learning clinical 
echocardiography.    
Staff, and other PhD students at the Menzies Institute for Medical Research for their 
assistance with starting my thesis. A very big thank you to Dr Kazuaki Negishi, for 
always offering his assistance when needed. Hilda Yang, for being my comrade 
sonography/PhD student throughout this experience. A big thank you to the Royal 
Hobart Hospital Department of Cardiology, specifically Dr Paul McIntyre and 
Janette Power, for always being supportive of mixing research and clinical work. My 
co-supervisor Dr Nathan Dwyer, for all of his experience and clinical knowledge of 
the pulmonary hypertension cohort, and help with formatting papers and this thesis.  
Finally, I would like to thank Baker Heart and Diabetes Institute for enabling me to 
complete my thesis while being based in Melbourne.  A massive thankyou to Lisa 
Riddell, who helped for many years with coordinating supervisor meetings, 
conference travel, and poster printing amongst many other things.   
Acknowledgments viii 
A big thank you to my primary supervisor Professor Tom Marwick, for encouraging 
me to enrol, and (patiently!) guiding me through the process.  
Finally, thank you to my friends and family for their encouragement and support 
throughout.  
Table of Contents ix 
Table of Contents 
Declaration of originality .............................................................................................. i 
Statement of ethical conduct ....................................................................................... iii 
Abstract ....................................................................................................................... iv 
Acknowledgments ...................................................................................................... vii 
Table of Contents ........................................................................................................ ix 
List of Tables............................................................................................................ xvii 
List of Figures ........................................................................................................... xix 
Abbreviations ........................................................................................................... xxii 
Publications and presentations relating to thesis ...................................................... xxv 
Statement of authorship.......................................................................................... xxvii 
Abstracts/ Presentations at national or international conferences ........................... xxxi 
Structure of the thesis ............................................................................................ xxxiii 
Aims .................................................................................................................... xxxviii 
1 Introduction .......................................................................................................... 2 
1.1.1 Basic physiology .................................................................................... 2 
1.1.2 Epidemiology ......................................................................................... 3 
1.2 Echocardiography to infer PAH diagnosis .................................................... 5 
1.3 Echocardiographic follow-up of PAH ........................................................... 6 
1.3.1 Haemodynamic assessment for diagnosis and follow-up ...................... 7 
1.3.1.2 Dynamic haemodynamic testing ............................................................ 9 
1.3.1.3 Imaging assessment of haemodynamics. ............................................... 9 
1.3.2 Quantification of RV performance ...................................................... 17 
1.4 Stroke Volume and Cardiac Output ............................................................ 17 
1.4.2 Markers of RV failure .......................................................................... 27 
1.4.3 Integration of RV markers with afterload status .................................. 28 
1.5 Conclusion ................................................................................................... 29 
2 Methodology ...................................................................................................... 32 
2.1 Echocardiographic equipment ..................................................................... 32 
2.2 Standard 2D echocardiography protocol ..................................................... 32 
2.2.2 Right Atrial Area .................................................................................. 33 
2.2.3 Right-sided Spectral Doppler ............................................................... 33 
2.2.4 Myocardial deformation imaging ......................................................... 34 
Table of contents x 
2.3 Vascular function ......................................................................................... 38 
2.3.1 Brachial Flow-mediated dilatation (Brachial FMD) ............................ 38 
2.3.2 Peripheral artery tonometry .................................................................. 38 
2.3.3 Laser Doppler flowmetry ..................................................................... 41 
2.4 Study patients .............................................................................................. 42 
2.5 Clinical data ................................................................................................. 43 
2.6 Right heart catheterisation. .......................................................................... 43 
3 Importance of Baseline and Longitudinal Evaluation in the Follow-up of 
Vasodilator Therapy in Pulmonary Arterial Hypertension ........................................ 45 
3.1 Preface ......................................................................................................... 45 
3.2 Abstract ........................................................................................................ 46 
3.3 Background .................................................................................................. 47 
3.4 Methods. ...................................................................................................... 48 
3.4.1 Patient selection. ................................................................................... 48 
3.4.2 Echocardiographic assessment. ............................................................ 48 
3.4.3 Functional testing. ................................................................................ 50 
3.4.4 Follow-up. ............................................................................................ 50 
3.4.5 Statistical analysis. ............................................................................... 50 
3.5 Results. ........................................................................................................ 51 
3.5.1 Patient characteristics. .......................................................................... 51 
3.5.2 Baseline predictors of outcome. ........................................................... 52 
3.5.3 Sequential measurement and outcome ................................................. 54 
3.6 Discussion .................................................................................................... 61 
3.6.1 RV function in PAH ............................................................................. 61 
3.6.2 Sequential assessment. ......................................................................... 63 
3.6.3 Limitations ........................................................................................... 64 
3.7 Conclusion ................................................................................................... 64 
3.8 Postscript ..................................................................................................... 65 
3.9 Appendix ..................................................................................................... 67 
4 The Afterload dependence of RV free wall strain in PAH ................................ 69 
4.1 Preface ......................................................................................................... 69 
4.2 Abstract ........................................................................................................ 70 
4.3 Background .................................................................................................. 71 
4.4 Methods ....................................................................................................... 72 
Table of contents  xi 
 
4.4.1 Patient selection. .................................................................................. 72 
4.4.2 Echocardiographic measurements. ....................................................... 75 
4.4.3 Right heart catheterisation.................................................................... 75 
4.4.4 Functional testing. ................................................................................ 76 
4.4.5 Statistical analysis. ............................................................................... 76 
4.5 Results ......................................................................................................... 77 
4.5.1 Patient characteristics. .......................................................................... 77 
4.5.2 Associations of baseline measurements ............................................... 77 
4.5.3 Baseline vs follow-up. .......................................................................... 77 
4.5.4 Invasive measurements. ....................................................................... 78 
4.5.5 Afterload dependence and RV function markers. ................................ 79 
4.5.6 Differences in echocardiographic measurements................................. 83 
4.5.7 Predictors of change in RV function. ................................................... 84 
4.5.8 Intra- and inter-observer variability. .................................................... 85 
4.6 Discussion ................................................................................................... 85 
4.6.1 Afterload and RV function measurement. ........................................... 85 
4.6.2 Clinical implications. ........................................................................... 89 
4.6.3 Study limitations. ................................................................................. 89 
4.7 Conclusions. ................................................................................................ 90 
4.8 Postscript ..................................................................................................... 91 
4.9 Appendix ..................................................................................................... 92 
5 Acute vs chronic afterload increases and the RV myocardium ......................... 94 
5.1 Preface ......................................................................................................... 94 
5.2 Abstract ....................................................................................................... 95 
5.3 Background ................................................................................................. 96 
5.4 .Methods ...................................................................................................... 97 
5.4.1 Study design. ........................................................................................ 97 
5.4.2 Standard echocardiography. ................................................................. 97 
5.4.3 Speckle tracking strain analysis. .......................................................... 98 
5.4.4 Statistics. .............................................................................................. 98 
5.5 Results ......................................................................................................... 98 
5.5.1 Patient characteristics ........................................................................... 98 
5.5.2 Echocardiography ................................................................................ 99 
Table of contents xii 
5.5.3 McConnell sign. ................................................................................. 101 
5.5.4 RV longitudinal function. ................................................................... 101 
5.5.5 The validity of RV function markers over a spectrum of measurements.
103 
5.5.6 Comparison of RVFWS with standard echo for prediction of acuity.106 
5.5.7 Combination of parameters. ............................................................... 107 
5.5.8 Reproducibility. .................................................................................. 109 
5.6 Discussion .................................................................................................. 109 
5.6.1 Acute vs chronic PAH. ....................................................................... 109 
5.6.2 RV assessment in PAH. ..................................................................... 111 
5.6.3 Limitations. ........................................................................................ 112 
5.7 Conclusions ............................................................................................... 112 
6 Determinants of change in functional capacity ................................................ 115 
6.1 Preface ....................................................................................................... 115 
6.2 Abstract ...................................................................................................... 117 
6.3 Methods ..................................................................................................... 120 
6.3.1 Patient selection. ................................................................................. 120 
6.3.2 Functional testing. .............................................................................. 122 
6.4 Results ....................................................................................................... 123 
6.4.1 Baseline .............................................................................................. 123 
6.4.2 Follow-up. .......................................................................................... 123 
6.4.3 Echocardiographic features independently associated with exercise 
capacity. ............................................................................................................ 124 
6.4.4 Incremental value of RV function in assessing exercise capacity. .... 127 
6.4.5 Features associated with a change in 6MW. ...................................... 128 
6.5 Discussion. ................................................................................................. 131 
6.6 Limitations. ................................................................................................ 133 
6.7 Conclusion. ................................................................................................ 134 
6.8 Postscript ................................................................................................... 135 
7 Left and right ventricular function in systemic sclerosis; Tools for advanced 
imaging and prediction of outcome .......................................................................... 142 
7.1 Preface; Myocardial imaging for differential diagnosis ............................ 142 
7.2 Abstract ...................................................................................................... 144 
7.3 Background ................................................................................................ 145 
Table of contents  xiii 
 
7.4 Methods ..................................................................................................... 145 
7.4.1 Study design. ...................................................................................... 145 
7.4.2 Clinical data. ...................................................................................... 146 
7.4.3 Echocardiography. ............................................................................. 146 
7.4.4 LV strain and tricuspid annular velocity. ........................................... 147 
7.4.5 Follow-up. .......................................................................................... 148 
7.4.6 Statistical analysis. ............................................................................. 148 
7.5 Results ....................................................................................................... 149 
7.5.1 Clinical characteristics. ...................................................................... 149 
7.5.2 Echocardiographic characteristic ....................................................... 151 
7.5.3 Events. ................................................................................................ 153 
7.5.4 Associations of outcomes. .................................................................. 154 
7.5.5 Incremental value and independence of RV and LV function for 
outcome. ........................................................................................................... 157 
7.5.6 Reproducibility. .................................................................................. 157 
7.6 Discussion ................................................................................................. 158 
7.6.1 Mechanism of LV dysfunction in SSc. .............................................. 158 
7.6.2 Prognostic value of LV dysfunction in SSc. ...................................... 159 
7.7 Study limitations. ....................................................................................... 159 
7.8 Conclusion. ................................................................................................ 160 
7.9 Appendix ................................................................................................... 161 
7.10 Postscript. ............................................................................................... 164 
8 PAH differential diagnosis; Echocardiography for the Differential diagnosis of 
pre versus postcapillary pulmonary arterial hypertension ....................................... 166 
8.1 Preface; Differential diagnosis of pre versus postcapillary pulmonary 
hypertension ......................................................................................................... 166 
8.2 Abstract ..................................................................................................... 168 
8.3 Background ............................................................................................... 169 
8.4 Methods ..................................................................................................... 170 
8.4.1 Patient selection. ................................................................................ 170 
8.4.2 Echocardiography. ............................................................................. 170 
8.4.3 Right heart catheterisation.................................................................. 171 
8.4.4 Statistical analysis. ............................................................................. 173 
8.5 Results ....................................................................................................... 174 
Table of contents  xiv 
 
8.5.1 Patient characteristics. ........................................................................ 174 
8.5.2 Association of raised PCWP .............................................................. 176 
8.5.3 Estimation of raised PCWP. ............................................................... 176 
8.6 Conclusion ................................................................................................. 182 
8.7 Postscript ................................................................................................... 182 
8.8 Appendix ................................................................................................... 183 
9 Right atrial pressure estimation with echocardiography .................................. 188 
9.1 Preface; Right atrial pressure estimation with echocardiography ............. 188 
9.2 Abstract ...................................................................................................... 190 
9.3 Background ................................................................................................ 191 
9.4 Methods. .................................................................................................... 192 
9.4.1 Patient selection. ................................................................................. 192 
9.4.2 Conventional echocardiography ......................................................... 192 
9.4.3 Strain. ................................................................................................. 193 
9.4.4 Right heart catheterisation. ................................................................. 194 
9.4.5 Statistics. ............................................................................................ 195 
9.5 Results ....................................................................................................... 195 
9.5.1 Patient characteristics (Table 9.1). ..................................................... 195 
9.5.2 Associations with invasively determined RAP. ................................. 196 
9.5.3 Comparison of echocardiographic and invasive RAP. ....................... 196 
9.5.4 Between reader variability. ................................................................ 200 
9.6 Discussion .................................................................................................. 202 
9.6.1 Echocardiographic assessment of RA pressure. ................................. 203 
9.6.2 Right atrial function within the cardiac cycle. ................................... 203 
9.6.3 Right atrial deformation ..................................................................... 204 
9.7 Limitations. ................................................................................................ 205 
9.8 Conclusion. ................................................................................................ 205 
9.9 Postscript ................................................................................................... 205 
10 RV and PASP response to provocative testing ................................................ 208 
10.1 Preface; Early detection of myocardial disease in systemic sclerosis. .. 208 
10.2 Abstract .................................................................................................. 209 
10.3 Background ............................................................................................ 210 
10.4 Methods. ................................................................................................. 211 
Table of contents xv 
10.4.1 Patient recruitment. ............................................................................ 211 
10.4.2 Fluid loading. ..................................................................................... 212 
10.4.3 Echocardiography. ............................................................................. 212 
10.4.4 Statistical analysis .............................................................................. 212 
10.5 Results. ................................................................................................... 213 
10.5.1 Baseline data ...................................................................................... 213 
10.5.2 Fluid loading response ....................................................................... 214 
10.5.3 Echocardiographic characteristics of fluid response group ............... 216 
10.5.4 Univariate associates of changes in pulmonary haemodynamics after 
fluid load. ......................................................................................................... 217 
10.5.4.1 Detection of Pulmonary Arterial hypertension based on DETECT 
guidelines 217 
10.5.5 ROC characteristics for pre versus post capillary pulmonary 
hypertension ..................................................................................................... 218 
10.6 Discussion. ............................................................................................. 220 
10.7 Conclusion ............................................................................................. 222 
10.8 Postscript ................................................................................................ 223 
11 Early detection – microvascular function and pulmonary vascular disease .... 225 
11.1 Preface ................................................................................................... 225 
11.2 Abstract .................................................................................................. 227 
11.3 Background ............................................................................................ 228 
11.4 Methods ................................................................................................. 228 
11.4.1 Study group. ....................................................................................... 228 
11.4.2 Total skin scores. ................................................................................ 229 
11.4.3 Brachial flow-mediated dilatation. ..................................................... 229 
11.4.4 Finger plethysmography..................................................................... 230 
11.4.5 Laser Doppler Flow-mediated dilatation: .......................................... 230 
11.5 Echocardiography. ................................................................................. 230 
11.5.1 Statistical analysis. ............................................................................. 231 
11.6 Results .................................................................................................... 231 
11.6.1 Associations of vascular function. ..................................................... 234 
11.6.2 Vascular function and echocardiographic findings. ........................... 237 
11.7 Discussion .............................................................................................. 238 
11.7.1 Vascular function measures. .............................................................. 238 
Table of contents xvi 
11.7.2 Echocardiography in systemic sclerosis. ............................................ 239 
11.7.3 Limitations. ........................................................................................ 240 
11.8 Postscript ................................................................................................ 241 
11.1 Appendix ................................................................................................ 242 
12 Conclusion ........................................................................................................ 243 
13 References ........................................................................................................ 251 
List of Tables xvii 
List of Tables 
Table 1-1. Invasive variables in the diagnosis of pulmonary hypertension and its 
subgroups ..................................................................................................................... 8 
Table 1-2 .  Changes of RV parameters in response to treatment of PAH ................ 19 
Table 1-3. Association of PAH therapy and Echocardiographic RV parameters ..... 21 
Table 3-1. Baseline echocardiographic and clinical parameters ............................... 51 
Table 4-1. Baseline characteristics (n=187) .............................................................. 78 
Table 4-2. Baseline associations of Doppler PASP and 6MWD .............................. 79 
Table 4-3. Baseline and follow-up* clinical and echocardiographic markers .......... 83 
Table 4-4. Association of invasive PASP with echocardiographic variables ........... 84 
Table 4-5.Independent associations of the response of RV function (RVFWS) to 
change in PASP (R2=0.09, p=0.007 ........................................................................... 85 
Table 4-6. Baseline and follow-up clinical and echocardiographic findings in 
patients on treatment .................................................................................................. 92 
Table 5-1. Clinical characteristics of PE patients, matched and unmatched PHT 
controls ..................................................................................................................... 100 
Table 5-2. . Clinical characteristics of positive versus negative McConnell sign ... 102 
Table 5-3. Associations of right ventricular longitudinal strain (standardised OR) 104 
Table 5-4.  Incremental and independent value of RV free wall strain for acute vs. 
chronic afterload....................................................................................................... 105 
Table 5-5. The diagnostic ability of RV measurements to predict acuity of 
pulmonary hypertension ........................................................................................... 107 
Table 5-6. The relationship between the diagnostic strength of different RV systolic 
function parameters and the magnitude of RV failure ............................................. 108 
Table 6-1. Baseline Characteristics ......................................................................... 123 
Table 6-2. Baseline and follow ................................................................................ 125 
Table 6-3  Regression analysis of 6MW distance ................................................... 126 
Table 6-4. Associations with delta 6MW distance .................................................. 129 
Table 6-5. 6MW responders versus non responders ............................................... 130 
Table 6-6.  Bivariate logistic regression for improved versus decline 6MW .......... 130 
Table 7-1. Baseline characteristics in patients with systemic sclerosis and controls
 .................................................................................................................................. 150 
Table 7-2. Echocardiographic characteristics in patients with systemic sclerosis and 
controls ..................................................................................................................... 152 
Table 7-3.  Univariable Cox regression analysis for the association of all-cause 
admission or death in patients with systemic sclerosis ............................................ 155 
Table 8-1. Baseline measurements. Groups are compared with PCWP  <15 and 
>15mmHg ................................................................................................................ 175 
Table 8-2. Echocardiographic parameters associated with elevated PCWP. In this 
logistic regression, the only significant associations were with E/e’ and LA volume
 .................................................................................................................................. 176 
Table 8-3. Echocardiographic features associated with each PCWP group ............ 177 
List of Tables  xviii 
 
Table 8-4 Appendix. Baseline measurements in all 190 patients, divided by groups 
with EF<50% and >50%. ......................................................................................... 183 
Table 8-5 Appendix. Pre versus postcapillary pulmonary hypertension ................ 184 
Table 9-1. Baseline demographics ........................................................................... 197 
Table 9-2. Factors associated with invasive right atrial pressure (n=125) .............. 198 
Table 9-3. Associations with right atrial strain parameters ..................................... 199 
Table 9-4. Echocardiographic as compared to invasive RAP groupings ................ 200 
Table 9-5. Non-Invasive RAP as compared to invasive RAP readings and 
differences in RA strain values ................................................................................ 201 
Table 10-1. Baseline clinical and echocardiographic values of fluid load PAH ..... 214 
Table 10-2. Invasive haemodynamic response to fluid loading .............................. 215 
Table 10-3. Echocardiographic comparison of  PCWP response to fluid loading .. 216 
Table 10-4 Echocardiographic associates of delta invasive haemodynamic pressures
 .................................................................................................................................. 219 
Table 11-1. Patient baseline demographics ............................................................. 232 
Table 11-2. Vascular and echocardiographic function ............................................ 233 
Table 11-3. Vascular function markers and SSC disease status .............................. 235 
Table 11-4. Vascular markers and RV function ...................................................... 236 
Table 11-5. Bivariate logistic regression and traditional cardiovascular disease risk 
factors ....................................................................................................................... 242 
List of Figures  xix 
 
 
List of Figures 
Figure 1-1. Echocardiographic evaluation for pulmonary hypertension follow-up .. 10 
Figure 1-2. Tricuspid regurgitant jet measurement and common problems with 
signal interpretation. ................................................................................................... 13 
Figure 1-3.  RV dysfunction with near-normal PASP. ............................................. 16 
Figure 1-4. Common RV systolic Function measures; Fractional Area Change (1.4a) 
and Tricuspid Annular Plane Systolic Excursion (1.4b) ............................................ 24 
Figure 1-5. Right ventricular free wall strain (Figure 1.5a); Measurement of 
isovolumetric acceleration (Figure 1.5b). .................................................................. 26 
Figure 2-1. Left ventricular global longitudinal (LV GLS) strain measurement of the 
apical long axis, apical 4 chamber and apical 2 chamber .......................................... 35 
Figure 2-2. Right ventricular free wall strain ............................................................ 36 
Figure 2-3. Measurement of right atrial strain. RA reservoir, RA contraction and RA 
conduit function ......................................................................................................... 37 
Figure 2-4. Measurement of left atrial strain............................................................. 37 
Figure 2-5 Brachial artery flow-mediated dilatation ................................................. 40 
Figure 2-6. Measurement of endothelial function with Peripheral artery tonometry 
with EndoPAT2000 showing normal versus abnormal response .............................. 41 
Figure2-7 Laser Doppler flowmetry. Figure2.7a-Abnormal Laser Doppler 
hyperaemia response. Figure 2.7b-Normal Laser Doppler hyperaemia response. .... 42 
Figure 3-1. ROC curves with echocardiographic markers and outcome. Quartiles of 
RVfree wall strain ...................................................................................................... 52 
Figure 3-2. ROC curves with echocardiographic markers and outcome. Quartiles of 
Pulmonary Artery Systolic Pressure .......................................................................... 53 
Figure 3-3. ROC curves with echocardiographic markers and outcome. Quartiles of 
Tricuspid Annular Plane Systolic Excursion. ............................................................ 54 
Figure 3-4. Incremental value of baseline RV function to the estimation of PASP for 
prediction of outcome. Nested Cox model analysis. .................................................. 58 
Figure 3-5. The longitudinal follow up of echocardiographic markers over the time 
course of the study ..................................................................................................... 59 
Figure 3-6. Differences over time in surviors versus non survivors for 
echocardiographic parameters .................................................................................... 60 
Figure 3-7. Comparison of the delta’s between time points for RVFWS, TAPSE and 
PASP. ......................................................................................................................... 61 
Figure 3-8. Median Cumulative survival .................................................................. 67 
Figure 4-1. Study flow chart, with patient exclusions. ............................................. 74 
Figure 5-1. Strain patterns of the segments and whole right ventricular free wall in 
PAH compared in PE. Strain is consistently impaired in the PE than the PAH 
patients. ...................................................................................................................... 99 
Figure5-2.Positive McConnell versus negative McConnell sign and regional strain 
patterns. .................................................................................................................... 101 
Figure 5-3. ROC curves for prediction of acute versus chronic increase in afterload
 .................................................................................................................................. 106 
List of Figures  xx 
 
Figure 5-4. Bland-Altman plots and between reader correlation for RVFWS, FAC 
and RVEDA ............................................................................................................. 110 
Figure 6-1. Sequential linear regression model for baseline visit.. ......................... 127 
Figure 6-2. Sequential linear regression model for follow-up in all patients. ......... 128 
Figure 6-3 Appendix. Variation in degree of change in 6MW distance at baseline 
and follow up ............................................................................................................ 137 
Figure 6-4 Appendix. Variation in degree of change in RV free wall Strain at 
baseline and follow up  ............................................................................................. 138 
Figure 6-5 Appendix. Variation in degree of change in Pulmonary artery systolic 
pressure at baseline and follow up ........................................................................... 139 
Figure 6-6 Appendix. The incremental predictive ability of RV function markers 
over clinical parameters before treatment (baseline) ............................................... 140 
Figure 7-1. Bull’s-eye diagram of a percent difference of left ventricular segmental 
strain (Longitudinal strain: 18 segments; Circumferential strain: 6 segments) between 
patients with SSC and controls ((strain in SSc/strain in control) x 100 (%)). Blue 
segments show a significant deterioration of strain ................................................. 151 
Figure 7-2. The relationships between global longitudinal strain (7.2a), global 
circumferential strain (7.2b), and systolic pulmonary artery pressure in patients with 
SSC. The dotted line shows 95% confidence interval ............................................. 154 
Figure 7-3. ROC curves for predicting all-cause admission or death (7.3a) and HF-
specific admission or death (7.3b) in patients with SSC. GCS indicates global 
circumferential strain; Ts’, tricuspid annular peak systolic velocity; 6MWD, 6-
minute walk distance; 95%CI, 95% confidence interval ......................................... 156 
Figure 7-4.  Incremental value of Ts’ over clinical parameters and GCS as a 
correlate of all-cause readmission or death in patients with SSC. GCS indicates 
global circumferential strain; Ts’, tricuspid annular peak systolic velocity ............ 157 
Figure 8-1. Diastolic dysfunction interpretation and comparisons with invasive 
pressure assessment .................................................................................................. 172 
Figure 8-2. Incorrect identification of normal PASP .............................................. 173 
Figure 8-3. Incorrect identification of normal PCWP, with elevated pulmonary 
pressures identified. .................................................................................................. 174 
Figure 8-4 Appendix. Study flow chart .................................................................. 185 
Figure 8-5 Appendix. Discrimination of raised PCWP (> or < 15 mmHg) by 
echocardiographic markers ...................................................................................... 185 
Figure 8-6. Boxplot with median and 95% ranges for normal, precapillary and 
postcapillary PH ePLAR ranges ............................................................................... 186 
Figure 8-7. Receiver-operating characteristic curves area under the curve using 
ePLAR to differentiate pre versus postcapillary PH ................................................ 186 
Figure 9-1. Echocardiographic assessment of right atrial pressure RAP ................ 193 
Figure 9-2. Echocardiographic measure of right atrial strain. Speckle tracking right 
atrial strain measurements ........................................................................................ 194 
Figure 9-3. Between reader Pearson’s correlation for right atrial strain components.
 .................................................................................................................................. 202 
Figure 9-4. Bland-Altman plot for right atrial strain ............................................... 202 
List of Figures xxi 
Figure 10-1. Patient flow chart ................................................................................ 212 
Figure 10-2.  Individual variation in response to fluid load for PAPm, PAPs, PADP 
and PCWP. ............................................................................................................... 215 
Figure 11-1. Associations with RV function parameters and microvascular function.
 .................................................................................................................................. 237 




3DE- three dimensional echocardiography 
6MW - Six minute walk 
AF – atrial fibrillation 
BSA – body surface area 
CAD – coronary artery disease 
CCBs - Calcium channel blockers 
CHD- Congenital heart disease 
CMR – cardiac magnetic resonance imaging 
CO – cardiac output 
CTD – connective tissue disease 
CTEPH – chronic thromboembolic pulmonary hypertension 
DICOM - digital imaging and communication in media 
EF – Ejection fraction 
Ea- arterial elastance  
MV E - mitral valve early peak velocity 
Mv A - mitral valve atrial contraction velocity 
MV e' - Peak mitral early contraction velocity 
Ees- end-systolic elastance 
ESP - end systolic pressure 
ESV- end systolic volume 
FAC – fractional area change 
HR – heart rate 
IVCT - isovolumetric contraction  
Abbreviations xxiii 
IVV - isovolumetric contraction velocity 
IVRT - isovolumetric relaxation time 
IVS - interventricular septum 
IVC – inferior vena cava 
JVP – jugular venous pressure 
LAV - left atrial volume 
LV – left ventricle 
PAPm-mean pulmonary artery pressure (invasively derived) 
mRAP- mean right atrial pressure (invasively derived) 
PAPs- pulmonary artery systolic pressure 
PAH – Pulmonary arterial hypertension 
PASP- pulmonary artery systolic pressure 
PCWP- pulmonary capillary wedge pressure 
PH – Pulmonary hypertension 
PV – pulmonary valve 
PVR – Pulmonary vascular resistance 
RA – right atrium 
RA ƐCT- RA contraction strain 
RA ƐR- RA reservoir strain 
RA ƐCD -RA conduit function 
RAP – right atrial pressure 
RHC – right heart catheterisation 
RHH - Royal Hobart Hospital  
RV – Right ventricular 
RV IVA- right ventricular isovolumetric acceleration  
Abbreviations  xxiv 
 
RVS'- Right ventricular peak systolic velocity  
RVEDA – right ventricular end diastolic area 
RVESA – right ventricular end systolic area 
RVFWS - RV free wall strain  
RVOT VTI- right ventricular outflow tract velocity time integral, equivalent to RV stroke volume 
sPAP- systolic pulmonary artery pressure (invasively derived) 
SSC- systemic sclerosis 
stroke volume - SV 
TPG – transpulmonary gradient 
TR – tricuspid regurgitation 
WU – Wood Units 
 
  
Publications relating to thesis xxv 
Publications and presentations relating to thesis 
Published/accepted/submitted papers to peer-reviewed journals 
Chapter Publication Status 
1. Introduction Wright LM, Dwyer N, 
Celermajer D, Kritharides 
L, Marwick TH. Follow-
Up of Pulmonary 
Hypertension With 
Echocardiography. JACC 
Cardiovasc Imaging. 2016 
Jun;9(6):733-46. 
Published 2016 
2. Methods N/A 
3. RV strain and prognosis Relative Importance of 
Baseline and Longitudinal 
Evaluation in the Follow-
up of Vasodilator Therapy 




4. Load-dependence of RV
strain
Wright L, Negishi K, 
Dwyer N, Wahi S, 
Marwick TH. Afterload 
Dependence of Right 
Ventricular Myocardial 
Strain.  J Am Soc Echo 
2017 Jul;30(7):676-684. 
Published 2017 
5. Acute and chronic PHT
and remodelling
Wright et al. Right 
Ventricular Systolic 
Function Responses to 
Acute and Chronic 
Pulmonary Hypertension: 
Assessment with 
Myocardial Deformation. J 
Am Soc Echocardiogr. 
2016 Mar;29(3):259-66.  
Published 2016 
6. RV strain and 6MW Association of Right 
Ventricular Strain with 
Exercise Capacity in 
Submission 
Journal of the 
American Society 
of 








7. Post-capillary PHT and
LV strain
Saito M. Mechanics and 
prognostic value of left 
and right ventricular 
dysfunction in patients 




8. Post-capillary PHT and
LV diastology
Echocardiographic 
Evaluation of Dyspnoea in 
the Context of Diastolic 
Evaluation Guidelines: 
Implications for 








9. PA pressure and RA
strain
Association with Right 
Atrial Strain with Right 
Atrial Pressure: An 
Invasive Validation Study 
Under review 





10. RV strain vs fluid
response in preclinical
disease
11. Vascular markers and
preclinical disease
12. Conclusion
Statement of Authorship xxvii 
Statement of authorship 
This thesis includes several papers, in which Leah Wright (LW) is not the sole 
author. LW took the lead in this research. She designed the studies, collecting the 
data, measuring echo parameters, performed analyses, interpreted the findings and 
prepared the manuscripts, with contributions from the co-authors.  
The contributions of each of the authors are detailed as follows. 
Chapter 1 
Wright LM, Dwyer N, Celermajer D, Kritharides L, Marwick TH. Follow-Up of 
Pulmonary Hypertension with Echocardiography. JACC Cardiovasc Imaging. 2016 
Jun;9(6):733-46. 
 LW contributed to narrative review concept design, performing analyses, composed
the drafts of manuscript and revisions of the manuscript.
 ND contributed to concept input and revised the manuscript
 JP contributed to concept input and revised the manuscript
 LK contributed to concept input and revised the manuscript
 DC contributed to concept input and revised the manuscript
 THM contributed to the design of the review, critical revision and final approval.
Chapter 3. 
Wright LM, Dwyer N, Wahi S,, Marwick TH. Importance of Baseline and 
Longitudinal Evaluation in the Follow-up of Vasodilator Therapy in Pulmonary 
Arterial Hypertension. 
 LW contributed to narrative review concept design, performing analyses, composed
the drafts of manuscript and revisions of the manuscript.
 ND contributed to data acquisition and revised the manuscript
 SW contributed to data acquisition and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval.
Chapter 4: 
Leah Wright, Kazuaki Negishi, Nathan Dwyer, Sudhir Wahi; Thomas H Marwick. 
Afterload-Dependence of Right Ventricular Myocardial Strain. J Am Soc Echo 2017 
(30(7)676-684 e1) 
Statement of Authorship Statement of Authorship xxviii 
The contributions of each author are as following: 
 LW contributed to study design, data extraction, performing analyses, interpreting
findings, composed the drafts of manuscript and revisions of the manuscript.
 KN contributed to , interpretation of finding and revised the manuscript
 ND contributed to data extraction, provided statistical expertise analysis and revised
the manuscript
 SW contributed to data acquisition and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval.
Chapter 5 
Wright L, Dwyer N, Power J, Kritharides L, Celermajer D, Marwick TH. “Right 
Ventricular Systolic Function Responses to Acute and Chronic Pulmonary 
Hypertension: Assessment with Myocardial Deformation”. J Am Soc 
Echocardiogr. 2016 Mar;29(3):259-66. doi: 10.1016/j.echo.2015.11.010. 
The contributions of each author are as following: 
 LW contributed to study design, data extraction, performing analyses, interpreting
findings, composed the drafts of manuscript and revisions of the manuscript.
 ND contributed to data acquisition and revised the manuscript
 JP contributed to data acquisition and revised the manuscript
 LK contributed to , interpretation of finding and revised the manuscript
 DC contributed to  interpretation of finding and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critically revision
and final approval.
Chapter 6 
Wright LM, Dwyer N, Wahi S, Marwick TH. Importance of Baseline and 
Longitudinal Evaluation in the Follow-up of Vasodilator Therapy in Pulmonary 
Arterial Hypertension. Association of Right Ventricular Strain with Exercise 
Capacity in Pulmonary Arterial Hypertension 
 LW contributed to narrative review concept design, performing analyses, composed
the drafts of manuscript and revisions of the manuscript.
 ND contributed to data acquisition and revised the manuscript
Statement of Authorship Statement of Authorship xxix 
 SW contributed to data acquisition and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval.
Chapter 7 
Makoto Saito*, Leah Wright *, Kazuaki Negishi MD, PhD1, Nathan Dwyer, Thomas 
H Marwick. Mechanics and Prognostic Value of Left and Right Ventricular 
Dysfunction in Patients with Systemic Sclerosis*Joint first authors. Journal of the 
American College of Cardiology; Imaging; Aug; 2017 
The contributions of each author are as following: 
 LW contributed to study design, data extraction, performing analyses, interpreting
findings, composed the drafts of manuscript and revisions of the manuscript.
 MS contributed to study design, data extraction, performing analyses, interpreting
findings, composed the drafts of manuscript and revisions of the manuscript.
 KN contributed to , interpretation of finding and revised the manuscript
 ND contributed to data acquisition, interpretation of finding and revised the
manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval
Chapter 8 
Wright LM, Dwyer N, Wahi S, Marwick TH.PAH differential diagnosis; 
Echocardiography for the Differential diagnosis of pre versus post capillary 
pulmonary arterial hypertension 
 LW contributed to narrative review concept design, performing analyses, composed
the drafts of manuscript and revisions of the manuscript.
 ND contributed to data acquisition and revised the manuscript
 SW contributed to data acquisition and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval.
Statement of Authorship Statement of Authorship xxx 
Chapter 9 
Wright LM, Dwyer N, Wahi S, Marwick TH . Right atrial pressure estimation with 
echocardiography 
 LW contributed to narrative review concept design, performing analyses, composed
the drafts of manuscript and revisions of the manuscript.
 ND contributed to data acquisition and revised the manuscript
 SW contributed to data acquisition and revised the manuscript
 THM contributed to the design of the study, interpreting findings, critical revision and
final approval.
Abstracts/Presentations relating to thesis xxxi 
Abstracts/ Presentations at national or international 
conferences  
Cardiac Society of Australia and New Zealand 2017 
- Oral presentation “Pulmonary Arterial Hypertension and outcome; How does
baseline RV function compare to sequential follow up for predicting
outcome?”
American Society of Echocardiography 2017 
- Oral presentation “Progression of Pulmonary Artery Pressure and RV
Function as Predictors of Outcome in Pulmonary Arterial Hypertension”
American College of Cardiology 2016 
- Determinants of Overt and Masked Pulmonary Hypertension in Scleroderma
- Distinction of Pre- versus Post-capillary Pulmonary Arterial hypertension
- Importance of Right Atrial Conduit Function to Right Atrial Pressure
Estimation with Echocardiography: A Role for Atrial Strain Assessment
American Heart Association 2016 
- Are All Diastolic Parameters Equal?
American Society of Echocardiography 2016 
- Brachial Flow-Mediated Dilatation is Associated with Pulmonary Artery
Pressure in Scleroderma
- Endothelial Function as a Potential Marker for Pulmonary Hypertension in
Scleroderma
- Use of Isovolumetric Acceleration as an Afterload-Independent Marker of RV
Dysfunction in Scleroderma
Cardiac Society of Australia and New Zealand 2016 
Is Provocative Testing Necessary for Diagnosis of Heart Failure with 
Preserved Ejection Fraction? A Comparison with Non-invasive 
Haemodynamics and Myocardial Mechanics 
Cardiac Society of Australia and New Zealand 2015 
- Baseline RV Function is a stronger predictor of Response to Vasodilators in
Pulmonary Hypertension than Six-Minute Walk
European Society of Cardiology 2015 
Abstracts/Presentations relating to thesis xxxii 
- Independent Association of Right Ventricular Strain with Functional Strain
with Functional Capacity in Pulmonary Arterial Hypertension
American Society of Echocardiography 2014 
- Right Ventricular Free Wall Strain can Discriminate Acute Pressure Overload
from Chronic Conditions
European Society of Cardiology 2014 (moderated Poster) 
- Right Ventricular Free Wall Strain can Discriminate Acute Pressure Overload
from Chronic Conditions
World Congress of Cardiology 2014 
- Nonlinear Afterload Dependence of RV Strain: A Follow-up Study During
Vasodilator Therapy
American Heart Association 2013 
- Nonlinear Afterload-dependence of RV strain: A Follow-up Study During
Pulmonary Vasodilator Therapy
Structure of thesis xxxiii 
Structure of the thesis 
Chapter 1 reviews the use of echocardiography in the clinical follow-up of pulmonary 
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relating to RV parameters and outcome. Considerations in the clinical use of different 
haemodynamic and RV size and systolic function measurements are assessed. This 
section introduces the concept that using RV free wall strain for follow-up in 
pulmonary arterial hypertension is clinically appropriate, and offers substantial benefit 
over non-invasive haemodynamic assessment, as well as traditional measures of right 
ventricular systolic function.  
Chapter 2 provides a review of the methods. A comprehensive explanation is given 
of standard 2D echocardiographic performance of right heart size, systolic function 
and haemodynamic assessment. Left ventricular systolic and diastolic assessment 
measurement are summarised. A review of speckle tracking imaging of left and right 
ventricles and right and left atria follow. Statistical techniques are detailed, with 
specific details on techniques used in each chapter.  
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catherisation lab database. The Queensland cohort was identified from the Pulmonary 
Hypertension database required for PBS supplied therapy.  
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The central tenet of this thesis is that decision-making in pulmonary hypertension 
requires more than an assessment of pulmonary pressure. Chapter 3 documents the 
association of baseline RV free wall strain with mortality in PAH, but also shows the 
limitations of attempting to follow changes in echocardiographic parameters in follow-
up. Finding this limitation is an essential observation because some studies measuring 
outcome in PAH have come under criticism for using poorly defined endpoints. There 
can be significant learning effects with functional tests, with often overlooked complex 
interactions that lead to reductions in exercise capacity. 
Myocardial strain is afterload-dependent. Establishment of the relationship between 
RV afterload and systolic function is required to integrate RV strain into clinical 
practice. Chapter 4 addresses this concern in a clinical cohort and demonstrates how 
best to adjust for the relationship through follow-up.  
The chronicity of afterload increase (e.g. chronically elevated afterload in pulmonary 
arterial hypertension, as opposed to the acute elevation as seen in pulmonary 
embolism) may influence the RV response to loading. Chapter 5 demonstrates the 
value of RV free wall strain in differentiating in these two conditions.  
Exercise capacity – measured as 6MW distance – has been a cornerstone of assessing 
pulmonary vasodilator responses. Recent work has cast doubt on the value of 6-minute 
walk (6MW) distance as an outcome marker to determine treatment efficacy. The use 
of haemodynamics as a surrogate for functional status simplifies the determinants of 
exercise capacity in PAH patients. Cardiopulmonary exercise testing shows an only 
moderate correlation between exercise capacity and invasive haemodynamics. 
Chapter 6 examines the associations of RV free wall strain and 6MW distance.  
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Pulmonary hypertension may have several potential aetiologies – an important 
distinction being pre- and post-capillary pulmonary hypertension, because patients 
with post-capillary pulmonary hypertension do not respond to pulmonary arterial 
vasodilators. Patients with connective tissue disease may have left- or right-sided 
pathophysiology. Chapter 7 explores the use of not only RV but also LV strain in 
patients with systemic sclerosis and shows that an abnormal LV myocardial signal 
provides a source of information regarding post-capillary disease, that is separate from 
the usual haemodynamic measures. Moreover, chapter 8 emphasises the limitations 
of the current guidelines for the diagnosis of diastolic dysfunction, especially as it 
pertains to the distinction of post-capillary pulmonary hypertension. This chapter 
involves a cohort in which pulmonary hypertension groups are distinguished with right 
heart catheterisation. 
Part of the problem with echocardiographic measurement of pulmonary artery systolic 
pressure (PASP) is that it is obtained by combining RV and estimated right atrial (RA) 
pressure. Inferior vena cava (IVC) size is traditionally used to calculate right atrial 
pressure. The IVC method has inaccuracies which can compromise the accuracy of 
estimation of pulmonary a (PA) pressure. Chapter 9 explores whether RA strain can 
improve the accuracy of echocardiographic assessment of RA pressure. Unfortunately, 
this chapter shows that this novel tool is unable to adjust for errors in the 
echocardiographic assessment of right atrial pressure (RAP).  
Having shown that RV assessment provides incremental prognostic information and 
is robust to small changes in afterload, we next sought whether this could be used for 
the identification of early disease. Chapter 10 evaluates the response to 
echocardiographic predictors of response to fluid loading during right heart 
catheterisation in an at-risk population, with particular attention to the information 
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provided by measurement of left ventricular strain. The results suggest that while RV 
strain is a marker of clinical disease, provocative testing identifies abnormal responses 
in patients with preserved RV strain.  
Apart from fluid loading, tests of the peripheral vasculature might be another means 
of detection of early disease in pulmonary arterial hypertension, in some disease 
entities that involve both the pulmonary and systemic vasculature. It is possible that 
the small vessel disease in the lungs associated with small vessel disease elsewhere – 
in which case the measurement of this parameter may help with diagnosis and 
following response to therapy. Chapter 11 establishes the correlates of novel vascular 
markers in patients with and without established PAH.  
The thesis shows the limitations of PASP measurements, the robustness of RV strain 
(especially relative to afterload) and the association of RV strain with functional 
capacity, and emphasises the utility of considering not only RV but also LV strain 
responses.  
Figure xxxix.1. Flowchart of cohorts involved in thesis chapters.   
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The majority of studies focused on the Pulmonary Hypertension cohort of Tasmania 
(PAH Tas), Tasmanian scleroderma database (TAS SSC), the Royal Hobart Hospital 
Echocardiographic database and the Royal Hobart Hospital catherisation lab 









The aims of this thesis are: 
 To define the optimal method for follow-up in pulmonary hypertension. We 
propose that the use of right ventricular strain will add substantially to 
traditional right ventricular function markers.  
 Examine whether right atrial strain measurements can be used to improve the 
diagnostic accuracy of RAP estimation using the IVC method for estimation of 
pressure 
 Determine how RV free wall strain can be used to track systolic function over 
a range of afterload conditions 
 Examine how global and regional systolic strain can be used to differentiate 
acute versus chronic increases in afterload 
 Determine the frequency and prognostic relevance of RV dysfunction at 
baseline in PAH 
 Determine the frequency of change in RV parameters in follow-up and their 
prognostic relevance 
 Discover whether RV myocardial deformation is incrementally predictive of 
functional capacity above haemodynamic measures 
 Determine the predictive ability of left ventricular versus right ventricular 
myocardial deformation in a connective tissue disease cohort  
 Determine the effectiveness of current guidelines for prediction of Pre versus 
post-capillary pulmonary arterial hypertension within a substantial connective 
tissue disease cohort.   
 Determine whether microvascular function testing results  in SSC is a surrogate 
for disease endpoints in pulmonary hypertension 
The goal of this thesis is to determine the role of right ventricular strain in the clinical 
management of pulmonary hypertension 
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1 Introduction 
1.1.1 Basic physiology 
The heart is designed to be a conduit and a pump, with the right heart acting as an intermediary 
between the venous system and lungs. For this purpose, the right ventricle (RV) is designed to 
act as a conduit for venous blood, and pump against the low resistance within the pulmonary 
arteries, where blood is oxygenated and then delivered to the left heart. Pulmonary hypertension 
(PH) an increase in pressure within the pulmonary arteries, which opposes the RV’s inherent 
design of a low resistance pump. This rise in pressure can come from diverse pathologic origins, 
described in the WHO classification system, in which there are five groups of PH. Post-capillary 
PH (Group 2) is due to left heart changes, with a transfer of hydrostatic pressure causing an 
elevation in the pulmonary arteries. The characteristics of PAH (Group 1) are intimal 
proliferation, smooth muscle hypertrophy, in-situ thrombosis and the development of plexiform 
lesions in the small pulmonary arterioles. Generally regarded as idiopathic, there are conditions 
associated with an increased risk of developing PAH, such as the connective tissue disease 
(CTD) related more commonly with systemic sclerosis (SSC), as well as human 
immunodeficiency virus (HIV) related, congenital heart disease (CHD) related, and heritable 
forms.  Until a decade ago, limited treatment options existed, with median life expectancy being 
2.8 years from diagnosis 1, but current registry data show increases to 7 years 2. There have 
been three primary pathways identified for treatment, endothelin receptor antagonism, 
prostacyclin augmentation and nitric oxide augmentation. The diagnosis and follow-up of 
pulmonary arterial hypertension (PAH) involves the use of echocardiography, right heart 
catheterisation (RHC) and patient functional status with 6-minute walk testing (6MW).  
Invasively, the response of the RV to changes in pressure are documented by RV pressure-
volume loop studies. The RV responds with high compliance (as compared to the left ventricle 
Chapter 1 Introduction   3 
 
(LV)). To accommodate load changes, the RV dilates to increase stroke volume, in agreeance 
with the Frank-Starling. Larger volumes are required to stimulate this than the LV. This curve 
underpins the RV response to loading.  
A clinical classification3 has been established, with groupings based on pathological and 
hemodynamic characteristics. 5 groups with the term “pulmonary hypertension” are defined; 
Group 1 PAH, Group 2, PH due to left heart disease, Group 3, PH due to chronic lung disease 
and/or hypoxia, Group 4, PH due to chronic thromboembolic pulmonary hypertension 
(CTEPH), and Group 5, PH due to unclear or multifactorial mechanisms 
This thesis will mainly focus on two groups, Group 1 PAH and Group 2 PH. Group 2 PH 
consists of patients with left heart disease-related pathogenesis. Classically PH is associated 
with advanced heart failure (both heart failure with reduced and preserved systolic function), 
and mitral valve disease. Downstream pulmonary venous congestion leads to increases in 
pulmonary pressures and progression to right heart disease. The association between 
development of  PH and mortality in the left heart failure cohort 4 is an established concept.  
1.1.2 Epidemiology 
Within Group 1 PAH, the epidemiologic data presented by different registries vary slightly. 
The French registry describes the populations as 40% idiopathic PAH, CTD associated ~ 15%, 
and ~11% with CHD related PH. Another potent clinical influence on survival is the 
concomitant of interstitial lung disease. Although the cost-effectiveness of screening CTD 
patients routinely has been argued, treating patients in WHO class 2 with PAH-specific 
therapies has been shown to be beneficial in this cohort, with patients deriving symptomatic 
benefit5. An argument for early screening is made for those at risk of PAH, for example, CTD 
patients or people with a family history of PAH. 
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The insidious onset of PAH (non-specific feelings of breathlessness, fatigue or exercise 
impairment) means patients are diagnosed in late stages. Tracking disease development in PAH 
is more difficult than in LV disease progression, as patients often already present in overt right 
heart failure. Another cohort which is of interest concerns those with SSC. SSC is a disease 
manifested by fibrosis and thickening of the skin, which is associated with endothelial 
dysfunction and organ disease. There is an increased risk of developing PAH within this cohort 
(~ 15% prevalence). In contrast to CHD-associated, SSC-associated PAH has higher mortality 
rates. Guidelines recommend routine echocardiographic screening the SSC cohort, but current 
methods of early diagnosis do not appear to be sufficient. The tricuspid regurgitant (TR) jet, 
required for the echocardiographic estimation of PASP, is unmeasurable in  ~20-40%6,7 of 
people, and these pressured are only elevated when ~ 65-708% of the pulmonary capillary bed 
has been affected.  
The heterogeneity of the CTD group makes heart disease progression difficult to follow, in 
particular, the rates of development of LV associated disease. Ventricular-vascular uncoupling 
can lead to the development of LV associated PH. Pre-capillary PH is differentiated through 
invasive assessment of wedge pressure (PCWP). The classical definition of LV dysfunction (an 
ejection fraction (EF) of <55%) is present in <6% of SSc patients9. The prior classification does 
not include heart failure with preserved EF, which is a consequence of chronic LV dysfunction 
and has been reported to be as high as 50%. Importantly, treatment of Group 2 PH with PAH-
specific drugs has not been clinically proven and may lead to clinical worsening.  
Limitations of the current approach 
Currently, the Pharmaceutical Benefits Scheme in Australia is undergoing a review with regards 
to inconsistencies with current international treatment guidelines, these being: 
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- Requiring failure to respond to six or more weeks of appropriate vasodilator treatment 
for WHO class III patients with mean right atrial pressure (mRAP) 8 mmHg or less 
- Failing to allow treatment of functional class II patients 
- Failing to allow combination therapy   
To define if the “failure to respond” criteria have been met, this can include a RHC, 
echocardiography and 6MW test. Two of these criteria must be evaluated every six months to 
qualify for continuation or change in therapy. The echo composite assessment is defined as “an 
ECHO result demonstrating stability of improvement of disease, as assessed by a physician”, 
which is not well defined. The 6MW test must also demonstrate “disease stability” defined by 
less than a 20% decline from baseline values. Although pharmaceutical intervention has shown 
mortality reduction with for a variety of drugs, common endpoints, are used as surrogates 
including, RHC haemodynamics, echocardiographic parameters and 6MW tests. 1 2 
1.2 Echocardiography to infer PAH diagnosis 
The ESC taskforce has determined criteria that should raise suspicion of the presence of PH. 
Initial screening involves Doppler echocardiography 10, followed by the presence of secondary 
echocardiographic PAH signs (e.g. D-Shaped flattening of the interventricular septum). An 
estimation of right atrial pressure (RAP) is not included in the criteria, due to inaccuracies in 
this estimation. Related echocardiographic signs can be broken down into three criteria; the 
ventricles, pulmonary artery, and the inferior vena cava (IVC). The ventricle component 
includes a ratio of the RV to LV base of >1.0 and LV eccentricity index of >1.1. The pulmonary 
artery right ventricular outflow Doppler acceleration time <105 m/sec, and presence of mid-
systolic notching is also supportive, as is an early diastolic pulmonary regurgitation velocity of 
>2.2 m/sec. Although RAP is not included, this is a secondary marker, with a RAP estimate of 
> 15 mmHg or a right atrial area >18 cm2 suggestive of PH.  The probability of PH is low if TR 
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max velocity is ≤2.8 or not measurable, with no other echocardiographic signs of PH. 
Echocardiographic techniques will be discussed further on in this chapter.  
1.3 Echocardiographic follow-up of PAH 
In patients with PAH treated with pulmonary vasodilators, continuation of therapy is 
conditional on the demonstration of treatment effect. Early clinical trials used PASP in the 
assessment of pulmonary vasodilator treatment response; these trials were limited by small 
sample size, with often limited follow-up 11. The assumption that pressure changes reflect 
mortality is disputed by clinical trials and systematic reviews, it is recognised that PASP 
responses to PAH-specific drugs are heterogeneous, with differences related to sex, race and 
disease patterns 12. Mortality rates in PAH trials have improved, with an average five-year 
survival of 61%, increasing to 75% in those aged under 50 years 13. Hence, the endpoints of 
PAH trials are under review; invasive haemodynamics are recommended as secondary, not 
primary endpoints14.  
As the risk and cost of performing RHC make this test unsuitable for six monthly follow-up, 
Doppler is used to document changes in cardiac function, and 6MW distance is used to assess 
functional performance.  Recommendations are based on level C evidence, supported by expert 
opinion and small retrospective studies and registries 15. Moreover, there are considerable 
differences between echocardiographic and invasive measurements 15. Clinical trials have 
established clinical correlates of mortality in PAH patients. These range from subjective 
measures such as baseline WHO functional class, 6MW distance, echocardiographic measures, 
to invasive measures of mixed venous O2 saturation. The National Institutes of Health registry 
shows that changes in the cardiac index, mRAP and mean pulmonary artery pressure (mPAP) 
have a substantial influence on survival. However, RV impairment has significant prognostic 
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implications, and the presence of RV myocardial disease cannot be distinguished from RV 
impairment due to pressure overload unless RV afterload can be estimated.  
1.3.1 Haemodynamic assessment for diagnosis and follow-up 
1.3.1.1 Resting haemodynamics  
The use of RHC to document a PAPm >25mmHg is required for PAH diagnosis (Table 1.1), 
although this is also supported by only level C evidence 15.  
Complete haemodynamic assessment includes measurements of the RA, right ventricular (RV) 
and pulmonary capillary wedge pressure (PCWP), cardiac output (CO) (Fick or thermodilution) 
and mixed venous oxygen saturation. The normal pulmonary circulation is characterised by low 
pulmonary vascular resistance (PVR), with compliant vessels. Calculation of PVR (in dynes or 
Wood units) is the ratio of diastolic pulmonary gradient or transpulmonary gradient (TPG) and 
CO, and this is especially important for the diagnosis of left heart-derived PH.   
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Some clinical trials have shown that PASP is unrelated to clinical endpoints 16. Medications 
available for PAH therapy show differing results in regards to changes in haemodynamic 
parameters; 
Calcium channel blockers (CCBs) - Acute pulmonary vasodilator testing can detect responders to 
CCB treatment. A >10 mmHg reduction of PAPm defines responders to <40 mmHg in the setting of 
unchanged or increased CO. However, as only about 5% of patients with idiopathic PAH are CCB-
responders, and as very few patients related to CTD respond 17, the value of this step is limited. 
Prostanoids- Invasive assessment has shown improvement of RV stroke work index (the 
product of mean PAP-mean RAP with CI/HR in g.m/m2/beat) and invasively-measured 
pulmonary capacitance in response to intravenous or inhaled prostanoids 18. PASP reductions 
at follow-up are documented as secondary outcomes in trials.  
Pulmonary hypertension 
type 
Measurement Clinical Group 
Pulmonary hypertension Mean PAP >25 mmHg All 
Pre Capillary  Mean PAP >25 mmHg 
PCWP <15 mmHg 
CO normal or reduced 
 Pulmonary arterial 
hypertension 
 PH due to lung disease 
 CTEPH 
 PH with unclear and 
multifactorial origins.  
Post Capillary  Mean PAP> 25 mmHg 
PCWP>15 mmHg 
Passive TPG < 12 mmHg 
Reactive TPG >12 mmHg 
PH due to left heart 
disease 
PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; CO, cardiac output; PH, pulmonary 
hypertension, CTEPH, chronic thromboembolic pulmonary hypertension; TPG, trans pulmonary gradient 
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Endothelin receptor antagonists- Most studies with endothelin antagonists have used 6MW 
as the primary outcome. Assessment of RHC derived haemodynamics in clinical trials 5,19-21 
show reductions of mRAP and PVR 5,19-22. 
Phosphodiesterase type 5-inhibitors- One of two studies comparing sildenafil versus placebo 
used Doppler echocardiography 23, showing an improvement in CO but not PASP 23. However, 
in another study of mixed PAH and Eisenmenger’s Syndrome, there was a significant fall in 
PASP 24.  
1.3.1.2 Dynamic haemodynamic testing.  
In healthy subjects, pulmonary artery vasodilation permits the increased stroke volume 
associated with exercise, without an increment in PASP.  An increase in stroke volume can 
unmask masked PH (reduced CO). However, stress protocols used to achieve this vary between 
centres, with modalities including supine and arm cycle ergometry, and arm and leg press, as 
well as dobutamine. Moreover, normal ranges are variable, especially in athletes and normal 
elderly subjects, a rise in PAPm >30 mmHg is not necessarily pathological 25. Consequently, 
exercise responses are not part of current guidelines 15.  Incorporating multiple components of 
the PVR equation (PAPm, LAP and flow) in the haemodynamic assessment of exercise 
response would improve this. A fluid challenge of ~500 ml saline is thought to be safe for the 
diagnosis of masked PAH. Pulmonary venous hypertension is distinguished on the stability of 
wedge pressure following infusion, with an increment of >15 mmHg suggesting pulmonary 
venous hypertension. However, fluid loading and dynamic testing are not validated for clinical 
use. 
1.3.1.3 Imaging assessment of haemodynamics.  
The echocardiographic evaluation of haemodynamics in PAH should not be limited to PASP, 
although PASP and PVR are central to the evaluation of RV dysfunction (Figure 1.1) 13. Critical 
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components in the accurate quantification of preload and afterload should include mRAP, 
PAPm, PA diastolic pressure, LV filling pressure, RV stroke volume (RVOT VTI) and PVR.  
Figure 1-1. Echocardiographic evaluation for pulmonary hypertension follow-up 
 
1.3.1.4 Pulmonary artery systolic pressure.  
The measurement of pulmonary artery systolic pressure (PASP) from the addition of 
estimated RA pressure to RV systolic pressure derived from application of the Bernoulli 
equation to the TR maximum velocity (with or without contrast enhancement) has been a 
cornerstone of non-invasive Doppler assessment since the 1980’s 26,27.  
 This tricuspid gradient method of PASP estimation has been validated by numerous studies 
28,29, but not all validations have been favourable 30, and accuracy appears to vary depending 
on centre and population. PASP may be over- and under-estimated by Doppler 31, with 
Doppler being >10 mmHg different than RHC in 48% of cases, potentially leading to 
inaccurate diagnosis.  While Doppler assessment of PASP may be accurate for population-
based studies, individual patient diagnosis may be problematic 32.  
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Figure 1.2 summarises main causes of inaccuracies. An incomplete TR signal from mild TR 
(Figure 1.2a) or Doppler angle errors are likely the most common sources of underestimation 
of PASP. Severe TR may lead to rapid equalisation of RV and RA pressures, with 
underestimation of PASP (Figure 1.2c). Another factor, which is especially relevant in PH, is 
the impact of reduced stroke volume due to RV dysfunction. Studies of bosentan have shown a 
reduction of invasive measures of PVR and PASP over a wide range of PAH severity 5,22, but 
this does not seem to be consistent across all studies 33. Moreover, PASP values plateau after 
initial changes. Follow-up of PASP responses to therapy requires contextualisation with 
changes of stroke volume (or as PVR, Figure 1.3). 
To optimise imaging of the tricuspid regurgitation jet, sonographers should image from multiple 
windows, have sweep speed optimised for HR, and avoid measurement on beats which are post 
ectopic (atrial fibrillation (AF) beats should be averaged). Spectral Doppler gain signals should 
also be optimised, decreasing the signal to noise ratio. Disease setting could also affect the 
accuracy of echocardiographic prediction ability (for example, advanced lung disease, severe 
tricuspid regurgitation) 34.  
1.3.1.5 Secondary markers of pulmonary hypertension.  
Pulmonary valve (PV) acceleration time is measured from pulsed-wave Doppler at the level 
of the PV leaflets, with a measurement of time from baseline to peak modal velocity. 
Echocardiographic-invasive correlations have led to the proposal of a 100ms cut-off for 
detection of sPAP of 38 mmHg 35. Although this is an attractive alternative to PASP in the 
~25% of patients who lack an adequate tricuspid regurgitation signal, the correlation of PV 
acceleration time <90 ms with PVR >3 wood units (W.U) is only modest 36. In the absence of 
an evidence base in patients undergoing PAH therapy, we do not use it in this setting.  
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Mid- and late systolic notching in the RVOT outflow tracing is a qualitative marker for PH. 
However, this is insufficiently sensitive to “rule out” PH, with studies reporting this in only 
53% of PAH patients. However, this marker may provide insight into the underlying physiology 
of elevated PASP; it is believed to be affected by large artery stiffness and transient flow 
deceleration related to early systolic pulmonary artery wave reflection. Increased vascular 
resistance is thought to play a crucial role, with the early arrival of wave reflection denoting a 
more constricted and less compliant vascular bed. Late systolic notching is more likely to be 
present in PH due to left heart disease 37. 
A number of echocardiographic measures are used to estimate Mean PAP.  Most common are 
planimetry of the TR jet (RV-RA gradient), application of the Bernoulli equation to the opening 
maximum pulmonary regurgitation velocity when a full pulmonary valve regurgitation signal 
is available 38, and from the combination of PASP with diastolic PA pressure, obtained from 
the end-diastolic PR velocity 39. Increased mPAP his shown to predict NYHA status, elevated 
LV mass and all-cause mortality 40,41 in stable coronary artery disease (CAD), it is obtainable 
in a large number of patients. It is not part of our routine clinical practice in following up PAH 
patients but has strengths for internal consistency and validation of measurements. 
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Figure 1-2. Tricuspid regurgitant jet measurement and common problems with signal 
interpretation. 
 
a) Mild Tricuspid Regurgitation, an increase of signal using agitated saline; b) Stroke volume 
dependence of tricuspid regurgitation); c) PASP may be underestimated when severe TR 
leads to high RAP (TR velocity <3 m/s) 
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1.3.1.5.1 Right atrial pressure. 
RAP has shown to be a valuable diagnostic marker in outcome studies 1,42. Early in the history 
of echocardiography, RAP was derived from clinical jugular venous pressure (JVP) assessment. 
The use of an assumed RAP of 10 mmHg leads to under- and over-estimation of PASP, and 
more importantly, ignores the striking correlation RAP with mortality in PAH 16,43.  
Echocardiography has value as the intermediate between invasive RHC assessment and clinical 
evaluation of central venous pressure (which is unreliable). We use a combination of IVC 
assessment and Doppler waveform analysis of the hepatic veins or superior vena cava.  
Measurement of IVC dimension is from the subcostal view, 1-2 cm from the junction of the 
right atrium (RA) (from a long-axis view). We still routinely assess IVC distensibility in 
response to respiratory measures that alter intra-thoracic pressure 44; 50% collapsibility 
provides optimal sensitivity and specificity for detecting RAP greater or less than ten mmHg. 
In a study of over 4000 participants, a non-dilated and collapsible IVC associated with survival 
and survival free of admission 45. This measurement has strong links to outcomes 16,43 but is 
underestimated when values exceeded 12 mmHg. Diastolic flow prominence is appreciated by 
assessment of velocity-time integrals (VTI) of the hepatic veins (or superior vena cava) and 
indicates elevated RAP.  Hepatic vein systolic filling fraction (VTI systolic/ (VTI systolic +VTI 
diastolic) provide a semi-quantitative assessment of RAP46, with a measurement of <55% 
predicting RAP>8 mmHg with good sensitivity and specificity. This technique offers 
advantages over IVC measurements in patients with falsely elevated IVC diameters (athletes, 
large BSA, mechanically ventilated patients). However, in AF there can be a reduction of 
hepatic vein systolic flow, regardless of RAP.  
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Although the ratio of the early tricuspid inflow to annular diastolic velocity (RV-E/e’) may be 
used to estimate RA filling pressures, we rarely use this. An E/e’ >4 is a marker of RAP>10 
mmHg and is associated with cardiac events in a PH cohort. 
1.3.1.5.2 Estimated Pulmonary Vascular Resistance  
The assessment of PVR is a means of compensating for changes in stroke volume. The most 
widely used echocardiographic technique involves indexing the peak TR velocity for RV 
outflow velocity-time integral (VTI) (Figure 1.2b) and has been validated against RHC, using 
the equation 10 x TRV/RVOT-VTI 47. Echocardiographic estimation of PVR may not track 
changes of PVR assessed by RHC 48. Work from five validation studies has been combined to 
generate a new equation for elevated PVR (TRV2/RVOT-VTI), for use when PVR is likely >6 
WU 49.  
Nonetheless, evidence shows PVR improves post prostacyclin treatment 50,51, although this 
seems to be therapy-specific 20.  The underestimation of PVR using echocardiography is 
independently associated with RV systolic dysfunction 48. We use this routinely as a screening 
tool for identifying patients with PVR >2 Wood units (WU), but it is less useful in follow-up 
as it underestimates the degree of elevated PVR in the presence of high PASP 48,52 
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Figure 1-3.  RV dysfunction with near-normal PASP. 
In this case, the RV is enlarged (a) and RV strain is reduced to <12% (1.3b). Although PASP is considered near-normal (1.3c) (TR velocity 
2.8 m/s); RAP elevated as demonstrated by IVC size (1.3h) (3.0 cm) and hepatic s wave blunting, with a predominance of the diastolic 
filling (1.3i). A reduction in stroke volumes produces a decreased right ventricular outflow tract VTI (1.3d), leading to an elevated PVR 
(~ 2.5 w.u). Thus, despite near-normal PASP, other features point to increased afterload, so RV dysfunction should be interpreted in this 
context
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1.3.2 Quantification of RV performance 
Measures of RV function (Figure 1.4 and 1.5) are well known to be associated with 
outcome in PAH (Table 1.2) and improve in response to therapy (Table 1.3). The 
assessment of PASP and PVR are central to the evaluation of RV dysfunction, and if 
ambiguous, invasive measurement of PA pressure may be required. The reversibility 
of pressure-overload induced RV dysfunction is well –illustrated in patients after lung 
transplantation or pulmonary artery thrombo-endarterectomy. Nonetheless, those with 
higher baseline PASP values displayed significantly less remodelling 53. There are at 
least 20 available echocardiographic variables for RV assessment, although not all 
have are associated with mortality in PH. The reference standard for RV assessment is 
cardiac magnetic resonance imaging (CMR), but cost and limited availability 
somewhat outweigh the high specificity and sensitivity of this test54. 3DE is now 
increasing in popularity for RV assessment and can add incrementally to the prediction 
of pre versus postcapillary PH 54.  
1.4 Stroke Volume and Cardiac Output 
Cardiac stroke volume (amount of blood ejected from the heart in one contraction) is 
routinely performed using the left ventricle. Cardiac output is the product of SV by 
HR.  Ideally, 3D ultrasound measures are preferred, but 2D echocardiography is an 
acceptable surrogate55 with cardiac CMR the gold standard. The Simpsons biplane is 
a 2D method of estimating both the systolic and end-diastolic chamber sizes in the 2 
and 4 chamber view. LV stroke volume = LV EDV- LV ESV.  The second manner 
with echocardiography is the Doppler VTI method; Cross-sectional area of the LV 
outflow tract during mid-diastole is multiplied by the VTI measurement at the level 
of the aortic valve leaflet tips. There are caveats to each method. The biplane 
estimation of the volume is dependent on image quality and accurate tracing of the 
myocardium. In PH dilatation of the RV causes significant LV compression. The 
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accuracy of tracing to calculate cardiac volumes is contingent on normal LV 
geometry56. Tracing of the biplane volumes becomes technically challenging due to 
the inability to acquire images from a true LV apex as shown in figure 1.4.  The 
Doppler measurement of SV involves assumptions which can create errors.  
Measurement of the CSA is 𝑎𝑑𝑖𝑢𝑖𝑠 = 𝜋𝑟2 ; any errors in measurement are squared. 
The CSA of the outflow tract is considered to be circular but in reality in many 
patients it is elliptical. Overall, small bias exists with a high percentage error in the 
Doppler calculation as compared to thermodilution 57. Using CMR a clinically 
meaningful change of SV in PH is 10 ml58, but the echocardiographic range for this 
measures has not been calculated.  
Cardiac output has a strong correlation with 6MW performance in PAH59. A failure 
to augment output for increasing cardiac demand60 exists likely mediated by a 
decreased chronotropic response59.  
Figure 1-4. Technical challenges of LV volume measurement in a dilated Right 
Ventricle 
As the RV dilates it becomes apex forming and the LV is compressed. Correct alignment 
for a Simpson’s biplane measurement is difficult due to foreshortening of the LV 
cavitycavityeshortened 
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RVEDA, right ventricular end diastolic area; TAPSE, tricuspid annular plane systolic excursion; RAA, right atrial area; PVR, pulmonary vascular resistance; RV MPI, Right ventricular myocardial 
performance index; CMR, cardiac magnetic resonance imaging.  
Table 1-2 .  Changes of RV parameters in response to treatment of PAH 





Echo 1 year follow-up 
Not placebo-controlled 
48 Significant improvement in: RVEDA, RVED 
mid cavity, TAPSE, RAA, PVR 
Epoprostenol 22 Echo 12  week  81 NA  
Epoprostenol 61 Echo 1 year 7 Significant changes in: RA size, Diastolic 
eccentricity index, Pericardial effusion score 
Epoprostenol 62 Echo Follow-up 5.9±4.6 
months 
16 Significant change in RV MPI (p=0.05). RV 




Bosentan Echo   Significant change in RV size (qualitatively 
assessed) 
No significant change in RV MPI & TR Vmax 
Bosentan BREATH-1 
study 33 
Echo 16 weeks of treatment 
 
85 (56 treated) Change in RV systolic eccentricity (p=0.03) 
No change in TRV, RVEDA, RV diastolic 
eccentricity  
Combined therapy Bosentan & prostanoid 63 Echo 8 ± 3 months 
Not placebo-controlled 
37 Significant changes in TAPSE, RV strain, RV 
strain rate, RV MPI index 
 Conventional therapy+ 
prostacyclin 64 
Echo 12 week N=81, N=40 on 
combined therapy 
Significantly greater change in RVEDA, 
systolic and diastolic eccentricity index in the 
combined arm. No comment on combined 
group changes between baseline and follow-up 
 Sildenafil versus 
Bosentan 65 
 
CMR & echo 16 weeks 25 (13 sildenafil, 
12 bosentan) 
A significant change in RV mass with 
sildenafil, not shown with bosentan 
No significant change in RV MPI index 
 Predominantly ERA 66 
 
CMR & echo 12 months 91 
 
Significant change in ejection fraction 
(p=0.0001). No significant change in RVEDVI 
(p=0.22) or RV mass (p=0.68) 
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1.4.1.1 Right ventricular size and structure 
1.4.1.1.1 RV ejection fraction.  
Echocardiographic assessment of this parameter is completed by calculation of 
volumes using geometric assumptions from the traced right ventricular end-diastolic 
area (RVEDA) and right ventricular end-systolic area (RVESA), or by direct 
measurement of RV volumes by 3D.  Impaired RV (EF) is a manifestation of right 
heart failure, and linked to outcome 16,67, possibly through its association with RA 
size and TR. Fractional area change (FAC) is a widely-used surrogate of EF, 
calculated from diastolic and systolic areas (Figure 1.5a) 44. Both 2-dimensional 
techniques are particularly affected by the non-geometric nature of the RV and 
potentially off-axis imaging planes. Some investigators have reported no significant 
change in RV size and EF, despite treatment with a spectrum of medication types 
33,66,68,69. Mortality in PAH also does not have a strong relationship with these 
variables 67,70,71, although there are some favourable reports 64. For these reasons, we 
do not use RVEF and FAC in serial follow-up. CMR can measure EF more 
accurately than echocardiography, as the RV is traced in the appropriate imaging 
plane. However, the cost and potential access limitations of CMR are barriers to its 
use as a follow-up test.  
1.4.1.1.1 RV size.  
RV remodelling is indicative of long-term outcomes 72. RVEDV (RV end-diastolic 
volume, measured by CMR) or RVEDA by 2DE have been proposed as prognostic 
markers 50 in uncontrolled studies that record the prognostic effects of a slower 
progression of dilatation or reduced systolic function. This process is a complex 
interplay of factors, RVEDA was only indicative of poor outcome when RV wall 
thickness (RV free wall thickness measured from the subcostal view) had not increased 
73, potentially showing an adaptive remodelling process.   
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Table 1-3. Association of PAH therapy and Echocardiographic RV parameters  
Study First Author Population N Treatment Results 
Raymond16  Initial data also 
published64 
N=81 Follow-up 37 months 
(SD 15.4 months) 
Survival 
RA area index (5 cm2/m) 1.54 (1.13–2.10) 0.005 
Pericardial effusion (Y/N) 3.89 (1.49–10.14) 0.003 
Maximum TR velocity (0.5 m/s) 0.90 (0.62–1.31) 0.591 
Forfia 43 Initial data also 
published74 
N=63 Survival Baseline TAPSE predicted survival (sensitivity, specificity AUC .87, p<.0001) 
Esymann 67 NHLBI PPH 
registry 
N=26 Survival FAC, pericardial effusion, independently associated variable(p=0.006) 
 
Yeo 75 PAH N=53 Survival RV MPI index (HR 1.3, CI 1.09-1.56, p=.004) 
TR severity not significant 
Brierre76 PAH N=89 Survival RV MPI >.98 (5.411.12-26.1, p=.035 
TAPSE .84 _.72-.98) p=.024 
Pericardial effusion 5.18(1.85-14.5), p=.002 
Abnormal septal curve 5.33(1.21-23.5),p=.027 
Fine77 PAH N=575 
(406 PH) 
Survival RV free wall strain (HR 1.46 (1.05-2.12, p<.001) (multivariable model) 
Univariate HR 2.59(CI 1.89-3.57, p<.001) cut off of 6.7% used. 
Sig for other RV echo parameters 
Sachdev78 PAH N=80 Survival RV free wall strain (<12.5%) significant in Kaplan Meir for survival (p<.005) 
Sano 72 PAH N=51 Survival RV free wall of patients with events was significantly lower (17.8 vs 23%, p=.02). 
RV free wall strain added significantly to haemodynamic predictors. 
RV reverse remodelling was associated with improved survival ( p=.001)  
Ghio73 PAH N=72 Survival In patients with RV wall thickness <.66 dilated RV (>36.5) was associated with poorer 
survival.  
Fijalkowska71 PAH N=55 Survival RV area change NS, RAA NS, RV MPI NS; Pericardial effusion significant 
Mahapatra79 PAH N=54 Survival RV MPI RR 1.66 (1.05-2.6), p=.04 
RVSP RR1.07 (1.02-1.12), p=.032 
RAP via echo NS 
Invasive RAP RR 1.13 (1.04-1.23),P=.004  
Nagaya80 PAH N=53 Survival Pericardial effusion RR 2.37(1.317-4.3), p=.04 
LV deformity index RR1.88 (1.010-3.53), p=.0463 
Neither sig in multivariate 
Mathai74 SSC associated 
PAH 
N=50 Survival N=50 
TAPSE <1.7 HR 3.81 (1.31-11.1) p=.01.  
As continuous variable  HR .87(.078-.96)p<.002. 
RAA index HR 1.11(1.02-1.19)p=.01 
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Pericardial effusion 1.11(.75-1.64), p=.59 
Tonelli50 PAH N=48 Survival Significant associations with mortality 
TRV HR .58(.37-.89) 
RV mid cavity dimension, HR .76 (.57-.93) 
RVEDA  HR .73(.57-.93) 
RVOT VTI HR .90 (.83-.98) 
RVSP HR.79(.63-1.0) 
Qualitatively measured RV function HR .55(.31-.96) 
RA, right atrium; TR V max, tricuspid regurgitation maximum velocity; PAH, pulmonary arterial hypertension; NHLBI, national heart, lung and brain institute; PPH, primary pulmonary hypertension; FAC, 
fractional area change; TAPSE, tricuspid annular plane systolic excursion; RVEDA, Right ventricular end-diastolic area; RVOT VTI, right ventricular outflow tract velocity time integral; RVSP, right 
ventricular systolic pressure; HR, hazard ration.       
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The RV eccentricity index 16 (which measures the RV diameter as a ratio to the LV) is 
a simple method to assess the “D-shaped” flattening of the septum quantitatively; a 
ratio of >1.0 44 is abnormal. Although changes are documented in response to therapy 
61, and associations with outcome shown 76, its prognostic role does not seem to be 
independent of other features 80. Studies done with prostacyclin suggest changes in 
this parameter could reflect improvement in LV filling.  
RV thickness- The traditional 2DE measurement of the RV free wall from the subcostal 
view is subject to tangential measurements, and three-dimensional echocardiography 
(3DE) is likely more accurate as compared to CMR 81. However, CMR measurements 
of baseline RV mass do not associate with survival 69, and follow-up CMR shows no 
significant change in RV mass with treatment 66,68,69, although this may be dependent 
on medication type 65. Consequently, we do not follow RV mass to assess treatment 
response. 
1.4.1.1.1 Myocardial Performance Index (MPI).  
Myocardial Performance Index is the ratio between the sum of isovolumetric 
contraction time (IVCT) and isovolumetric relaxation time (IVRT) and RV ejection 
time. Standard measurement is with pulsed Doppler, or from tissue Doppler of the TV 
lateral annulus 82. MPI is a prognostic marker 75,79; measures >0.98 are associated with 
mortality in PAH 76. Nonetheless, MPI is load-dependent, and may not reflect 
contractility – for example, elevated RAP causes a shortening of IVRT (due to early 
equalisation of pressures), so that MPI underestimates the severity of RV dysfunction 
83, accounting for its inconsistent association with outcome 71. MPI use in PAH has 
level C evidence 84. Responses of MPI to medication changes have been reported with 
epoprostenol 62 or combined bosentan and iloprost 63, but other studies have shown no 
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significant change 65, even over 2-year follow-up 51. Because of these inconsistencies, 
we do not use it in serial follow-up.  
Figure 1-5. Common RV systolic Function measures; Fractional Area Change (1.4a) 
and Tricuspid Annular Plane Systolic Excursion (1.4b) 
a) Measurement of RV systolic function with Fractional Area Change. Figure 1.4b. 
Tricuspid annular systolic plane excursion. Conventional parameters including FAC 
and TAPSE are supplemented or replaced with RV tissue Doppler and free wall strain. 
1.4.1.1.2 Tricuspid annular plane systolic excursion (TAPSE).  
TAPSE is the M-mode measurement of tricuspid annular motion in the apical 4 
chamber view (Figure 1.5b). The measurement of displacement relative to the 
transducer makes this parameter susceptible to angle dependence, translational motion 
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and changes in LV systolic function. Although a relationship between TAPSE <1.8cm 
and survival are reported 43,74,76, a recent meta-analysis showed TAPSE results from 
clinical trials to be too inconsistent to determine relevance with mortality outcomes 70. 
Nonetheless, the response to changes in TAPSE and PVR has a strong linear 
correlation 85, and TAPSE has been successfully used as a marker to document changes 
in response to therapy 50. 
1.4.1.1.3 Right ventricular systolic velocity (RVs’)  
Right ventricular systolic velocity is the Doppler measurement of TV annular motion, 
obtained in the RV apical 4 chamber view. It recommended in current guidelines 82, 
widely available and well-validated 86. A value of <9.5 cm/sec on the RV free wall is 
considered abnormal. Similar to TAPSE, angle dependency can lead to under-
estimation, and susceptibility to translational motion may cause over-estimation. 
Although echocardiographic cut-offs are described 44, there are limited data on the use 
of this method in the follow-up of PAH therapy. 
1.4.1.1.1 RV Isovolumic acceleration (RV IVA).  
This parameter, acquired from the same tissue Doppler trace as the RVs’, is measured 
as the isovolumetric contraction velocity (IVV), divided by the acceleration time 87. 
As it is a pre-ejection parameter, it may be especially useful for RV evaluation in PAH 
88.  The normal range is >1.1m/s2, but limited data on normal ranges and poor 
reproducibility make the clinical utility of this parameter limited in our experience. 
1.4.1.1.1 Right ventricular strain. 
Deformation (strain) of the myocardium is a strong predictor of outcome in left heart 
disease 89. The current measurement technique (speckle-tracking), is widely available 
as an “on-cart” feature and can be performed at the bedside. In recent guidelines 
normal ranges have been included to facilitate application in routine practice 82. RV 
free wall strain measurement is from the RV-focused apical 4-chamber view. The 
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inclusion of the septal wall incorporates the LV contribution to RV function, so we 
favour RV free wall strain (RVFWS) as a marker of RV performance. 
Figure 1-6. Right ventricular free wall strain (Figure 1.5a); Measurement of 
isovolumetric acceleration (Figure 1.5b). 
 
1.5a. Right ventricular free wall strain measured in the RV free wall, and RV septum. 
The free wall constitutes the basal, mid and apical segments. 1.5b shows Isovolumetric 
acceleration time (measured with PW Tissue Doppler) quantified as the isovolumetric 
contraction velocity, divided by the acceleration time 
This measurement is validated against CMR 90, and RV strain has been shown to 
predict outcome in PH 77,78. RV deformation parameters change in response to 
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haemodynamic changes 91, RV strain has been shown to respond to medical therapy 63 
as the only independent echocardiographic predictor of secondary endpoints. Although 
3D strain is correlated with clinical outcome in small studies, its feasibility (~75% in 
experienced hands) remains a barrier 92.  
1.4.2 Markers of RV failure 
1.4.2.1 Right atrial size.  
Right atrial area or volume is obtained from a single plane area-length measurement 
in the 2D apical 4 chamber view. Right atrial size is an important measurement, with 
links to outcome in PAH.  A measurement of RA area >27 cm2 is predictive of 
increased risk of mortality or transplantation 73,93. RA size has also been shown to 
respond to PAH therapy 50,61. 
1.4.2.2 Severity of tricuspid regurgitation.  
The quantification of severity of the tricuspid regurgitation jet is linked to mortality in 
studies 50,93, but this finding is inconsistent 75. Severe TR is identified through a V-
shaped cut-off of the TR spectral Doppler, or hepatic vein flow reversal (TR jet density 
is a weak indicator).TR severity has also not shown a change in response to bosentan 
33.  
1.4.2.3 Pericardial Effusion.  
The presence of pericardial effusion (often graded categorically in small, moderate and 
large) associates with adverse outcomes in PAH 43,76,94. Development of effusion is 
related to mean RAP, mediated by decreased lymphatic and subepicardial venous 
drainage. The diagnosis of tamponade in PAH presents difficulties; RA and RV 
collapse may not occur due to increased right-sided pressures, and the non-compliant 
RV limits RV inflow at all stages of respiration, so pulses paradoxus may not be 
evident  
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1.4.3 Integration of RV markers with afterload status 
1.4.3.1 Pressure-volume loops.  
Pressure-volume loops may be obtained using capacitance catheters or by combining 
an RV micromanometer-tipped catheter with another means of assessing RV volume.  
RV contractility is quantified using maximal end-systolic elastance (Ees=end systolic 
pressure (ESP)/end systolic volume (ESV)), defined from the slope through the end-
systolic pressure volume points under different levels of flow induced by IVC balloon 
occlusion 95. Afterload is assessed as arterial elastance (Ea=ESP/ stroke volume (SV)). 
Although this approach provides information regarding RV-PA coupling (the 
ventricular performance matched with arterial load), it is not amenable to clinical use. 
1.4.3.2 Stroke volume/end-systolic volume ratio.  
End-systolic elastance (Ees) is the ratio of end systolic pressure to ESV-V0 (V0 being 
the theoretical volume of the unstressed ventricle, which is assumed to be negligible 
in the RV). The ratio between stroke volume and RV end-systolic volume is a vital 
RV marker that is sensitive to impaired RV function in the setting of raised afterload 
96. V0 is assumed as 0, but it is likely ~ 8 ml/m2 97. Thus Emax is likely systematically 
overestimated. This ratio can be applied non-invasively 98, using RHC and CMR, or 
with CMR or 3DE alone 99. Optimal RV-arterial coupling is an Ees/Ea between 1.5-2. 
In a small cohort, this was a reliable marker of outcome 96, with a value of 
SV/ESV<0.52 predicting a higher risk of death or transplant. The use of 3DE is 
becoming a viable alternative to CMR for the measurement of RV volume and stroke 
volume, with good correlations and agreements between measurements between 3DE 
and CMR 100. However, it is constrained by technical difficulties 81 and can 
underestimate 3D volumes as compared to MRI, which is critical in the measurement 
of elastance. 
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1.5 Conclusion 
Pulmonary vasodilator therapy is expensive, and its continuation in the Australian 
setting requires evidence of responsiveness. Echocardiography is an appropriate 
screening method for PH, although underestimation of PASP may arise due to 
inadequate signal, reduced stroke volume, and equalisation of RA and RV pressure 
due to severe TR. Reverse RV remodelling occurs as a result of vasodilator responses 
to treatment in PAH (as opposed to direct effects on the myocardium), and it is the RV 
responses that determine patient outcome. Reliable echocardiographic assessment of 
RV function has become more feasible and provides valuable prognostic information. 
The following points are important:  
 The goals of therapy include not only the reduction of PA pressure but also decrease 
in PVR, improvements in CO and tricuspid regurgitation. These should be 
highlighted in the report, with attention on RV function, which is the primary 
determinant of outcome.  
 As management decisions require repeat studies, laboratory processes for quality 
control are essential for controlling test-retest variation, and quantification is a 
critical component of this process. 
 RV-focused windows are key. RV dilation causes a change in cardiac orientation, 
and optimal probe positions may be non-standard. Side-by-side comparison with 
previous studies is important to limit inter-study variation. 
 A respirometer is often of value in Doppler assessment, especially if pulmonary HT 
is related to chronic pulmonary disease. The capture of long cycles (~10 beats) may 
be required to follow the response of the interventricular septum (IVS) during the 
breathing cycle especially in patients with pericardial effusion.  
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 Consideration of RV pressure overload etiology is required. Likewise, RV volume 
overload does not necessarily pertain to RV failure (other causes that warrant 
consideration include shunts and regurgitant valve lesions). 
 Research work needs to focus on the applicability of novel echocardiographic 
techniques, in particular RV free wall strain and 3D techniques. Long-term follow 
up of patients is required with validation of traditional markers against the gold 
standard. 
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2 Methodology 
2.1 Echocardiographic equipment 
Echocardiographic studies were performed on a number of machines (GE Vivid 7, 
Vivid I and Vivid e9, Horten, Norway; Philips ie33, Bothell, WA). Measures were 
performed by a single reader, on vendor-independent measurement software for all 2D 
DICOM measures (GE Health Medical, Horten, Norway) 
2.2 Standard 2D echocardiography protocol 
All left and right ventricular measurements were performed according to standard 
guidelines presented by the American Society of Echocardiography (ASE) 101. These 
included parasternal long axis and short axis views of the LV, RV apical focused views 
and subcostal images. Pulse and continuous wave spectral Doppler was performed on 
all patients. Spectral Doppler signal-noise ratio was optimised to ensure a clear 
window. Measurements were not performed on beats which were post ectopic.  In AF 
recordings were averaged, with three beats measured. Measurements used the modal 
velocity. 
2.2.1.1 Left side quantification 
LV mass calculation was performed according to the ASE 2D linear formula101 in the 
parasternal long axis view, and values indexed to body surface area (BSA) (DuBois 
equation). LVEF was measured from the Simpson’s biplane method from the apical 4- 
and 2-chamber views. The endocardial border was manually traced in systole and 
diastole. Stroke volume was calculated as the LV ESV subtracted from the LV EDV.  
Left atrial volume (LAV) measurements were from the apical 2- and 4- chambers 
(area-length method) in ventricular systole 101.  Spectral Doppler measures used pulsed 
wave Doppler, with the sample volume placed at the mitral valve leaflets. Peak 
velocities of the mitral valve early (E) and late (A) diastolic filling were derived from 
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the transmitral inflow pattern. Mitral valve deceleration time was measured as the 
modal velocity from the peak E wave, to the end of the flow of early diastole.  
Tissue Doppler imaging using the colour Doppler method with a pulse wave sample 
volume (2D guided) used to determine the peak diastolic early velocity (e’) of the 
lateral and septal mitral annulus from the apical 4-chamber view. LV filling pressures 
(E/e’) were estimated by calculating the mitral inflow E wave, divided by the average 
of the septal e’ wave, and lateral e’ wave.  
2.2.1.2 Right ventricular measures 
RV end-diastolic (RVEDA) and end-systolic area (RVESA) were calculated from the 
apical RV focused view; FAC was calculated as the percentage change in RVEDA 
and RVESA 101 (Figure 1.4a). 
2.2.1.3 Tricuspid annular plane systolic excursion 
TAPSE was measured from M-Mode and calculated as the distance travelled by the 
TV annulus between systole and diastole (cm) (Figure 1.4a). Care was taken to 
ensure M-Mode alignment was parallel to the movement TV annulus.   
2.2.2 Right Atrial Area 
Right atrial area measurements were traced in the RV apical focused view, with the 
maximal size during ventricular end systole identified.  
2.2.3 Right-sided Spectral Doppler 
2.2.3.1 Tricuspid regurgitation maximum velocity 
Continuous wave Doppler measurement of TR was assessed from multiple windows 
to ensure optimal Doppler alignment with maximum velocity of the recorded traces 
used. Saline enhancement was not routinely used to optimise the Doppler signal.  
2.2.3.2 Pulmonary vascular resistance 
To determine PVR, the RVOT VTI was acquired through placing a pulsed wave 
sample volume proximal to the PV insertion point. PVR was calculated from the 
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RVOT VTI, and TR signal using the Abbas method (PVR echo=TRV/TVIRVOT × 10 
+ 0.16 ) 47. 
2.2.3.3 Right ventricular systolic velocity  
Right ventricular systolic velocity (RVS’) was measured using pulse wave tissue 
Doppler imaging, with the sample volume placed at the tricuspid annulus. RVS’ was 
measured as the peak after QRS on the ECG.  
2.2.3.4 Right atrial pressure 
RAP assessment was with 2D echocardiography of the IVC from the subcostal view. 
2D linear measurements were performed in the long axis view with a change in 
diameter throughout the respiratory cycle assessed. Patients were categorised as 
follows: 
 IVC diameter <2.1 cm, with >50% collapsibility; RAP= 3 mmHg 
 IVC diameter >2.1 cm, with >50% collapsibility; RAP =8 mmHg 
 IVC diameter >2.1 cm, with <50% collapsibility; RAP= 15 mmHg 
2.2.4 Myocardial deformation imaging 
Myocardial deformation imaging was performed using wall motion tracking software 
(Image-Arena, Version 4.6.3.9 TomTec Gmbh, Unterschleissheim, Germany) to 
analyse 2D echocardiographic images. Frame rates of >30 fps were required for data 
analysis. Endocardial borders were manually traced during diastole. Borders were then 
tracked automatically frame-by-frame throughout the cardiac cycle. Manual 
adjustments were performed when necessary, and regions excluded if excessive noise 
or inadequate tracking was present. 
2.2.4.1 Left ventricular strain 
Optimal LV cavity views were selected, with the LV end-diastolic endocardial border 
manually traced along the myocardium (borders automatically tracked frame-by-
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frame). Manual adjustments were performed when necessary, and regions excluded as 
required (e.g. inadequate tracking). Apical 4, 2 and 3 chamber views with optimal wall 
definition were selected for analysis (Figure 2.1), each wall was split into 3 segments. 
Peak global strain was defined as the average of 18 segments.  
Figure 2-1. Left ventricular global longitudinal (LV GLS) strain measurement of the 
apical long axis, apical 4 chamber and apical 2 chamber 
 
2.2.4.2 Right ventricular strain 
RVFWS measurement was from the modified RV apical view (Figure 2.2). Specific 
RV algorithms for tracking were not available thus the LV program was manually 
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adjusted to track the RV border. The RV end-diastolic endocardial border was 
manually traced along the RV septal and RV free wall. For mean values, the basal, mid 
and apical segments of the free wall are included. Manual adjustments were performed 
when necessary, and regions excluded as required.  
Figure 2-2. Right ventricular free wall strain 
  
The RV free wall and the septal border were traced. The basal, mid and apical free 
wall segments were average. 
2.2.4.3 Right atrial strain 
Right atrial strain was performed using the left ventricular strain package, with borders 
manually altered to track the atrial walls. For each chamber, manual adjustments were 
performed when necessary, and regions excluded if excessive noise or poor tracking 
were present. For RA strain, P-P gating was used from the RV apical-focused view. 
RA measurement points (Figure 2.2), peak RA reservoir (RA ƐR) was measured as the 
mean peak of 6 segments of the RA, RA contraction (ƐCT) was measured as 6 
segments at peak RA ƐCT. RA conduit function (ƐCD) was the difference between 
RA ƐR and RA ƐCD. 
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Figure 2-3. Measurement of right atrial strain. RA reservoir, RA contraction and RA 
conduit function  
 
2.2.4.4 Left atrial strain 
Left atrial a strain was measured using R-R gating (Figure 2.4) utilising the left 
ventricular strain package. The first peak (between the R wave and T wave 
corresponds) to the reservoir function (LA ƐR), while the second peak (starting on the 
P wave) is the atrial contraction phase (LA ƐCT). The difference between the reservoir 
and atrial contraction strain relates to the LA conduit function (LA ƐCD).  
Figure 2-4. Measurement of left atrial strain.  
After tracing the atrial border, the strain curves are given. The LA reservoir is defined 
as the peak strain post T wave, the LA conduit is the peak deformation prior to 
termination of the P wave. LA conduit is LA reservoir with LA conduit subtracted.   
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2.3 Vascular function 
2.3.1 Brachial Flow-mediated dilatation (Brachial FMD) 
The peripheral vascular function was assessed using distensibility of the brachial artery 
with ultrasound. Endothelial response to shear stress was the change in diameter after 
a 5 minute occlusion period 102. Mediation of this response is through the endothelial-
derived nitric oxide. The second method of assessment, performed through an 
exogenous dose of nitric oxide through nitroglycerin spray or tablet (0.4 mg) was not 
performed for this study.  
Studies were performed according to published guidelines 103, using standard 
equipment (Philips iu22, Phillips Healthcare, Bothell, WA and Vivid I, General 
Electric Medical Systems, Milwaukee, WI). All studies were performed by a single 
expert sonographer.  A cuff was placed on the forearm, an ECG tracing obtained, and 
3 beat acquisitions were used (Figure 2.5). A cuff was pumped up to 220 mmHg (or 
>50 mmHg systolic), and longitudinal plane imaging was performed distal to the 
antecubital fossa, with the probe baseline position marked. Pulsed Doppler recordings 
were performed before cuff occlusion, and this was used to calculate baseline flow. 
Brachial flow readings were performed immediately post cuff release, and diameter 
readings were performed 1-minute post cuff release.  
2.3.2 Peripheral artery tonometry  
Peripheral artery tonometry is the non-invasive measurement of arterial tone changes 
in the peripheral artery beds. Probes placed on contralateral fingertips measure finger 
-arterial pulse volume changes in response to a 5-minute occlusion stimulus. Similar 
to brachial flow-mediated dilation, the surge in blood flow causes an endothelium-
dependent vasodilation response.  
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Peripheral artery tonometry (PAT) measurements were obtained with 
plethysmography (Endopat 2000, Haifa, Israel). After probe placement on the 
fingertips, a digital pulse wave is created, reflecting the peripheral arterial tone. 
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Figure 2-5 Brachial artery flow-mediated dilatation 
 
Measurement of brachial flow-mediated dilation at baseline (2.5a). Post-Hyperaemia 
measurement of brachial artery size and blood flow (2.5b). 
All jewellery was removed before testing. Testing followed recommend guidelines 104, 
and hyperemic measurements were performed simultaneously with brachial FMD 
measurements.  The index finger was used for the majority of testing (94%); if this 
finger was not available (due to digit amputation, or open wounds), the next finger 
with no open wounds was used-usually the ring finger (3.4%). The 3rd and 5th digit was 
used for 1 patient each. Blood pressure measurement occurred on the control arm, and 
the cuff placed in the same position for brachial FMD. Patients achieved a 
haemodynamically stable steady state (at least 15 minutes resting supine, no talking). 
Automated readings and measurements were performed (Figure 2.6).  The EndoPAT 
score was calculated as the ratio of the average amplitude of the PAT signal over a 1 
minute period, 1.5 minutes after cuff deflation 105, measured as the log reactive 
hyperemia index (log PAT). 
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Figure 2-6. Measurement of endothelial function with Peripheral artery tonometry 
with EndoPAT2000 showing normal versus abnormal response 
 
2.3.3 Laser Doppler flowmetry 
Laser Doppler probes (CP1, Moor Instruments, UK) were placed on the subcutaneous 
tissues on the dorsal side of the forearm. Participants skin was shaved and wiped with 
alcohol. Probes were fixed lightly with medical tape to the same arm as was used for 
brachial FMD and Endopat-2000. Measurement of data was performed according to 
the methodology of Roustit et al. 106. Figure 2.7 details measurement of baseline, peak 
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Figure2-7 Laser Doppler flowmetry. 
Figure2.7a-Abnormal Laser Doppler hyperaemia response. Figure 2.7b-Normal 
Laser Doppler hyperaemia response. 
2.4 Study patients 
PAH patients were recruited from two separate hospital sites, the Royal Hobart 
Hospital and The Princess Alexandra database. These patients were included in 
chapters 3, 4, 5(Hobart site only), 6, 7 (Hobart site only), 8, 9, 10. Patients were 
registered in nurse databases, for prescription of Medicare subsidised medications. 
Once patient details were retrieved, respective echocardiographic databases were 
queried with data stored in DICOM compliant format.  
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In chapter 4, the control cohort of pulmonary embolism patients was recruited from 
discharge summaries from the RHH. SSC patients in chapters 7 and 11 were recruited 
from the Tasmanian Scleroderma Registry. Postcapillary PH patients included in 
chapter 8 were recruited from patients undergoing invasive testing in the RHH cardiac 
catheterisation laboratory.  
2.5 Clinical data 
Clinical data were retrospectively acquired through PH tracking databases maintained 
by dedicated PAH nurses for chapters 3, 4, 5, 6, 7, 8, 9, 10 and 11. Clinical control 
groups included in chapters 5, 7, 8, 10 and 11 had clinical information gained from 
clinical chart reviews. Clinical data for study 11 was taken at the time of study by LW, 
history on SSC was acquired from nurse run database for the Tasmanian scleroderma 
cohort. All patients were defined as having PH through invasive measures as required 
in clinical guidelines.   
2.6 Right heart catheterisation. 
RHC studies were undertaken after premedication and local anesthesia. A 4-lumen 110 
cm 7-Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) was floated to 
the right heart, and resting measurements of mRAP, RVSP, PAPs, PAPm and PCWP 
were made at end-expiration using a pressure transducer (21BB, ITL Healthcare, 
Chelsea Heights, Australia). The transducer was calibrated to atmospheric pressure at 
the level of the RA (1/3 chest height) and re-checked at intervals to avoid zero drift. 
CO was determined by thermodilution, using an average of four consecutive values 
that varied less than 10%. Electrocardiographic (ECG) leads were connected to both 
arms and the left leg, allowing three ECG channels for the timing of signals. All 
haemodynamic monitoring was recorded using a Horizon SE Haemodynamic System 
(Mennen Medical Ltd., Yavne, Israel) and subsequently analysed off-line.
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3 Importance of Baseline and Longitudinal Evaluation in the 
Follow-up of Vasodilator Therapy in Pulmonary Arterial 
Hypertension 
3.1 Preface 
Classically, assessment of PH patients during clinical follow-up is with the 
echocardiographic evaluation of PASP. Quantification of disease severity is through a 
calculation of the tricuspid valve regurgitation signal with the peak value obtained 
used to determine RVSP. RVSP is added to assumed RAP, measured as IVC diameter, 
and its collapsibility. Pressure assessment with echocardiography was initially the 
primary measure for follow-up in outcome studies of PAH. As technology has 
advanced, our ability to quantify right ventricular function has improved, and the 
importance of RV systolic function in patient outcome is now better appreciated.  
In Australia, PAH diagnosis is confirmed with RHC, patients then undergo a routine 
clinical assessment to determine the efficacy of treatment. Clinical status is assessed 
using functional performance measures (6MW distance), RHC, or echocardiographic 
assessment of PASP. Two of three of these assessments are required.  
Right ventricular function is a robust baseline predictor of outcome. There has been 
limited work on long-term follow-up of patients and outcome predictors. As patients 
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3.2 Abstract 
Background: PASP and right ventricular (RV) evaluation with echocardiography is 
used in the assessment of therapeutic response to vasodilator therapy in PAH.  We 
sought the relative value of baseline and follow-up evaluation to risk assessment with 
standard clinical markers. 
Methods. Of 162 prospectively recruited patients with PAH, with 96 included in the 
analysis with >3 sequential echocardiographic studies. PASP and RV function 
(including RVFWS) were measured at baseline and follow-up 2D echocardiograms. 
Univariable and multivariable Cox regression, with nested models,  used to determine 
incremental and independent predictors of all-cause mortality.  
Results. Changes between visits were minimal for all parameters (RVWFS (p=0.46), 
RVEDA (p=0.48), PASP (p=0.66), TAPSE (p=0.32), RAA (p=0.39) and IVC 
(p=0.25)). Over 3 years follow-up, 29 patients died. Baseline RVFWS was an 
independent (HR 0.90 [95%CI 0.83-0.97], p=0.007), and incremental predictor 
(p<0.001) of outcome when accounting for PASP and other clinical covariates (C 
statistic 0.74, p=0.001). Those who died showed no differences in RVFWS (p= 0.50), 
PASP (p=0.90), and TAPSE (p=0.83) between visits. Patients were split into those 
who improved vs. declined over time, no changes in RVFWS (HR 1.3[0.59-2.70], 
p=0.55), or PASP (p=0.78) predicted outcome. When baseline measures and follow 
up time were accounted for RVFWS (0.78[95%0.63-0.96], p=0.002), RAA (1.2[1.07; 
1.4],p=0.003) and IVC (66.5[8.5;520.5],p<0.001) mean change over follow up were 
significant in predicting outcome. 
Conclusion. In PAH, baseline RV function (RVFWS) is a strong predictor of outcome, 
independent of PASP. Changes throughout therapy appear minimal, and the prognostic 
value of change appears limited.  
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3.3 Background 
While a decade of improving mortality rates 13 attests to the benefit of pulmonary 
vasodilator therapy in PAH, these treatments remain expensive, with inter-individual 
differences in efficacy. In Australia, the continuation of therapy is conditional on the 
demonstration of a treatment effect, and lack of an effect should lead to consideration 
of additional therapy. In Europe and USA, patients remain on treatment even without 
a marked improvement because, as this is believed to delay progression of the disease. 
Therefore, the treatment goals of normalisation or near-normalisation of right 
ventricular (RV) size and function 107, require sequential follow-up by RHC, 6MWD 
or echocardiographic parameters and, if accessible, by CMR. Clinical evaluation of 
PAH is through an assessment of functional class, combined with non-invasive tests 
including 6MWD and echocardiography 25. Because clinical trials of pulmonary 
vasodilators used PASP response as a primary outcome measure, PASP evaluation 
using echocardiography acts as a surrogate for invasive hemodynamic assessment. 
However, hemodynamic and RV function changes do not necessarily follow the same 
trajectory as PASP 108. RV function has also been shown to decline, even in patients 
deemed clinically stable 109.  
RVWFS is a novel marker of myocardial deformation, which has a growing body of 
evidence as to its utility in predicting outcome in PAH 77. In this current study, we 
sought to determine predictors of mortality. Our hypothesis was that baseline, and 
follow-up RV dysfunction would be a stronger marker than PASP for predicting 
outcome in PAH. The primary aims were to determine the severity and prognostic 
relevance of baseline PH and RV dysfunction, and its change in follow-up.   
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3.4 Methods. 
3.4.1 Patient selection.  
We prospectively enrolled 162 patients at two Australian regional centres (92 at Royal 
Hobart Hospital, Tasmania, and 70 at Princess Alexandra Hospital, Brisbane, 
Queensland), who were evaluated for pulmonary vasodilator therapy after invasive 
diagnosis of PAH (PAPm ≥25mmHg with PCWP ≤15 mmHg). We included 96 
patients (age 62±14) years, 73% women) who had >3 echocardiographic studies 
available. Patients were placed on a variety of treatments, 38 (40%) on endothelin 
receptor antagonists (ERA) and phosphodiesterase type 5 inhibitors (PDE-5), 32 
(33%) on ERA only, 15 (16%) on PDE-5 only, 7 (7%) on ERA+PDE-5+prostacyclin, 
and 4 (4%) on no treatment. 
The patient follow-up protocol involved re-evaluation at intervals of 6-12 months. 
After the baseline study (treatment initiation), the 2nd visit was after a median time 
frame of 9 months (4-14), the 3rd visit at 16 (10-26) and 4th at 27 months (16-36). There 
were 96 patients followed over 3 visits (n=96), with 62 patients assessed over 4 visits. 
3.4.2 Echocardiographic assessment.  
Echocardiography was performed using standard commercial equipment (Vivid 7, 
Vivid i and Vivid e9, GE Medical Systems Horten, Norway; ie33, Philips, Bothell, 
WA). A standard imaging protocol was obtained, including RV-focused views.  
Conventional measurements were performed by a single reader, according to ASE 
guidelines 101 by a single reader for all studies. PASP was measured from the peak 
tricuspid regurgitation velocity using the modified Bernoulli equation 29. RAP was 
derived from the IVC dimension and distensibility from the subcostal view 44. LV EF 
was measured from the Simpson’s biplane method from the apical 4- and 2-chamber 
views. Peak velocities of the early (E) and late (A) diastolic filling were derived from 
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the transmitral inflow pattern. Tissue Doppler imaging using the pulsed Doppler 
method was used to determine the peak diastolic early velocity (e’) of the lateral and 
septal mitral annulus from the apical 4-chamber view. RV end-diastolic area (RVEDA) 
and RV end-systolic area (RVESA) calculation was from an apical RV focused view. 
Fractional area change (FAC) was calculated as the percentage change between the 
RVEDA and RVESA. Tricuspid annular plane systolic excursion (TAPSE) was 
measured as the displacement (cm) of the lateral tricuspid annulus towards the RV 
apex in the RV 4-chamber view. Right atrial area (RAA) was measured from the RV 
apical focused view, with the largest maximal area traced in end-systole. The 
echocardiographic calculation of RV to PA coupling was calculated as the 
TAPSE/PASP ratio (mm/Hg). A second method, the RVFWS/PASP was calculated to 
elucidate the RV coupling process.  
Categorization of normal echocardiography ranges; Dichotomization of 
echocardiographic values were based on ASE ranges and are as follow; PASP>35 
mmHg, IVC>2.1, RVEDA >25 cm2, TAPSE <1.6cm, RAP>8 mmHg, FAC <35%, 
RVFWS <19%, PVR>3 Wood, RAA>18 cm2,  
Standard software (Image-Arena, TomTec Gmbh, Unterschleissheim, Germany) was 
used to analyse 2D speckle-tracking. Image selection included the optimal image in 
which the whole RV cavity was visualised. The RV end-diastolic endocardial border 
was manually traced along the RV septal and RV free wall. These borders were then 
tracked automatically frame-by-frame throughout the cardiac cycle. Manual 
adjustments were performed when necessary, and regions excluded if excessive noise 
or poor tracking was present. RVFWS was calculated from an average of three 
segmental RVFWS traces.  
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3.4.3 Functional testing.  
A 6MW test was performed at the time of the echocardiogram by a research nurse. 
Testing was done in a quiet corridor and followed a standard protocol 110. 
3.4.4 Follow-up.  
The cohort consisted of 96 patients with at least 3 follow-up scans (3 visits follow up 
time median 13 (11-23), 4 visits median follow up 23 months (18-32), 29 (30%) died. 
66 patients were excluded because of <3 scans (follow up time median 0 months (0-
14), 12 (18%) died. In 7, death was attributed to CVD, in 5 there was a final 
presentation with respiratory failure, in 2 the cause of death was liver failure related to 
right heart failure, and in a further 11, no other cause of death was identified, so it was 
attributed to PAH. One patient died from a stroke, and there were three cancer deaths.   
3.4.5 Statistical analysis.  
Statistical analysis was performed using standard software (SPSS 20.0, IBM, 
Chicago, IL) with statistical significance set to p<0.05. All-cause mortality was the 
primary outcome. Univariable and multivariable Cox regression used was used to 
determine a prediction of outcome. The first visit was used as the baseline.  The 
average between-visit changes were calculated from the mean difference ((Visit1-
Visit 0)+(Visit2-Visit1)+(Visit3-Visit2)/3), and final visit change was included in those 
with 4 visits. Follow up time was included as months from first to final 
echocardiographic study.  Patients were then categorised into those who displayed an 
overall improvement or decline as compared to baseline.  Kaplan-Meier curves were 
used to illustrate outcome based on standard cut-offs 82, with differences sought 
using the log-rank p-value. In models of the progression of each parameter, the risk 
associated with age and sex was summarised in three groups, created according to 
REVEAL registry data 111. The three tertiles of risk were i) men and women <60 
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years (n=34, 35%), ii) women >60 years (n=43, 45%), and men >60 years (n=19, 
20%). Harrell C statistic was used to determine model strength.   
3.5 Results. 
3.5.1 Patient characteristics.  
Baseline variables are shown in Table 3.1. RV systolic function (measured by TAPSE 
and RVFWS) was decreased by 73% and 38% of patients respectively. Measures of 
right ventricular filling pressures (RAA and RVEDA) were increased by 44% and 34% 
of patients, respectively. Primary PAH etiology was idiopathic (47%), with a large 
proportion having connective tissue disease (40%), portal pulmonary hypertension 
(6%), congenital heart disease (3%), undetermined (3%).  
Table 3-1. Baseline echocardiographic and clinical parameters 
   Mean (SD) Proportion abnormal 
Clinical features  Age (years)  62 (14.0)  
  BSA 1.8 (0.24)  
 6MWD (meters) 320 (134)  
 HR 75 (15)  
Right heart parameters RVFWS (%) 17 (5.7) 38% 
 RVEDA (cm2) 23 (8.3) 34% 
 FAC (%) 32 (14.2) 55% 
 TAPSE (cm) 1.8 (0.50) 73% 
 RVSP (mmHg) 52 (23) 74% 
 IVC (cm) 1.9 (0.60) 56% 
 PASP (mmHg) 57 (24.1) 79% 
 PVR (w.u) 3.7(1.8) 54% 
 RAA (cm2) 20.3(7.6) 50% 
Left heart parameters LV mass (gm) 150 (51)  
 EF (%) 62 (9.8)  
 LV EDV (ml) 84 (35)  
 LV ESV (ml) 35 (26.4)  
 SV (ml) 39 (14)  
 LA volume (ml) 61 (26.0)  
 MV DT (cm/s) 227 (52)  
 E’ septal (cm/s) 6 (2.3)  
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BSA, Body surface area; 6MWD, six-minute walk distance; HR, heart rate; RVFWS, right ventricular free wall strain; RVEDA, 
right ventricular end diastolic area; FAC, fractional area change;  TAPSE, tricuspid annular plane systolic excursion; RVSP, right 
ventricular systolic pressure; IVC, inferior vena cava; PASP, pulmonary artery systolic pressure, PVR, pulmonary vascular 
resistance; LV, left ventricular; EDV, end diastolic volume; end systolic volume; LA, left atrium; MV DT, mitral valve 
deceleration time.  
3.5.2 Baseline predictors of outcome.  
Table 3.2 summarises the prediction of outcome from baseline variables. Mortality 
was predicted by increasing age, lower functional capacity, RV size and function, and 
evidence of right heart failure. Baseline PASP was not independently associated with 
outcome. However, TAPSE/PASP (p=0.02) and RVFWS/PASP (p=0.006) were 
significant univariable predictors of outcome. Adjustment of echocardiographic 
variables for age and sex showed RVFWS to be an independent predictor of outcome 
(HR 0.89 [0.83-0.96], p=0.001), as were the measures of RV coupling (TAPSE/PASP, 
p=0.03; RVFWS/PASP p=0.007). Cumulative survival is shown in appendix figure 
3.8.  
 Based on categorization of normal 
ranges from clinical guidelines, 
RVFWS of ≤19% (p=0.03), 
RVEDA >25 cm2 (p=0.005), and 
PASP >35 mmHg (p=0.05) were 
associated with mortality. In 
Kaplan-Meier curves of quartiles of 
RVFWS, PASP and TAPSE (Figure 
 E’ lateral (cm/s) 9 (2.4)  
 E/e’ septal (cm/s) 13 (6.9)  
 E/e’ lateral (cm/s) 9 (4.7)  
Figure 3-1. ROC curves with echocardiographic markers and outcome. Quartiles 
of RVfree wall strain  
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3.1, 3.2, 3.3), only RVFWS quartiles were significantly different in regards to outcome 
(log rank p=0.03). RVFWS/PASP tertiles showed a significant difference in log-rank 
test between groups (p=0.023), but TAPSE/PASP tertiles did not show a significant 
difference between the groups (p=0.10). Nested Cox models showed that although 
PASP did not add incrementally to clinical features, RVFWS showed an incremental 
prognostic effect of RV function additional to the risk determined from age and sex 
groups (C statistic 0.74, p=0.001) (Figure 3.4). 
Figure 3-2. ROC curves with echocardiographic markers and outcome. Quartiles of 
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Figure 3-3. ROC curves with echocardiographic markers and outcome. Quartiles of 
Tricuspid Annular Plane Systolic Excursion. 
 
3.5.3 Sequential measurement and outcome 
Sequential measurements of echocardiographic parameters (Figure 3.5) showed no 
significant changes in the group as a whole. When groups were split according to 
survival status (Figure 3.6), survivors were associated with significantly better 
function at all time points for RVFWS, PASP, RAA, IVC, RVEDA and TAPSE. The 
association of change in RVFWS, TAPSE and PASP with survival is shown in Figure 
3.7. Standard deviations were large, indicating a large amount of individual variation 
present in the degree of change. The average change of RVFWS (p=0.46), RVEDA 
(p=0.48), PASP (p=0.66), TAPSE (p=0.32), RAA (p=0.39) and IVC (p=0.25) in the 
course of therapy was not significantly associated with outcome. Due to the time-
varying nature of follow up, we created two additional variables to add into models, 
follow up time between first and final echo, and the mean delta over the course of the 
three or four visits (Table 3.3). Time was not a predictor of the outcome within our 
model Traditional RV function markers such as TAPSE and PASP showed significant 
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baseline predictors of outcome, but the change over time was not. RAA size and IVC 
showed change over time, and baseline size to be predictive of outcome. RVFWS was 
significant at baseline and also showed change over time to be significant.  
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Table 3.2. Baseline univariable and multivariable predictors of outcome  
 Univariable Age/sex adjusted Variables  
  HR (95%CI) P value   
Age (years) 1.06(1.02;1.10) 0.002   
Male sex 0.45 (0.21;0.93) 0.03   
Age+Sex (female >60) 0.20(0.07;0.57) 0.003   
Age +Sex (Male >60) 0.49(0.22;1.09) 0.08   
6MWD (meters) 0.99(0.99;0.996) <0.001   
RVEDA (cm2) 1.08 (1.04;1.1) <0.001   
FAC (%) 0.97 (0.94;0.99) 0.01   
TAPSE (cm) 0.47(0.21;1.03) 0.06 0.46(0.20;1.04) 0.06 
RVFWS (%) 0.89(0.83;0.96) 0.001 0.89(0.83;0.96) 0.001 
IVC (cm) 3.5 (1.9;6.6) <0.001   
RAA (cm2) 1.07 (1.03;1.1) 0.001   
PASP (mmHg) 1.02 (1.0;1.03) 0.05 1.02(1.0;1.03) 0.08 
PVR (w.u) 1.1(0.90;1.4) 0.34 1.04(0.83;1.3) 0.72 
TAPSE/PASP 0.09(0.01;0.70) 0.021 0.10(0.01;0.79) 0.03 
RVFWS/PASP 0.04(0.004;0.39) 0.006 0.04(0.003;0.41) 0.007 
IVC, inferior vena cava size; RVFWS, right ventricular free wall strain; RVEDA, right ventricular end diastolic area; RAA, right atrial area; FAC, fractional area change; 6MWD, six-minute walk distance; 
TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance
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IVC, inferior vena cava size; RVFWS, right ventricular free wall strain; RVEDA, right ventricular end diastolic area; RAA, right atrial area; FAC, fractional area change; 6MWD, six-minute walk distance; TAPSE, 
tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance 
Table 3.3. Cox regression of RV echocardiographic markers 
Dependent Variable: 
All-cause mortality 
Univariable analysis Multivariable cox regression. 
Mean change over visits Time Baseline Variable Mean Change over time 
 HR(95%CI) P HR(95%CI) P HR(95%CI) P HR(95%CI) P  
RVFWS (%) 0.91(0.76;1.09) 0.30 0.99(0.95;1.03) 0.65 0.86 (0.79;0.93) <0.001 0.78(0.63;0.96) 0.02 
RAA (cm2) 1.2(1.04;1.4) 0.01 1.005(0.97;1.05) 0.81 1.08(1.03;1.13) 0.001 1.2(1.07;1.4) 0.003 
TAPSE (cm) 1.5(0.24;9.0) 0.68 0.98(0.94;1.02) 0.24 0.35(0.15;0.85) 0.02 0.39(0.05;3.2) 0.38 
PASP (mmHg) 1.01(0.97;1.05) 0.58 0.99(0.95;1.03) 0.54 1.02(1.003;1.04) 0.02 1.03(0.98;1.08) 0.24 
IVC (cm) 3.2(0.71;14.8) 0.13 0.98(0.94;1.03) 0.41 10.1(4.3;23.7) <0.001 66.5(8.5;520.5) <0.001 
6MWD (metres) 1.009(0.99;1.02) 0.09 0.97(0.93;1.01) 0.16 0.99(0.991;0.998) 0.001 1.005(0.996;1.01) 0.30 
TAPSE/PASP 0.34(0.005;23.4) 0.61 0.99(0.95;1.03) 0.55 0.03(0.002;0.33) 0.005 0.07(0.0001;38.9) 0.40 
RVFWS/PASP 0.04(0.004;0.39) 0.006 1.0(0.96;1.04) 0.99 0.009(0.001;0.14) 0.001 0.003(0.00002;0.50) 0.003 
Chapter 3 Baseline Vs. Longitudinal assessment in PAH 58 









Chapter 3 Baseline Vs. Longitudinal assessment in PAH 59 
Figure 3-5. The longitudinal follow up of echocardiographic markers over the time course of the study   
 
*,p<0.05; **, p<0.01, ***, p<0.001 
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Figure 3-6. Differences over time in surviors versus non survivors for echocardiographic parameters 
 
*,p<0.05; **, p<0.01, ***, p<0.001 
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The results of this study show that baseline RV markers have a strong and independent 
association with outcome in PAH. Mortality is associated with reduced RV function 
across all time points, although changes throughout therapy were minimal for both RV 
systolic function and RV pressure markers, and these were unrelated to outcome. 
When accounting for follow up time and baseline function, RVFWS, IVC size and 
RAA change were associated with outcome 
3.6.1 RV function in PAH  
The initial response to PAH is an increment in RV contractility and wall thickness, but 
eventually, the RV dilates to preserve stroke volume in the face of increasing afterload 
112. The progressive disease course of PAH leads to uncoupling between the RV and 
PA in late-stage disease 113. However, due to the vague and non-specific symptoms of 
PAH, patients can be diagnosed at any time point in the evolution of RV dysfunction. 
Pericardial effusion has long been established as a reliable outcome marker 114, but due 
to its association with right heart failure, this signal is of limited value to guide therapy. 
Markers of RV function may give greater insight into a patient’s current clinical status.  
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Echocardiography is widely used to guide the initiation of therapy for PAH, and follow 
patient response. Current guidelines 115 acknowledge that clinicians often rely on the 
subjective appearance of the RA and RV to make clinical decisions, even without 
formal size measurements. This stance reflected the difficulty in quantifying RV 
dysfunction, but the availability of objective measures as allowed quantification to be 
incorporated into current follow-up. Therefore, in addition to the primary focus on 
hemodynamic parameters, the strength of baseline RV dysfunction as a prognostic 
marker in this study support a meticulous baseline imaging work-up, including all 
aspects of the PA-RV uncoupling process.  
A variety of measures of RV function have been used. TAPSE has also shown 
associations with outcome 43 and has been used to assess PAH progression 116. The 
limitations of this technique are that it may not perform as a global marker of RV 
dysfunction, as basal segment translation is only measured. Falsely elevated values are 
also possible, as TAPSE does not take into account rocking of the RV 117. Previous 
work from our group has shown that RV strain is a sensitive parameter over small 
variations in PASP118, and appears to be more significant to changes than traditional 
measures such as RV FAC. Pivotal work by Fine et al. showed the importance of 
RVFWS to outcome in 575 echocardiographic studies, of which 406 had a diagnosis 
of PAH either via RHC or echocardiographic parameters. Results showed poorer 
baseline RVFWS associated with shorter 6MWD, higher BNP and presence of right 
heart failure. (6). RVFWS predicted survival when adjusted for age and sex.  
An essential aspect of our study is the use of sequential visits, over extended follow-
up time. We also selectively included participants with RHC confirmed PAH. We have 
shown that patients appear to plateau after an initial improvement. If the initial patient 
trajectories do not continue over an extended period, treatment effects over long-term 
Chapter 3 Baseline Vs. Longitudinal assessment in PAH 63 
are overestimated. Guidelines recommend the use of echocardiography for follow up, 
but there has not been guidance on the value of echocardiographic markers, or a clear 
consensus on how these data could improve outcome.  
3.6.2 Sequential assessment.  
Echocardiography is an attractive tool for the follow-up assessment of PAH patients. 
How to make the most out of this imaging technique is not well known. Pulmonary 
pressures are generally used, but these are not a strong predictor of outcome at 
baseline, and we have shown that changes over time do not account for outcome. The 
right ventricle is a notoriously tricky chamber to follow over time; the non-geometric 
shape leads to discrepancies in size, and lack of consistency when reporting RV size 
and function 119. A goal of treatment should be to achieve “normal of near-normal size 
and function” 119, quantitative markers are thus not defined.  A test must have sufficient 
reliability to detect a clinically significant change sensitively. A major problem with 
2D echocardiography of the RV is the discrepancies in size which come with probe 
positioning (due to the non-geometric shape of the RV). Variability data on right 
ventricular 2D markers over time is lacking. Newer techniques must justify 
performance, for example, the validation of 3DE against CMR 120,121 and speckle-
tracking imaging 122.  Some of the difficulties encountered in this work can also be 
applied to 2D echocardiographic follow up. Firstly, the RV is thin-walled and can be 
heavily trabeculated, (especially so in PAH), making border delineation a difficult 
task. Previously, we have published the reproducibility of traditional 2D RV function 
markers as compared to speckle tracking of the RV free wall 118, with speckle tracking 
imaging showing improvements over RV FAC% in variability. Within this paper, we 
show the strength of RVFWS to predict outcome at baseline, with changes over the 
course of follow up sensitive for predicting outcome.  
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Although strong outcome changes after therapy are seen with improvements in WHO 
functional class, these are not mirrored in parameters such as 6-minute walk distance 
123. A goal of >380 meters has been defined 119, but in meta-analysis, no relationship 
with change in six-minute walk distance and outcome were seen 124. Perhaps a more 
sensitive tool such as cardiopulmonary exercise testing should be routinely performed 
in patients to quantify functional capacity.   
 
3.6.3 Limitations 
Due to the complexity of the RV’s structure, CMR is considered a gold standard for 
RV quantification. Echocardiographic parameters have been compared to CMR 
measures for longitudinal follow up 125, and although a significant correlation was 
present, echocardiography was not able to detect changes in CMRI-derived RVEF (a 
change in CMR RVEF of >3%). Our cohort derived from 2 referral hospitals, with 
multiple sonographers used for image acquisition (with a single sonographer 
performing measures). Over the time course of therapy, there will be alterations of 
type and doses of therapy, and this has not been accounted for in the final analysis. 
The exclusion of patients with <3 subsequent visits could lead to survival bias. PH 
trials identify sex as a reliable outcome marker 126,127, and a determinant of treatment 
response 128, so RVFWS could have been dichotomised based on sex-specific ranges 
122.  
3.7 Conclusion 
In PAH, RVFWS is a robust prognostic marker of all-cause mortality, independent of 
clinical and other echocardiographic parameters. Baseline echocardiographic 
parameters, rather than interval changes observed during therapy, are more strongly 
associated with mortality.  
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3.8 Postscript 
New tools to track patient clinical status in PAH are required, although the 
development of these has been slow for a number of reasons. Firstly, as a rare 
condition, PAH patient numbers in studies are often small, with a diverse patient 
population displaying small treatment effects. Most outcome studies have short 
follow-up periods, with single measures used to predict the outcome. There is also 
criticism that endpoints may not be representative of the severity of disease 129.  
Follow-up of PAH patient status with echocardiography should incorporate an 
assessment of cardiac pressure, structure and function. Although RHC is the gold 
standard for pressure assessment, there are still pitfalls for using this as a follow-up 
method. Attention to detail is important. One issue has been differences in the level of 
zeroing of the pressure transducer 130. Another is the consistent performance of 
measurements at end-expiration. The test is also invasive. 
Primarily, echocardiography is used to assess changes in cardiac structure and 
function. The lower variability studies on speckle tracking imaging support its use over 
traditional systolic function markers for sequential follow-up.  RVFWS appears to be 
a reliable prognostic marker at baseline, with strengths over traditional 2D systolic 
function parameters. However, the use of RV markers to define treatment response 
brings some questions: 
o Afterload dependence 
o Responses in acute versus chronic PHT 
o How to identify early disease (provocative testing) 
o Could a myocardial approach replace the current haemodynamic 
approach to distinguishing categories of PHT, including the recognition 
of LV dysfunction? 
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o Could improvements in the haemodynamic approach be achieved with 
other measures? e.g., better RAP assessment.  
The remainder of this thesis pertains to gathering evidence regarding these aspects. 
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3.9 Appendix 
Figure 3-8. Median Cumulative survival 
 
Cumulative survival of the entire cohort over time  
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4 The Afterload dependence of RV free wall strain in PAH 
4.1 Preface 
Our previous chapter details the use of echocardiography as a follow-up tool in 
sequential PAH follow-up. Although we have separated PASP and right ventricular 
free wall function, in reality, these two parameters are intrinsically linked. Over the 
course of PAH treatment, variations occur in RV loading conditions. As mentioned 
previously, any new follow-up marker must display appropriate validity to be of 
clinical use. Afterload directly impacts our interpretation of systolic function. 
Ideally, PASP and RV systolic function should be considered together, rather than in 
isolation. The relationship between changes in ventricular function and afterload is 
directly measured with invasive sure-volume loop studies; significant differences 
between left and right ventricular responses to load are present. The load relationship 
is very difficult to consider non-invasively, research work shows in E max   can be 
quantified with cardiac MRI and 3DE. Assessment of myocardial contraction is a 
cornerstone of echocardiographic follow-up, and RV dysfunction is a strong predictor 
of outcome 77. 
There has been an acknowledgment of the impact of afterload on the LV 131, but there 
are limited data about sequential RV assessment. In particular, some oncology patients 
undergo sequential echocardiography, and afterload assessment is recommended in 
protocol guidelines 132. As patients with PAH are followed up over time, the 
measurement of systolic function to load needs to be considered. It is critical to 
understand how physiological variables impinge on our understanding of RV strain.  
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4.2 Abstract 
Background: RVFWS is a feasible method for quantitation and follow-up of RV 
function, and may have benefits over traditional markers such as FAC. However, like 
all ejection phase parameters, RVFWS is challenging to assess in the presence of 
changing afterload. We sought to compare RVFWS and traditional RV function 
parameters for tracking the progress of RV function in PAH over a range of PASP. 
Methods: Sequential echocardiograms were collected retrospectively at two-time 
points between years 2005-2015 in 186 patients (71% female, 63±14 years) 
undergoing pulmonary vasodilator therapy for Group 1PAH. Patients were either 
studied during PAH therapy (n=111) or before and after treatment initiation (n=76). 
Standard measurements of RV and LV function and PASP were performed, and 
speckle tracking strain was used to calculate RVFWS. The linear response of RVFWS 
to afterload (PASP) was assessed with standard regression equation. As it is unclear if 
the response might be non-linear, a quadratic association (PASP squared) was included 
in the regression model.  
Results: At visit 1, PAH patients showed impaired functional capacity (6MWD 
371±131 meters), raised PASP (54±26 mmHg), and borderline RVFWS (18±6%). 
Patients before PAH therapy showed a more pronounced reduction in 6MWD 
(302±136) and RVFWS (16±5%). RVFWS at baseline was associated with PASP 
(R2=0.25, p=0.001), RVEDA (R2=0.36, p<0.001) and FAC (R2=0.21, p<0.001). 
Change in RVFWS was more strongly associated with ΔPASP (Std β-0.20, p=0.02) 
than ΔPASP squared (Std β 0.11, p=0.20). RVFWS showed strength over FAC for 
sequential RV assessment over a range of PASP changes.  
Conclusion: Afterload changes should be taken into account in the evaluation of 
RVFWS during PAH follow-up, with the relationship to PASP likely to be linear.  
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4.3 Background 
Following the invasive diagnosis of PAH (PAPm >25 mmHg, with a pulmonary artery 
capillary wedge pressure (PCWP) <15 mmHg) 133, the efficacy of pulmonary 
vasodilator treatment is assessed by echocardiographic estimation of PASP. 
Echocardiographic derived PASP has shown adequate correlation with RHC134) 
although some have questioned its reliability 31. Echocardiography continues to be 
recommended to assess treatment efficacy at 6-12 month intervals over long-term 
follow-up of treated patients.  However, although much attention is paid to following 
PASP, the most robust echocardiographic markers of outcome in PAH are right atrial 
size, and pericardial effusion, both of which are related to late-stage disease 94.  
There is increasing evidence of the importance of RV systolic markers in PAH 77. The 
measurement of right ventricular (RV) strain using speckle tracking echocardiography 
is feasible for the quantification of RV function in PAH 135-137, with RVFWS shown 
to predict clinical deterioration and mortality 78. However, despite the longstanding 
appreciation of the role of afterload in the assessment of RV function 138, and the load 
dependence of traditional RV functional indices in PAH 139, there has been little 
attention paid to the importance of afterload on RV strain. Sequential changes in RV 
strain are challenging to interpret in the follow-up of treated PAH patients due to 
fluctuations in PVR. In a clinical cohort, follow-up of patients taking pulmonary 
vasodilator therapy is a proposed method to track afterload changes over time. The 
RVFWS to afterload response is assumed to be linear. Invasive animal (with artificial 
creation of PAH through pulmonary artery banding 140) studies have found mixed 
results, with a linear association found, but only when the “severe” category is 
removed. The non-association of the “severe” category indicates a “quadratic” 
relationship with PASP having differing effects on RV strain at increasing afterload 
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levels. The quadratic relationship has implications about how we adjust for afterload. 
Statistically, this might be best represented by a quadratic equation, which is the 
dependent variable (PASP) squared. We hypothesised that RVFWS would be a strong 
echocardiographic marker to track the progress of RV function in PAH over a range 
of ΔPASP, with changes in RVFWS showing a linear relationship to ΔPASP.   
4.4 Methods 
4.4.1 Patient selection.  
Recruitment of patients with idiopathic PAH and CTD-related PH was from the 
Tasmanian Pulmonary Hypertension Registry (Hobart, Australia), and the Princess 
Alexandra Hospital (Brisbane, Australia) (Figure 4.1).  After the initial search, 206 
patients were identified, but five patients did not have adequate tricuspid regurgitation 
traces at either baseline or follow-up. A further 14 patients had poor strain images at 
baseline or follow-up, precluding the calculation of the change in the relevant 
parameters. Retrospective data collection occurred between years 2005-2015 in 186 
patients (71% female, 63±14 years) at two-time points (median time between scans 6 
months) during treatment with either endothelin receptor antagonists, 
phosphodiesterase-5 inhibitors, intravenous/inhaled prostacyclin analogs, or their 
combination, according to current guidelines  
There were two groups of patients, the first being treatment naïve (in whom the 
baseline echocardiogram was available before treatment and repeated on therapy; 
n=76), and the second on therapy, who had echocardiograms performed to assess 
treatment response (n=110). This design was selected to provide a spectrum of change 
in PASP – our interest was the relationship of RV function to PA pressure rather than 
the response to particular treatments. Ethics approval was obtained from the Human 
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Research Ethics committee (Tasmania) Network (approval number H0013333) and 
the Metro South Human Research Ethics Committee (HREC 16/QPAH/008).  
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Figure 4-1. Study flow chart, with patient exclusions. 
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4.4.2 Echocardiographic measurements.  
Echocardiography was performed using standard commercial equipment (GE Vivid 7, 
Vivid i and Vivid e9, Horten, Norway; Philips ie33, Bothell, WA). RV-focused views 
were obtained in addition to a standard imaging protocol. All measurements were 
performed by a single reader, using standard views. 
Speckle-tracking strain analysis. Wall motion tracking software (Image-Arena, 
TomTec Gmbh, Unterschleissheim, Germany) was used to analyse 2D 
echocardiographic images. The optimal image in which the whole RV cavity was 
visualised was selected from each study. The RV end-diastolic endocardial border was 
manually traced along the RV septal and RV free wall. These borders were then 
tracked automatically frame-by-frame throughout the cardiac cycle. Endocardial 
borders were manually adjusted when necessary, and regions excluded if excessive 
noise or poor tracking was present. RVFWS was calculated from an average of three 
segmental RVFWS traces.  
4.4.3 Right heart catheterisation.  
RHC studies were undertaken after premedication and local anesthesia. A 4-lumen 110 
cm 7-Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) was floated to 
the right heart, and resting measurements of right atrial, right ventricular, pulmonary 
arterial and PCWP were made at end-expiration using a pressure transducer (21BB, 
ITL Healthcare, Chelsea Heights, Australia). The transducer was calibrated to 
atmospheric pressure at the level of the RA and re-checked at intervals to avoid zero 
drift. CO was determined by thermodilution, using an average of four consecutive 
values that varied less than 10%. Electrocardiographic (ECG) leads were connected to 
both arms and the left leg, allowing three ECG channels for the timing of signals. All 
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haemodynamic monitoring was recorded using a Horizon SE Haemodynamic System 
(Mennen Medical Ltd., Yavne, Israel) and subsequently analysed off-line. 
4.4.4 Functional testing.  
A 6MW test was performed at the time of the echocardiogram by a research nurse. 
Testing occurred in a quiet hospital corridor and followed a standard protocol 110. 
4.4.5 Statistical analysis.  
Statistical analysis was performed using standard software (SPSS 20.0, IBM, Chicago, 
IL) with statistical significance set to p<0.05.  Calculation of the delta between visits 
was the final visit values subtracted from visit 1. The change between baseline and 
follow-up was then plotted using linear and quadratic regression models. To 
understand which model showed the strongest relationship between variables, the 
ΔPASP mmHg2 (for the quadratic model) was added using sequential linear regression 
model, to assess whether there was a significant reduction in the mean of the squared 
errors. A relative change in LV GLS of 10% has been defined as being clinically 
relevant 141, based on the reproducibility of strain. We, therefore, used cut-offs of the 
relative change of 10% for FAC (%) and RVFWS (%) to evaluate the relationship 
between ΔPASP (mmHg) and ΔRVFWS.  One-way ANOVA with Tukey HSD was 
used to compare groups. Actual ΔRVFWS was compared with predicted ΔRVFWS 
from linear and quadratic models. 20 patients were randomly selected for inter and 
intra-variability analysis. Readers were blinded to originally measurement results. 
Bland Altman plots were used to asses level of agreement between measures, with the 
intra class correlation used to determine the reliability of measures. ICC readings of 
<0.5 classify as poor, 0.5-0.75 as moderate, 0.75-0.90 good, and >0.9 as excellent142 
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4.5 Results 
4.5.1 Patient characteristics.  
Baseline demographic details (Table 4.1) were similar to other PAH cohorts (age 
63±14 years, 134 females (72%), with most patients having idiopathic PAH (52%) 
followed by CTD (36%). The majority of patients were treated with endothelin 
receptor antagonists (57%) or phosphodiesterase type-5 inhibitors (28%), and some 
participants on multiple therapies (14%).  
4.5.2 Associations of baseline measurements  
Baseline PASP (mmHg) was significantly related to 6MWD (r -0.37, p<0.001) and 
RV function (Table 4.2). 6MWD had a significant relationship with RV function and 
LV diastolic markers, but not LV EF.  
4.5.3 Baseline vs follow-up. 
 At visit 1, 76 patients had echocardiography available for analysis before initiation of 
medication, and another 110 had sequential echocardiograms performed on PAH 
therapy. Between baseline and follow-up (Table 4.3), there was a decrease in PASP 
and an improvement in RV strain, with no significant difference in 6MWD, LV 
systolic function or estimated LV filling pressures. In the subgroup studied before and 
after initiation of pulmonary vasodilators (Appendix Table 4.6), there were no 
significant improvements in 6MWD, but the intervention group displayed a borderline 
improvement in RVFWS (p=0.06), and pulmonary artery systolic pressure (p=0.02) 
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HR, Heart rate; BMI, body mass index; PAH, pulmonary arterial hypertension; COPD, chronic obstructive pulmonary disease; 
ERA, endothelin receptor antagonist; PDE5; phosphodiesterase type 5 inhibitor;   
4.5.4 Invasive measurements.  
A subset of patients (n=64) had invasive measurements performed at two-time points 
(Table 4.3).  PA pressure showed a significant reduction after therapy initiation, but 
there was no significant change in PCWP. At visit 1, the time difference between RHC 
and echocardiography was at a median interval of 0 days (interquartile range 167 
days), with invasive PASP and Doppler-derived PASP showing a moderate significant 
correlation (r=0.71, p<0.001). The inter-class correlation coefficient at visit 1 was 
0.71(0.59-0.79), p<0.001. At visit 2 median interval 0 days (mean 11±101.2) the inter-
class correlation coefficient was 0.67 (0.50-0.78), p<0.001, with a moderate 
correlation (r=0.67, p<0.001). Similar to echocardiographic measures, there were 
modest significant correlations with invasive markers and echocardiographic variables 
(Table 4.4). 
 Mean (SD) 
Age (years) 63±14 
HR (bpm) 76±14 
BMI 28.1±7.0 
Female (%) 134 (72%) 
PAH Subtype  
- Connective Tissue Disease 66 (35%) 
- Idiopathic PAH 97 (52%) 
- Congenital 8 (4%) 
- COPD 3 (2%) 
- Unclear 9 (5%) 
Treatment  
- Any ERA 139 (74%) 
- PDE 5 70 (37%) 
- Iloprost 9 (5%) 
Multi Therapy 26 (14%) 
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Table 4-2. Baseline associations of Doppler PASP and 6MWD 
 PASP 6MW 
 R P r p 
RVFWS (%) -0.45 <0.001 0.36 <0.001 
FAC (%) -0.45 <0.001 0.24 0.002 
RVEDA (cm2) -0.46 <0.001 -0.31 <0.001 
PAPs (invasive) 
(mmHg) 
0.53 <0.001 -0.15 0.18 
HR (bpm) -0.17 0.01 -0.14 0.08 
EF (%) 0.08 0.29 0.06 0.46 
e’ septal (cm/s) -0.35 <0.001 0.39 <0.001 
e’ lateral (cm/s) -0.18 0.02 0.45 <0.001 
E/e’ septal 0.005 0.95 -0.19 0.03 
E/e’ lat -0.09 0.26 -0.19 0.03 
BMI 0.03 0.69 -0.16 0.06 
 
RVFWS, right ventricular free wall strain; FAC, fractional area change; RVEDA, right ventricular end diastolic area; PAPs, 
pulmonary artery systolic pressure; HR, heart rate; EF, ejection fraction; BMI, body mass index 
4.5.5 Afterload dependence and RV function markers.  
The decrease in PASP over follow-up in the group as a whole was associated with 
changes in 6MWD (r=-0.26, p=0.003), RV function with RVFWS (r=-0.25, p=0.001), 
but not FAC (r=-0.12, p=0.10), and heart-rate (r=0.16, p=0.03). A regression equation 
was then developed to predicted ΔRVFWS from the linear regression model 
(ΔRVFWS =0.75+-0.06*ΔPASP). The quadratic regression was (ΔRVFWS = 0.60 + 
[-0.047 * ΔPASP] + [0.0007 * ΔPASP* ΔPASP]). Both of these regression lines are 
shown in Figure 4.2. Figure 4.3a shows the actual versus predicted ΔRVWFS (derived 
from the regression equation; ΔRVFWS = 0.99+[-
0.11*ΔPASP]+[0.0006*ΔPASP*ΔPASP]) for the entire group (r=0.26, p=0.001), 
Figure 4.3b shows those restricted to the treatment intervention group 
(r=0.44,p<0.001). 
Figure 4.3c shows the linear and actual plotted against each other for the whole group 
(r=0.25, p=0.001) and for the treatment intervention group (ΔRVFWS=1.12+[-
0.12*ΔPASP]) (r=0.44, p<0.001). When models based on ΔPASP and ΔPASP squared 
were compared, this showed the linear model to show the stronger association (Std β-
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0.20, p=0.02, vs. Std β 0.11, p=0.20).  ΔFAC showed no significant association for the 
linear or quadratic model (std β 0.12 p=0.10 vs. std β 0.14 p=0.34) (Figure 4.3c). 
Results were similar in a group restricted to pre and post-treatment only (std β-
0.24,p=0.09 vs. std β -0.10, p=0.49) (Figure 4.3d).  
Figure 4-1. Quadratic and linear regression models in all patients (left) and patients 
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Figure 4-2. Actual change in RVFWS versus predicted change based on change of RV 
afterload.  
 
The overall and pre (4.2a) - and post-treatment groups (4.2b) for the Quadratic model. 
Figure 4.2c and 4.2d shows the predicted change based on RV afterload for the linear 
model in the pre (4.2c) and post-treatment groups (4.2d). 
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Figure 4-3. ΔPASP and common ΔRV variables   
 
4.3a and those studies both pre and post treatment (4.3b) with both linear and 
quadratic regression lines. ΔFAC and ΔPASP for the whole group (4.3c) and 
restricted to pre and post-treatment (4.3d) with linear and quadratic regression. 
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Table 4-3. Baseline and follow-up* clinical and echocardiographic markers 
4.5.6 Differences in echocardiographic measurements.  
FAC change within 10% (n=48) showed a Doppler-derived PASP change of -4.1±12.2 
mmHg. In those showing 10% improvement of FAC (n=79), the mean ΔPASP was -
4.8±17.6, for those who FAC declined by >10% (n=65), mean change in PASP was -
2.2±16.2 mmHg (Figure 4.5a). There was no significant within-group change (p=0.62) 
(Figure 4.5b). For the RVFWS group who had a change within 10% (n=76), the PASP 
mean change was -4.4±14.6 mmHg. For those who improved RVFWS by 10% (n=72), 
mean PASP change was-6.7± mmHg. Finally, those who RVFWS who declined by 





Six-minute walk (m) 371±130.8 380±130.6 9.7±71.2 0.12 
Heart rate (bpm) 76±13.8 75±14.2 -0.7±12.0 0.42 
Left ventricle     
-Ejection fraction (%) 62±9.1 63±8.0 0.65±9.6 0.40 
-LVEDV (ml) 72.3±24.8 73.9±24.2 1.6±17.1 0.22 
-LVESV (ml) 27.9 ±13.2 28.2±12.3 0.35±10.2 0.64 
-LV diastolic dimension (cm2) 4.6±0.70 4.6±0.73 0.02±0.70 0.65 
-PW (cm) 0.96±0.34 0.94±0.16 -0.02±0.32 0.42 
- e’ septal (cm/s) 6.2±2.3 6.2±2.2 -0.04±1.8 0.83 
-E/e’ avg 10.8±4.8 11.6±6.2 0.8±5.1 0.07 
- E/e’ lateral 9.3±4.5 9.0±5.0 -0.22±3.6 0.50 
-E/e’ septal 12.4±6.2 13.8 ±7.0 0.04±1.8 0.01 
Right ventricle     
-Estimated PASP (RVSP+RAP, 
mmHg) 
53.8±25.8 50.2±24.7 -3.6±15.8 0.001 
- End-diastolic area (cm2) 21.4±8.4 21.6±8.3 -0.02±0.32 0.71 
- Fractional area change (%) 33.3±12.0 34.2±11.2 0.92±11.0 0.24 
-TAPSE (cm) 1.9±0.53 2.0±0.55 0.10±0.48 0.006 
-RVS’ (cm) (n=75) 9.7±2.9 9.5±3.2 -0.16±2.6 0.59 
- RVFWS (%) 18.0±5.7 18.9±5.4 0.94±3.9 0.001 
-IVC (cm) 1.7±0.81 1.5±0.85 -0.2±0.93 0.002 
-RVFWS/PASP 0.44±0.30 0.49±0.31 -0.05±0.19 <0.001 
Invasive pressures     
- PAPs (n=58) 79.9±20.5 66.2±19.9 -3.7±14.7 0.06 
- PAPm (n=64) 43.8±13.1 40.2±13.2 -3.5±10.3 0.008 
- PCWP (n=58) 12.3±6.0 11.8±4.6 -0.57±6.1 0.48 
LVEDV, left ventricular end diastolic volume; LV ESV, left ventricular end systolic volume; PW posterior wall; PASP, pulmonary artery 
systolic pressure; RVSP, right ventricular systolic pressure, RAP, right atrial pressure; TAPSE, tricuspid annular plane systolic excursion; 
RVS’, right ventricular systolic peak velocity; Right ventricular free wall strain; IVC, inferior vena cava; PAPs, pulmonary artery peak 
systolic pressure; PAPm, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure.    
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10% (n=38) the mean change in PASP was 3.5±12.4mmHg. The between-group 
differences were highly significant (p=0.007).  
In 61 patients with a TAPSE change <10% the mean change in echocardiographic 
PASP was -2.3±13.0 mmHg, compared with 36 with a >10% reduction (n=36) in 
whom the mean ΔPASP was -5.2±20.3 mmHg. In 80 patients with a >10% 
improvement in TAPSE, the mean ΔPASP was -2.3±14.0 mmHg. There was no 
significant difference between groups (p=0.59). 
Table 4-4. Association of invasive PASP with echocardiographic variables 
 Invasive PASP baseline visit 1 Invasive PASP visit 2 
 R P r P  
RVWFS (%) -0.32 0.001 -0.23 0.08 
FAC (%) -0.17 0.19 -0.28 0.03 
RVEDA (cm2) -0.26 0.01 0.29 0.02 
TAPSE (cm) -0.32 0.002 -0.24 0.06 
PASP (mmHg) 0.71 <0.001 0.67 <0.001 
RVFWS, Right ventricular free wall strain; FAC, fractional area change, RVEDA, right ventricular end diastolic area; TAPSE, tricuspid 
annular plane systolic excursion; PASP, pulmonary artery systolic pressure  
 
4.5.7 Predictors of change in RV function.  
The associations of the response of RV function to change in PASP, independent of 
age, sex, HR and PAH therapy, are shown in Table 4.5. ΔPASP was the strongest 
predictor of ΔRVFWS (Std β -0.24, p=0.001), independent of whether there was 
initiation of therapy between baseline and follow-up. There was no significant 
relationship between ΔPASP and ΔFAC (r=-0.1, p=0.09), in either the treated or 
untreated group (treated  Std β -0.07, p=0.48 versus untreated Std β 0.19, p=0.11).  
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Table 4-5.Independent associations of the response of RV function (RVFWS) to 
change in PASP (R2=0.09, p=0.007 
 Std β (95%CI) P 
Age 0.03(-0.03;0.05) 0.73 
Sex -0.03(-1.5;1.0) 0.67 
HR -0.09(-0.07;0.02) 0.20 
PAH therapy 0.14(-0.003;2.3) 0.05 
ΔEcho PASP -0.24(-0.09;-0.02) 0.001 
HR, heart rate; PAH, pulmonary arterial hypertension, PASP, pulmonary artery systolic pressure 
4.5.8 Intra- and inter-observer variability.  
The intra-observer variability for RVFWS showed an intra-class correlation 
coefficient of 0.73 (95% CI 0.44-0.88, p<0.001), and a mean difference of 1.3±3.2%. 
The inter-observer variability showed an intra-class correlation coefficient of 0.62 
(95% CI 0.26-0.83, p<0.001, mean difference of 4.5±4.7%. 
4.6 Discussion 
This study shows that there is a highly significant correlation between ΔRVFWS and 
ΔPASP. Over the modest range of ΔPASP, this relationship appears linear. RV FWS 
appears to have superiority over traditional RV function measures when tracking 
patients during variations in PASP.  
4.6.1 Afterload and RV function measurement.  
The impact of afterload changes on the measurement of RV systolic function is 
routinely overlooked. In general, a pressure load on the RV is less tolerated than a 
volume load 143. Volume load toleration is well-exemplified in the preservation of RV 
function in tricuspid regurgitation. Remarkable differences between LV and RV 
physiology preclude the use of the same assumptions about afterload-dependence 144. 
The RV has an intrinsically different mechanical function to the LV, with lower 
afterload 145 and a substantial proportion of systolic function occurring in the 
longitudinal plane 146. Differences between LV and RV are readily apparent from a 
comparison of RV pressure-volume loops 147, with the myocardial response of the LV 
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148. An animal model showed a linear association of increasing RV pressure on RV 
circumferential strain, but only when the severe category was removed 140. There was 
no significant change in RVFWS & RV FAC at increasing degrees of pulmonary artery 
banding 140. It is possible that among “normal” variations of PASP, the response may 
be linear, but after a specified increase is reached, this relationship increases 
exponentially, as would be best represented with a quadratic model. Although, this 
does not appear to occur throughout ranges generally encountered during the clinical 
follow-up of PAH patients.  
This study used PASP as the sole measure of RV afterload. In reality, a number of 
facets influence the RV response to afterload. These include resistance from the 
pulmonary valve, wave reflections in the main pulmonary artery and early bifurcations 
as well as impedance of the proximal pulmonary arteries and arterioles 149,150. In an 
animal model, proximal PA pressure loading caused greater diastolic dysfunction than 
increased peripheral resistance 151. Wall stress itself has many different components;  
resistance to blood flow during steady state, compliance of the vascular system, arterial 
wave reflections and inertia of blood during ejection 152. 
A number of caveats need consideration during patient follow-up with 
echocardiography. There is not only the variability that exists in the measurement of 
Doppler-derived PASP but also individual variation in the degree of RV structural 
remodelling. RV remodelling occurs after prolonged exposure to afterload 153, but 
there are differences in this process in PAH and congenital heart disease. Changes in 
RV function at increasing afterloads are maintained through structural remodelling, as 
opposed to modifying myocardial function 153.  
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Figure 4-4. Degree of change in RV systolic function variables, and relation with ΔPASP  
 
4.4a shows participants within 10% FAC change; FAC increased by >10% or FAC reduced by 10% and the mean PASP for each group. 
Figure 4.4b shows ΔRVFWS groups and corresponding PASP changes. 4.4c shows ΔRVFWS with 15% cut off ranges
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Variability impacts the utility of 2D-derived RV FAC as a tool for longitudinal follow-
up, as this measure of RV systolic function is based on RV cavity size. RV FWS and 
TAPSE may, therefore, have benefits over this method. Minor degrees of RV recovery 
are shown after initiation of sildenafil to bosentan therapy 154 over a 12 month period. 
Invasive procedures such as pulmonary artery endarterectomy and lung transplantation 
provide evidence that the RV has capacity to remodel over short periods after dramatic 
afterload changes155. The six month period chosen in this study eliminates some of the 
variations produced by RV reverse remodelling.  The chronicity of afterload elevation 
is also important, with acute changes (such as pulmonary embolism) leading to RV 
enlargement and RV decompensation. The amount of remodelling that has occurred 
within the ventricle, before afterload increases, affects the ability of the RV to maintain 
function through heterometric autoregulation 156 
After combined efforts from industry and academia, the concordance of speckle 
tracking echocardiography strain has improved 157, and may even be superior to 
traditional 2D echocardiographic measures. The performance of vendor independent 
software, which can be used to measure retrospective data using DICOM images at 
frame rates of >30 frames/second, has been shown to be acceptable for strain analysis 
158, as well as providing results comparable to online software 157. Velocity vector 
imaging is based on speckle tracking echocardiography, and angle dependence (which 
was a limitation of previous tissue Doppler-based techniques), is not an issue. 
The ability to define RV function in the presence of altered loading conditions may 
help the successful application of echocardiography to track RV status. This response 
has not been accurately defined in the past, with pulmonary artery constriction studies 
showing mixed results in the linear association of PASP to RVFWS 140,159.  
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4.6.2 Clinical implications.  
Outcome studies have shown the importance of RV function in determining outcome 
in PAH. Routine studies of RV function and PASP are required when tracking 
therapeutic response in patients. RV systolic function is a significant predictor of 
patient outcome, but interpretation needs to consider changes in afterload. Perhaps the 
two most common situations of changing pulmonary afterload are in the evaluation of 
patients undergoing pulmonary vasodilator therapy, and in post-cardiopulmonary 
bypass patients, where PH may be transient.  
The results of this study show that changes in RV afterload have a modest impact on 
changes in RV function and that this is linear within commonly observed changes in 
pulmonary artery systolic pressure with pulmonary vasodilator treatment afterload 160. 
These considerations are essential because longitudinal measurements of RV function 
and dynamic changes in afterload can influence clinical management. 
4.6.3 Study limitations.  
The number of studies in which patients displayed a significant change in afterload 
was limited. The original studies did not include assessment of tricuspid annular e’ or 
isovolumic acceleration (which is afterload independent), which could have 
strengthened the assessment of the RV-PASP relationship. Patient clinical status and 
etiology of PAH are possible confounding factors. A prospective longitudinal study 
design, with simultaneous RHC and echocardiography, would have been an ideal study 
design. Nonetheless, a 6-12 month follow-up time would still be desirable as this 
period is the one that is usually used to assess response to pulmonary vasodilator 
therapy, and therefore corresponds to the clinical question about the afterload-
dependence of RV change. Use of a more extended timeframe would also increase the 
likelihood of confounding by RV remodelling. 
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4.7 Conclusions.  
RVFWS is superior to FAC for tracking RV response to changes in PASP. The linear 
association of RVFWS with RV afterload has significant implications for the 
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4.8 Postscript 
As discussed in the previous chapter, afterload and sequential follow up are 
intrinsically linked when quantifying RV systolic function. As studied from a PAH 
cohort afterload entails a lasting impact on the heart. Patients with adult congenital 
heart disease constitute a well-defined cohort with chronically increased afterload 
and have a different outcome than idiopathic PAH161. Registry outcome data 
primarily focus on clinical variables and traditional 2D markers. RV free wall strain 
is measurable retrospectively but requires adequate imaging of the RV free wall and 
access to specialised imaging software. For this reason, our data set is unique and 
adds significantly to current literature. In Australia, unless symptom status changes, 
patients are routinely follow up with echocardiography.  Limited data were available 
on sequential right heart catherisation and echocardiography thus were unable to 
validate findings with an invasive cohort.  
Aside from this, presentations of afterload stress can also occur acutely, primarily, as 
an acute pulmonary embolism. A pulmonary embolism is associated with high 
morbidity and mortality rates162. Generally, this group presents with raised afterload, 
with the insult primarily occurring to a healthy myocardium (one that has not been 
exposed to chronically increased afterload). As the RV is not accustomed to this 
increment of pulmonary pressure, its response involves increases in RV size, and 
reductions in systolic function, despite the lower levels of PASP as compared to 
chronic PAH. Speckle tracking is an underutilised tool for RV tissue characterisation, 
which could be helpful in this acute clinical setting.  
We have evaluated the effect of afterload on RV strain, in the next chapter we will 
address chronicity of afterload 
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4.9 Appendix 
Table 4-6. Baseline and follow-up clinical and echocardiographic findings in 
patients on treatment 
Variable Visit 1  Visit 2 Delta p 
Six-minute walk (m) 302±135.7 315±139.8 12.6±50.0 0.39 
Heart rate (bpm) 77±14.3 77±17.2 0.41±14.9 0.81 
Left ventricle         
-Ejection fraction (%) 62±9.9 63±7.4 1.0±9.9 0.42 
-LVEDV 71.7±25.3 75.1±25.3 3.3±18.4 0.12 
-LV diastolic dimension (cm) 4.4±0.74 4.4±0.83 0.04±1.0 0.70 
-PW (cm) 1.0±0.50 0.97±0.17 -0.06±0.48 0.23 
- e’ septal (cm/s) 5.3±1.8 5.6±2.4 0.30±1.8 0.25 
-E/e’ 10.7±5.0 12.8±8.4 2.02±6.8 0.03 
-E/e’ septal 12.3±6.0 14.9±8.7 0.30±1.8 0.02 
-E/e’ lat 9.2±5.1 9.7±6.2 0.54±4.0 0.34 
Right ventricle         
- Estimated PASP 
(RVSP+RAP, mmHg) 
60±23.3 55.5±23.0 -4.6±17.0 0.02 
- End-diastolic area (cm2) 24.2±8.2 23.6±7.7 -0.63±6.1 0.37 
- Fractional area change (%) 29.5±13.5 30.2±12.0 0.70±12.1 0.62 
- RVFWS (%) 15.5±5.3 17.1±5.3 1.65±4.7 0.003 
-RVFWS/PASP 0.31±0.19 0.38±0.21 -0.06±0.18 0.003 
LVEDV, left ventricular end diastolic volume; PW, posterior wall; PASP, pulmonary artery systolic pressure; RVSP, right 
ventricular systolic pressure; RAP, right atrial pressure; RVFWS, right ventricular free wall strain;  
 
 





Acute versus chronic afterload increase 
and the RV myocardium 
 
 
Article “Right Ventricular Systolic Function Responses to Acute and 
Chronic Pulmonary Hypertension: Assessment with Myocardial 
Deformation” accepted for publication in March 2016  
Journal of the American Society of Echocardiography 
 
Wright L, Dwyer N, Power J, Kritharides L, Celermajer D, Marwick TH. 
  
Chapter 5.  Acute versus chronic afterload increase and the RV myocardium 94 
5 Acute vs chronic afterload increases and the RV 
myocardium 
 
5.1 Preface  
The interaction between afterload and systolic contraction underpins our 
understanding of cardiac function. Increases in afterload can arise from varying 
clinical conditions. There are frequent delays in the diagnosis of PAH, due to the non-
specificity of symptoms, as well as failure to recognise due to its rarity, so patients 
may not be started on afterload reducing therapy until late in the disease course. 
Substantial remodelling is often present at the initial imaging visit. This remodelling 
is manifest by a dilated RV, with reduced systolic function.  
A rapid increase in afterload may occur during an acute pulmonary embolism, leading 
to acute RV dilation, and significant reduction of systolic function. As the right 
ventricular pressure increases, the shape of the pressure-volume loop alters and tends 
to resemble the LV, with maximal elastance (Emax) occurring at end-systolic pressure 
(ESP).  
The morphology of the RV is similar in acute versus chronic RV afterload with 
significant RV dilatation present. The question is how the reasons for afterload 
increase affects the RV function. Prior methods of right ventricular assessment using 
2D ultrasound can be hampered by the crescentic shape of the RV, or by translational 
motion. In patients with chronic pressure overload, speckle tracking may aid with the 
differential diagnosis.  
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5.2 Abstract 
Background: The distinction between right ventricular (RV) dysfunction due to an 
acute etiology (pulmonary embolism, PE) or chronic afterload (pulmonary arterial 
hypertension, PAH) has significant therapeutic implications. We hypothesised that RV 
remodelling would alter RVFWS and differentiate chronic from acute RV afterload.  
Methods. In this retrospective study, PE patients (n=45) with echocardiography within 
48 hours of computed tomography pulmonary angiography were matched 1:1 for age, 
gender and PASP with PAH patients (n=45), and a larger un-matched PAH control 
group (n=116). RV function was evaluated with RVEDA, FAC, and RVFWS by 2D 
speckle-tracking. The ability of RVFWS to distinguish acute versus chronic RV 
dysfunction was assessed using receiver operating characteristic curves (ROC), and its 
incremental value sought with stepwise models. 
Results. RVEDA, FAC and RVFWS were significantly impaired in PE (p<0.001) with 
no significant differences in other clinical variables. In matched patients, ROC analysis 
revealed RVFWS had a significantly better discriminative power than the McConnell 
sign (p=0.02), with a cut-off of -17.9%, sensitivity 87.5%, specificity 62.5%, AUC 
0.76. Sequential logistic regression demonstrated an incremental and independent 
benefit of using RVFWS to predict acute PE versus chronic PAH (p=0.01). Interclass  
concordance was superior in RVFWS compared to FAC (p<0.01).   
Conclusions: RVFWS is more predictive than RVEDA and less variable than FAC in 
distinguishing acute from chronic RV pressure overload. RVFWS adds incremental 
and independent information to standard measures of RV function in assessing the 
acuity of PH. 
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5.3 Background 
The distinction between pulmonary embolism (PE) and chronic PAH may have 
significant therapeutic implications. Although right ventricular (RV) function and size 
are important prognostic markers in both patients with PE 163 and chronic PAH,69,73 
RV function may differ between these entities. In chronic pressure overload, the 
myocardium can adapt and remodel to compensate and maintain CO164 evidenced by 
previous experimental models using pulmonary artery banding.165 In contrast, the RV 
myocardium has limited time to increase contractility in acute pressure overload, 
resulting in RV dilation and impaired function.  
The distinction between these causes might be facilitated by a technique which can 
quantify RV dysfunction, to the degree that has not been feasible with standard 
imaging.166 This information is not readily gathered from computed tomographic 
pulmonary angiography (CTPA). PA systolic pressure (PASP) will only increase if 
>30-50% of the pulmonary artery bed is occluded,167 and generally, 
echocardiography has limited value in submassive PE(negative predictive value of 
40-50%). Historically, subjective markers (such as the McConnell sign, the  “apical 
sparing” in the RV) have been used to diagnose acute pulmonary embolism,168 but 
this is limited by a sensitivity of 70% and specificity of 33%.169 Strain imaging using 
speckle tracking of the RV free wall (RVFWS) is an emerging technique to measure 
myocardial deformation, which has been validated using sonomicrometry,159 and is 
now readily available –  on most echocardiography machines, even at the bedside 
allowing clinical utility. Previous work has shown the ability of RVFWS to identify 
RV dysfunction in PAH.136 However, the load dependency of functional 
measurements can complicate the evaluation of systolic dysfunction.138 We sought to 
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determine whether RV global and regional strain could be used in a clinical context 
to differentiate acute versus chronic increases in RV afterload 
5.4 .Methods 
5.4.1 Study design.  
In this cross-sectional study of RV function, patients with acute PE were compared 
with control patients with PAH. Patients with acute PE (n=45) were retrospectively 
identified from administrative records and were eligible for the study if 
echocardiography was performed within 48 hours of computed tomography 
pulmonary angiogram. These patients were anticoagulated; none underwent 
thrombolysis. Most were haemodynamically stable, although two had documented 
systolic blood pressure <90 mmHg. Patients with documented CTEPH were excluded. 
Control patients were obtained from a chronic PAH registry cohort from the Royal 
Hobart and Launceston General Hospitals between years 2005-2013 with diagnosis 
through RHC. Patients were treated with an endothelin receptor antagonist, a 
phosphodiesterase-5 inhibitor, intravenous/inhaled prostacyclin analogues, or their 
combination, in accordance with current guidelines. The primary control group 
comprised of PAH patients matched for age, gender and PASP (as derived from 
transthoracic echocardiography, TTE) (n=45). As matching is rarely perfect, an 
unmatched group from the same patient cohort (n=116) was run as a sensitivity 
analysis. 
5.4.2 Standard echocardiography. 
 Studies were performed on commercially available GE (Vivid E9, Vivid 7 and Vivid 
I, General Electric, Milwaukee, WI) and Philips (IE33 and EPIQ, Philips, Andover, 
MA) equipment. The acquisition followed a standard protocol, including RV-focused 
views, and measurement of pulsed-wave Doppler of the RV outflow tract for 
estimation of PVR.166. Full details are provided in the methods section (3.0) 
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5.4.3 Speckle tracking strain analysis.  
RVFWS was performed from an apical RV focused view, using speckle tracking 
(Image arena, Tomtec, Unterschlessheim, Germany).  
5.4.4 Statistics.  
Data were assessed for normality using the Shapiro-Wilk W test and transformed if 
necessary. For PVR values the “linear trend at point” method was used for missing 
data. Patients were placed into equal tertiles for PVR due to inability to normalise. 
Comparison of patients and controls was performed by matching 1:1 for age, gender, 
and PASP, as well as the inclusion of all controls into statistical models. Acuity of 
afterload increase was assessed as a binary variable (PAH versus PE). Associations of 
RV systolic function were determined using univariable and multivariable logistic 
regression. Anticipated associations were placed into the model (age, sex, gender and 
PASP). The incremental benefit was assessed by comparing the global chi-square 
value for each model.  Receiver operating characteristic (ROC) curves were created to 
determine the diagnostic ability of RV functional measurements to distinguish those 
with and without acute increases in RV afterload with an area under the curve (AUC) 
calculated. Cut-off values were obtained using the Youden index. Inter-operator 
variability was performed in both the chronic PAH (n=30) and pulmonary embolism 
(n=25) studies. Variability studies were randomly selected, with the second reader not 
aware of reader 1’s results, or which cardiac cycle and image window were measured.  
Bland Altman analysis was used to assess the mean difference and limits of agreement, 
and the intra-class correlation coefficient was calculated.  
5.5 Results 
5.5.1 Patient characteristics 
Patients in the PAH group were divided into 81 (50%) with idiopathic PAH, 68 (42%) 
with CTD-related PAH, 7 with congenital heart disease (3%), 4 with chronic 
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obstructive pulmonary disease (2.5%) and 1 with Porto-pulmonary hypertension 
(0.6%) (Table 5.1). The primary clinical differences between PE and the PHT controls 
were in BMI, HR, SBP and renal function. AF was present in 4 of the PE cohort (9%) 
and 5 in the PAH group (3%). The severity of tricuspid regurgitation in PAH patients 
was mild in 119 (74%), moderate in 27 (17%), and severe in 15 (9%).  
5.5.2 Echocardiography  
Comparison between PE and controls showed differences in echo estimated PVR 
(higher in PE) and all RV function indices (reduced in PE) (Table 5.1). RV size 
(RVEDA) was increased in PE patients. Figure 5.1 shows the pattern of right 
ventricular regional strain. LV EF showed a significant difference with the matched 
group (59±10% vs. 64±7, p=0.03). Diastolic function between groups was similar.  
 
 
Figure 5-1. Strain patterns of the segments and whole right ventricular free wall in PAH 
compared in PE. Strain is consistently impaired in the PE than the PAH patients. 
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Table 5-1. Clinical characteristics of PE patients, matched and unmatched PHT 
controls 
 Matched  
Variable PE (n=45) PAH (n=45) P value 
Age 64±15 62±13 0.57 
Sex (F) 69% 69%  
BMI 34.5±8.3 28.5±9.1 0.01 
SBP 115±32 126±18 0.09 
DBP 69±19 69±8 0.90 
HR (bpm)  92±16 71±12 <0.001 
eGFR 58±17 66±15 0.07 
BUN 7.7±3.6 6.7±2.9 0.24 
Creatinine 97±36 83±27 0.06 
PASP (mmHg) 48.2±18.2 46.3±17.1 0.61 
PVR (W.u.) 4.1±1.7 2.9±.90 0.001 
EF% 59±10 64±7 0.03 
E/e’ 10±4 11±5 0.29 
Basal RV FWS (%) -17.4±8.6 -22.8±7.6 0.002 
Mid RV FWS (%) -13.1±8.4 -19.6±4.7 <0.001 
Apical RV FWS (%) -10.3±5.4 -14.4±8.3 <0.007 
RV FWS (%) -13.6±5.7 -19.6±4.7 <0.001 
FAC (%) 25.6±11.8 37.7±11.8 <0.001 
RVEDA (cm2) 24.8±6.1 21.02±7.1 0.01 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; eGFR, 
estimated Glomerular Filtration Rate; BUN, blood urea nitrogen; PASP, pulmonary artery systolic pressure; PVR, 
pulmonary vascular resistance; EF, ejection fraction; RV, right ventricle; FWS, free wall strain; FAC, fractional 
area change; RVEDA, right ventricle end diastolic area 
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5.5.3 McConnell sign.  
Both PE and PAH groups were evaluated for the presence of the McConnell sign. This 
sign was identified in 41 patients, 18 (40%) with PE and 23 (14%) of PAH (Table 
5.2). Generally, those presenting with the McConnell sign had higher HR, PVR, lower 
RVFWS, higher RVEDA, and lower FAC. Figure 5.2 shows the regional variation in 
strain between positive and negative McConnell sign patients. We created a ratio of 
RV free wall basal-mid/ apical free wall ratio (RV apex/[average basal + mid]*100). 
Patients who demonstrated the McConnell sign showed similar RV apical strain 
compared to those without this sign (59±54% vs 52±36%, p=0.27), with the same 
finding when restricted to PE patients (64±78% vs 47±25%, p=0.33). The RV strain 
showed the same pattern of reduction from base to apex, irrespective of afterload. 
Figure5-2.Positive McConnell versus negative McConnell sign and regional strain 
patterns. 
 
5.5.4 RV longitudinal function.  
RVFWS was significantly decreased in the PE as compared to the unmatched 
(p<0.001), and the matched groups (p<0.001). This pattern was noted in all segments 
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of the RV free wall, with highly significant differences between the basal, mid and 
apical segments (p<0.001). 
Table 5-2. . Clinical characteristics of positive versus negative McConnell sign 
HR, heart rate; PASP, pulmonary artery systolic pressure; EF, Ejection fraction; PVR, pulmonary vascular; 
RVFWS right ventricle free wall strain; RVEDA, right ventricle end diastolic area; FAC, fractional area change.  
 
The associations of RV dysfunction are shown in Table 5.3. Univariable analysis 
showed that age, sex, PASP, acuity of afterload, RVEDA and PVR were significantly 
associated with RVFWS. In multivariable models, even when taking into account 
PASP, acuity of afterload was still significantly associated with RV strain (OR -5.7 
[95% CI:-7.4 to 4.0, p<0.001]). When PVR replaced PASP, this association still held 
true (OR -4.4 (95% CI: -6.0 to 2.1, p<0.001). 
Variable Positive Negative p 
HR 89±19.5 76±13.2 <0.001 
PASP (mmHg) 53.9±21 46.8±22.5 0.07 
EF 61±8.8 65±9.6 0.07 
e’ 6.0±1.8 6.8±2.3 0.13 
E/e’ 12.5±7.2 11.6±4.8 0.45 
PVR 4.3±2.3 3.2±1.4 0.007 
Basal RVFWS (%) -17.3±8.3 -22.3±8.4 0.001 
Mid RVFWS (%) -15.3±9.9 -19.8±7.4 0.009 
Apical RVFWS (%) -12.9±8.4 -14.8±8.2 0.18 
RVFWS (%) -15.2±7.5 -19.0±5.5 0.004 
RVEDA 24.2±7.0 20.0±7.1± 0.001 
FAC 27.4±10.9 36.2±11.2 <0.001 
RV apical-/mid ratio 59.4±54.2 51.6±36.4 0.27 
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Acuity remained a significant association of GLS when RVEDA was taken into 
account (OR-3.9 [95% CI: -5.7 to 2.2], p<0.001).  
The incremental value of each factor for discrimination of acuity using sequential 
logistic regression is shown in a series of models in Table 5.4. Using standard clinical 
predictors, HR, PASP and RVEDA were significantly associated with acuity (model 
X2=60.5, p<0.001). The addition of PVR did not significantly increase the association 
(X2=63.0, p=0.12), and PVR itself was not significant in the model (OR 0.80 [0.60-
1.06), p=0.12). However, the addition of RVFWS was significant (p<0.001), and 
significantly increased the strength of the model (X2 70, p=0.008).  
5.5.5 The validity of RV function markers over a spectrum of 
measurements.  
The diagnostic strength of different RV systolic function parameters may depend on 
the magnitude of RV failure. ROC analysis was performed, with groups divided based 
on quantification of RV systolic function; Group 1 contained those with mildly 
reduced/normal FAC values (>35%)101, whereas group 2 contained those with 
moderate/severely reduced FAC (Figure 5a and b). If FAC is normal, discriminative 
power between variables is poor (Table 5.5a). When RV systolic function is at least 
moderately reduced, RVFWS retains its predictive ability (AUC 0.77). A second 
analysis was performed, with groups created based on RVFWS values (Normal/mildly 
reduced<-20% 101 or moderate/severely RVFWS). Similar results are seen, with 
RVFWS the most reliable predictor (AUC .69) (Table 5.5b), although some diagnostic 
strength is lost.  
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Table 5-3. Associations of right ventricular longitudinal strain (standardised OR) 
 Univariable PASP model  PVR model RVEDA 
Variable OR(95% CI)  P  OR(95% CI)  P  OR(95% CI)  P  OR(95% CI)  P  
Age (yrs) -0.06 (-0.12, -0.003) 0.04 -0.06 (-0.11, -0.01) 0.01 -0.05 (-0.10, -0.002) 0.06 -0.06 (-0.11, -0.01) 0.01 
Sex 2.10 (0.21, 3.99) 0.030 1.50 (-0.06, 3.07) 0.06 1.85 (0.27, -3.44) 0.02 0.37 (-1.27, 2.01) 0.66 
PASP (mmHg) 0.12 (0.08, 0.15) <0.001 0.11 (0.08, 0.15) <0.001         
PE (vs PAH) -5.7 (-7.61 to -0.38) <0.001 -5.7 (-7.4, -4.0) <0.001 -4.4  (-6.1, -2.1) <0.001 -3.9 (-5.7,  -2.15) <0.00
1 
RVEDA (cm2)  0.45 (0.35, 0.56) <0.001      0.38 (0.28, 0.49) <0.00
1 
PVR 1.81 (1.35, 2.27) <0.001    1.49 (1.04, 1.93) <0.001   
PASP, Pulmonary artery systolic pressure; PE, pulmonary embolism; PAH, pulmonary arterial hypertension; RVEDA, right ventricular end diastolic area; PVR, 
pulmonary vascular resistance. 
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Table 5-4.  Incremental and independent value of RV free wall strain for acute vs. chronic afterload 
 Model  1  
Global X2 60.5  
(p<0.001) 
Model 2  (+PVR) 
Global X2 63.0 (p<0.001)  
Increment p=0.12 
Model 3 (+RVGLS) 
Global X2 70.0 (p<0.001)  
Increment p=0.008 
 
  OR p OR p OR p 
HR(bpm) 0.92 (0.89-0.95) <0.001 0.92 (0.89-0.95) <0.001 0.93 (0.90-0.97) <0.001 
Age (yrs) 0.99 (0.95-1.01) 0.159 0.97 (0.94-1.01) 0.12 0.97 (0.93-1.00) 0.05 
Sex 1.74 (0.67-4.52) 0.252 1.69 (0.64-4.45) 0.29 1.87 (0.70-5.05) 0.214 
PASP (mmHg) 1.04 (1.02-1.07) 0.002 1.05 (1.02-1.08) 0.001 1.05 (1.02-1.09) 0.001 
RVEDA (cm2) 0.88 (0.81-0.94) <0.001 0.88 (0.81-0.94) <0.001 0.90 (0.83-0.97) 0.01 
PVR   0.80 (0.60-1.06) 0.12 0.86 (0.64-1.15) 0.29 
RVFWS     0.89 (0.81-0.97) 0.01 
PASP, pulmonary artery systolic pressure; PE, pulmonary embolism; PAH, pulmonary arterial hypertension; RVEDA, right ventricular end diastolic area; PVR, 
pulmonary vascular resistance; RVFWS, right ventricular free wall strain.  
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5.5.6 Comparison of RVFWS with standard echo for prediction of acuity.   
ROC curves were used to evaluate the diagnostic potential of RV functional measurements to 
differentiate chronic from acute pressure overload (Figure 5.3).  
Table 5.5 summarises the AUC, cut-offs, sensitivity and specificity of RVS, RVEDS, FAC and 
PVR. RV strain was similar to FAC, PVR, RVEDA, for the distinction between PE and chronic 
PAH. RVFWS was significantly better than McConnell sign (p=0.016) and PASP (p<0.001) 














RVFWS (green) showed significantly greater discriminative power than the McConnell sign 
(yellow) (p=0.016), or PASP (blue) (p<0.001) 
 
Figure 5-3. ROC curves for prediction of acute versus chronic increase in afterload 
 
Chapter 6.  Determinants of Change in Functional Capacity 107 
Table 5-5. The diagnostic ability of RV measurements to predict acuity of pulmonary 
hypertension 
RVEDA, right ventricular end diastolic area; FAC, fractional area change, PVR, pulmonary vascular resistance; 
PVR, pulmonary vascular resistance; PASP, pulmonary artery systolic pressure. 
5.5.7 Combination of parameters.  
To evaluate the combined effect of RVFWS and FAC, four groups were created, combining 
RV systolic function markers. Groups were split into median values for FAC (FAC< 34% vs 
FAC >34%); and RVFWS (RVFWS<18%, RVFWS >18%). 
Most PE patients fell into groups 3 and 4 (RV strain abnormality the predominant feature). 
Interestingly, the PAH group had higher FAC in group 4, despite higher PASP.  
Also, patients were split into two groups: normal RV strain (irrespective of FAC being normal 
or abnormal) and abnormal RV strain (irrespective of FAC being normal or abnormal).  
In group 1 (RVFWS preserved), only FAC showed a difference between PE and PAH. PAH 
patients in Group 2 (RVFWS reduced) maintained higher FAC values (31.5±11.4 vs 
24.2±10.5%, p=0.001) and significantly higher PASP (61.3±27.4 vs 50.3±17.7, p=0.015) 
(Table 5.6) than those with acute afterload increases.  
Variable Cut off Sensitivity Specificity AUC p (vs RVFWS) 
RV free wall strain -17.9 88% 63% 0.76  
RVEDA 18.7 88% 55% 0.70 0.21 
FAC 26.3 63% 85% 0.74 0.55 
PVR 3.34 90% 53% 0.72 0.33 
PASP 32.5 80% 32% 0.54 <0.001 
McConnell Sign  45% 86% 0.65 0.02 
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Table 5-6. The relationship between the diagnostic strength of different RV systolic function 
parameters and the magnitude of RV failure 
 
 
In a series of ROC analyses, separation by FAC (Table 5.6a) or RVFWS (Table 5.6b) showed that if RV function 
was normal, discriminative power of the variables was poor.  
Table 5.6 shows the results. On the basis of RV strain abnormality being the predominant 
feature, most PE patients fell into groups 3 and 4. Interestingly, the PAH group had improved 
FAC (25.3±8.0 vs 19.2±6.4), p=0.001) in group 4, despite higher PASP (65.5±23.3 vs 50±18.2 
mmHg, p=0.006).  
Finally, groups were split into two groups, based on FAC values being above or below the 
group median.: 
 Group 1: FAC strain normal, RVFWS normal/abnormal 
 Group 2: FAC strain abnormal, RVFWS normal/ abnormal 
In the normal FAC group, PE patients displayed significantly lower RVFWS (21.4±4.5 vs 
16.8±6.7%, p=0.04) at similar FAC values, with no significant difference in PASP (41.3±19.2 
vs 48.5±16.8% mmHg, p=0.19). In group 2 (FAC values below median), PE patients displayed 
significantly worse RVFWS (16.5±6.2 vs. 12.5±4.8%, p=0.001), FAC (26.7±7.0 vs 19.7±6.6%, 
Table 5.6 FAC normal/mild FAC abnormal 
Variable AUC 
 
95% CI p AUC 
 
95%CI p 
FAC 0.54 0.37-0.71 0.65 0.43 0.28-0.57 0.29 
RV free wall strain 0.49 0.31-0.67 0.89 0.76 0.62-0.90 <0.001 
RVEDA 0.40 0.23-0.57 0.25 0.77 0.69-0.85 <0.001 
 
RVFWS normal (<-20%) RVFWS abnormal (>-20%) 
Variable AUC 
 
95% CI p AUC 
 
95%CI p 
FAC 0.70 0.26-1.0 0.25 0.28 0.18-0.37 <.001 
RV free wall strain 0.20 0.03-0.36 0.076 0.69 0.59-0.78 0.001 
RVEDA 0.81 0.68-0.94 0.07 0.60 0.50-0.70 0.06 
FAC, fractional area change; RVEDA, right ventricular end diastolic area.  
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p<0.001). Interestingly, PASP values in the PAH group were trending towards being 
significantly higher (57.6±25.1 vs 48.1±18.9 mmHg, p=0.059)) 
5.5.8 Reproducibility.  
Reproducibility of RVFWS, RVEDA and FAC were sought in randomly selected patients in 
both the PE and PAH (n=55) (Figure 5.4), with Bland-Altman analyses to examine bias and 
variability. RVFWS showed an interclass coefficient (ICC) of 0.85, (R=0.78) which was 
significantly better than FAC with an ICC of 0.66, (R=0.57) (RVFWS vs FAC, p<0.001). 
RVEDA showed an ICC 0.81, (R=0.82) which was not statistically different from RV strain. 
The variability of RVFWS was less than FAC (p<0.01), but comparable to RVEDA (p=0.14).  
5.6 Discussion 
The results of this study confirm the value of echocardiographic measurements into 
differentiating chronic from acute changes in RV afterload. While both RVFWS and FAC were 
helpful for detecting the acuity of RV pressure overload, RVFWS was more reproducible. 
Finally, the addition of RVFWS provided incremental value to clinical and traditional 
echocardiographic variables. 
5.6.1 Acute vs chronic PAH.  
The determination between acute from chronic RV overload has immediate consequences for 
patient management in critical settings. The standard echocardiographic approach to assessing 
RV dysfunction in patients with pulmonary embolism is based on subjective indices such as 
the McConnell and 60/60 signs (Pulmonary valve acceleration time ≤60ms and tricuspid 
regurgitation pressure gradient ≤60mmHg) 170 which demonstrate high specificity and low 
sensitivity. In addition, these fail to quantitate RV systolic function, which is most strongly 
linked with mortality.171 
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Figure 5-4. Bland-Altman plots and between reader correlation for RVFWS, FAC and RVEDA 
 
Figure 5.4a shows the variation in RVFWS, with an ICC of .851 & r=0.78. (Mean= 0.7 95% 
CI ; 9.3 - -7.9).  Figure 5.4b shows RVEDA variability, with an ICC of .814, r=0.82 
(mean=4.8, 95% CI: 14.7-  -5.1). FAC is shown in Figure 5.4c, ICC is 0.66, r=0.57 (mean= 
7.9, 95% CI: 31.3- -15.6). 
Historically, RV hypertrophy assessed from RV free wall thickness in the subcostal view has 
been used to identify chronic PAH. In addition to the standard angle- dependence of M-mode 
calculations, increases in RV thickness are not specific to chronic pressure overload, also 
being seen in infiltrative and hypertrophic cardiomyopathy, and in patients with established 
LV hypertrophy.  Strain has been used to distinguish normal from abnormal RV function in a 
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number of settings,159,172 with work done in a PH cohort to support its clinical utility.136,172 
Echocardiography has the advantage of being a bedside diagnostic tool. 
5.6.2 RV assessment in PAH.  
The RV has a non-geometric shape that presents challenges to the quantitation of size and 
function.  The clinical uptake of RV strain has lagged the measurement of strain for LV 
evaluation, especially for assessment of subclinical RV dysfunction.  Limited evidence about 
RV strain variability was cited as a significant limitation in recent guidelines.166 In this study, 
RVFWS outperformed most currently recommended measurement techniques.173 
RV dysfunction in PE is due to a combination of factors, including the extent of the embolic 
obstruction, the severity of pre-existing cardiopulmonary dysfunction, the impact of hypoxia 
and the presence of RVH.  The most common cause of death at 90 days is RV failure. In a study 
specifically examining echocardiographic markers of 6 -month patient outcome and recovery 
of RV function, the time course of recovery showed that RV dilatation improved after three 
weeks, but subclinical RV dysfunction persisted for up to 3 months.174 We found that RVEDA 
was the weakest discriminator of chronic versus acute pressure overload.  
The subjective evaluation of apical sparing of the RV, known as the “McConnell Index”168, is 
thought to reflect a hyperdynamic LV. Previous work Lopez Candales demonstrated that basal 
strain exceeded apical strain, but there was no significant difference in strain in the apical 
segments between PAH and PE in small numbers of patients.175 This change in strain from base 
to mid ventricle was observed in our study, with impaired strain being less prominent in the 
apex.176. The RV hyperdynamic apical contraction has been postulated to occur through 
tethering to the LV apex. This movement could result in translational, as opposed to 
deformation of the apex, which is calculated with strain imaging. A more robust way to detect 
these changes could be through a technique proposed by Rajagopal et al177, with right 
ventricular strain measured from 3 RV focused views.  This technique can detect regional 
patterns, which adds substantially to what is visually identified during the “McConnell sign”.  
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5.6.3 Limitations.  
Out of plane motion remains a potential limitation of 2D segmental strain, which may be 
overcome by 3-dimensional imaging. However, recent reports of 3D strain in PH emphasise the 
susceptibility of this approach to suboptimal image quality.178 The availability of a reference 
method such as cardiac MRI would have been helpful but is usually not considered in acute 
pulmonary embolism. For the current studies, patients were treated for PAH, which could have 
affected the impact of right ventricular size as remodelling may have occurred.  The 
heterogeneity of the PAH group could have affected results here, potentially resulting in an 
underestimation of RVEDA. CTEPH patients represent an interesting subgroup which we were 
unable to investigate. Those treatable with pulmonary artery endarterectomy (PEA) may have 
complete resolution of PAH. Studies have been performed looking at RV function pre and post 
PEA and have shown that right ventricular mass changes in response to PVR alterations155. This 
change in resistance also seems to alter the efficiency of cardiac contraction, with improvements 
in left to right dyssynchrony.179. 
5.7 Conclusions 
RV strain is feasible and useful to help distinguish chronic versus acute pressure overload by 
differences in RV remodelling. The results show that echocardiography can diagnose different 
clinical RV loading conditions, and that echocardiography has a good discriminative ability 
within a clinical cohort. RV remodelling is an essential aspect of the adaptation process to 
increased afterload, but before afterload increases are detected with echocardiography, there is 
a gradual increase in PASP, which may progress over an extended period.  
This ability to quantify remodelling is an important capability of strain echocardiography. Other 
methods which may quantify remodelling, including RV free wall thickness and RV end-
diastolic volume, may not have adequate sensitivity to detect change. Due to the non-geometric 
nature of the RV, both of these methods carry substantial error, as probe placement can 
drastically change values, this suggests that RVFWS is more appropriate to use for sequential 
Chapter 6.  Determinants of Change in Functional Capacity 113 
follow-up of patients. The last two chapters have established the effect of afterload and its time 
course on RV strain. Another aspect of establishing the role of RV strain is to understand its 
place relative to functional testing, such as 6MW, which has a traditional role in the assessment 
of PAH. 
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6 Determinants of change in functional capacity 
 
6.1 Preface 
PAH patients classically present with insidious declines in functional capacity. 
Cardiopulmonary fitness can be assessed quantitatively with cardiopulmonary exercise testing 
(CPET). CPET testing gives an accurate assessment of aerobic capacity, determination of 
sustained exercise performance (ventilator/anaerobic threshold), and assessment of ventilatory 
efficiency. Declines in functional capacity in PAH may originate from problems in the 
cardiac, pulmonary and skeletal systems180. For the test to be accurate, patients must exercise 
to exhaustion. Historically, maximal exercise testing has been considered a contraindication 
in PAH. 
Functional status is routinely assessed using either the New York Heart Association or World 
Health Organisation scales, with patients placed into 4 or to 5 categories of increasing 
severity 181, respectfully this is essentially is a qualitative measure, with a significant degree 
of variation in grading between clinicians 181. The sensitivity of class assessment to track the 
decline in status over time is limited.   
The 6MW distance fits between these two parameters (functional class and VO2). It is a low-
cost procedure, safe in the majority of patients, and provides a quantitative gauge of exercise 
capacity. Since the introduction of specific pharmacotherapy, 6MW has been established as a 
marker to track functional status and outcome in PAH. It has also shown better reliability than 
CPET in a PAH cohort 182.  
Follow-up of patients for continued treatment under Australian PBS reimbursement 
guidelines requires the ongoing demonstration of echocardiographic and functional stability 
every six months. Interestingly, the strength of the relationship between pulmonary pressure 
and exercise capacity is not well established in PAH. Small studies are looking at 
cardiopulmonary exercise testing in combination with invasive pressure studies, finding an 
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only moderate correlation with PVR and max V02183.  Both 6MW and NYHA have been used 
as outcome markers in clinical PAH trials. The associations between outcome, functional 
capacity and echocardiographic markers need to be established. Work performed in this 
chapters seeks to establish the relationship between novel RV markers and 6MW performance 
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6.2 Abstract 
Background. The continuation of pulmonary vasodilator therapy for pulmonary arterial 
hypertension (PAH) is based on responses of echocardiographic or exercise markers. As right 
ventricular (RV) function is a powerful prognostic marker in PAH, we compared the association 
of RV free wall strain (FWS) with conventional indices before and after initialisation of PAH 
therapy. 
Methods. The study was a retrospective analysis of prospectively acquired data. 121 patients 
had exercise capacity (measured as 6-minute walk distance, 6MWDD) performed at baseline 
with echocardiography (including RV-FWS by speckle tracking), with a further subgroup 
analysis of 79 patients with baseline assessment available before PAH therapy initiation. 119 
patients had measures performed at two-time points (21±15 months), follow up of the 79 
patients having the initial visit before treatment was  19±15 months.  
Results.  6MWD and RV-FWS improved after treatment (p=0.003 and p<0.001 respectively). 
Age, RV-FWS, RV end-diastolic area, RV fractional area change and LV E/e’ showed 
univariable association with 6MWD distance. RV-FWS was the only RV function parameter to 
show association with 6MWD distance, independent of clinical variables (R2=0.38, p<0.001, f 
change p=0.005). Change in RV-FWS showed a weak but significant association with change 
in the 6MWD distance before and after therapy(r=0.27 p=0.02), or throughout therapy 
regardless of treatment initiation (r=0.25 p=0.007). In all patients throughout therapy, there was 
a weak association with delta pulmonary artery systolic pressure (PASP) and 6MWD (r=-0.21, 
p=0.03), but this was not apparent in the group before and after treatment initiation (r=-0.12, 
p=0.31). In a secondary analysis, those with higher baseline PASP are also more likely to show 
a decline in 6MWDD (58 ±18.9 vs 41±20 p=0.004).  
Conclusion. RV-FWS is strongly associated with exercise capacity in PAH and is a useful 
adjunct to the assessment of treatment response. 
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Although the echocardiographic assessment of pulmonary artery systolic pressure (PASP) has 
been the primary indicator of response in the management of pulmonary arterial hypertension 
(PAH), recent guidelines suggest that changes in PASP do not necessarily correspond to a 
change in clinical status 10. Assessment of right ventricular (RV) performance has a potential 
role in predicting patient outcome, but traditional measures of RV function (e.g. tricuspid 
annular displacement and RV peak systolic velocity) can be affected by translational 
movement. Speckle tracking has improved RV function assessment. The measurement of RV 
free wall strain (RV-FWS) - which measures the contribution of longitudinal myocardial 
deformation – has been recommended over global RV strain in recently published guidelines 
101. RV-FWS is a significant predictor of outcome in pulmonary hypertension 77, but the 
guidelines do not recognise RV-FWS as superior to other markers of RV function 101.  
Exercise limitation is a primary symptom of PAH 184, and the baseline, follow-up and change 
of exercise capacity represent another means of following PAH response. Although novel drugs 
have had substantial mortality benefits 2,185, improvement of exercise capacity is a crucial 
outcome goal in the treatment of PAH. Scoring systems such as the NYHA and WHO scales 
are used to assess symptom status and titrate therapy. The 6-minute walk test (6MWD) test is a 
quantitative measure of exercise capacity. It is a submaximal test that is significantly related to 
peak VO2, anaerobic threshold and VE/VO2 slope 186 in primary PAH. A baseline low 6MWD 
distance is an independent predictor of survival 187, and those who do not improve their 6MWD 
distance after therapy are at higher risk 187,188.  In our previous work on changes in PASP over 
time, the association with changes in RV-FWS was more significant than traditional 2D RV 
systolic function parameters 118. This study will determine the clinical utility of change in RV-
FWS in PAH patients over sequential visits. We aimed to determine whether RV function 
markers correlated with changes over time in patient exercise capacity as measured with 
6MWD. We hypothesised that RV dysfunction is associated with a measure of submaximal 
exercise capacity (6MWD), with RV-FWS the best correlate over time.   
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6.3 Methods 
6.3.1 Patient selection.  
Study design  was a retrospective analysis of a prospectively acquired dataset. Patients were 
recruited from Pulmonary Hypertension Registries at Royal Hobart Hospital, Hobart and 
Princess Alexandra Hospital, Brisbane, Australia, from August 2005 to October 2015. All 
patients had PAH confirmed using invasive right heart catheterisation, as recommended by 
treatment guidelines 10. Of 143 patients in the registries, 22 were excluded due to insufficient 
baseline 6MWD data, leaving 121 with baseline 6MWD and echocardiography, 79 of whom 
were PAH treatment naïve during the echocardiography and 6MWD test. Of the 42 patients on 
therapy, mean treatment time before visit 1 was 12±16 months. Ongoing treatment access 
during follow-up required 2 of 3 tests (invasive RHC, echocardiography or 6MWD), so most 
patients underwent echocardiography and 6MWD (if RHC was acquired, 6MWD was not 
performed). Thus, although 119 patients attended echocardiographic follow-up after 21±15 
months, a further 26 patients did not perform the 6MWD test at follow up. An intention to treat 
analysis was used to assess treatment response.  
Echocardiography protocol.  
Echocardiography was performed using standard commercial equipment (Vivid 7, Vivid i and Vivid e9, 
General Electric Medical Systems, Milwaukee, WI; ie33, Philips, Andover. MA). Data were stored as 
DICOM files.  In patients with atrial fibrillation, three beats were averaged.  
Standard measurements Left ventricular (LV) and RV measurements were performed according 
to ASE/EACVI guidelines 101 by a single reader for both studies. LV ejection fraction was 
measured from the Simpson’s biplane method from the apical 4- and 2-chamber views. RV 
end-diastolic area (RVEDA) and RV end-systolic area (RVESA) were measured from an apical 
RV focused view. Fractional area change (FAC) was calculated as the percentage change 
between the RVEDA and RVESA. Peak velocities of the early (E) and late (A) diastolic filling 
were derived from the transmitral inflow pattern. Tissue Doppler imaging was used to 
determine the peak diastolic early velocity (e’) of the lateral and septal mitral annulus from the 
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apical 4-chamber view. Tricuspid annular plane systolic excursion (TAPSE) was obtained from 
M-mode measurement of tricuspid annular motion in the apical 4 chamber focused view. The 
distance the annulus travelled between systole and diastole was measured in cm. Right atrial 
area (RAA) was traced in a single plane area-length measurement in the 2D apical 4 chamber 
view during the largest size in systole. PASP was measured from the peak tricuspid 
regurgitation velocity using the modified Bernoulli equation 29. Right atrial pressure was 
derived from the inferior vena cava dimension and distensibility from the subcostal view 44. 
Pulmonary vascular resistance was calculated from the RVOT VTI, and tricuspid regurgitant 
signal using the Abbas method (PVR echo=TRV/TVIRVOT × 10 + 0.16 ) 47.PV acceleration time 
(PV AT) is measured from pulsed-wave Doppler at the level of the pulmonary valve leaflets, 
with a measurement of time from baseline to peak modal velocity. Hemodynamic variables 
referred to in results are echocardiographically-derived. Tricuspid valve systolic excursion 
velocity was measured in a subset of patients; these data were not included in the final analysis 
due to the significant degree of missing data, and risk of bias.  
Speckle-tracking strain analysis. Wall motion tracking software (Image-Arena, TomTec Gmbh, 
Unterschleissheim, Germany) was used to analyse the optimal 2D echocardiographic image in 
which the whole RV cavity was visualised. The LV measurement package was formatted to 
track the RV free wall. Velocity vector imaging converts images to a DICOM frame rate of 
30fps for analysis. The RV end-diastolic endocardial border was manually traced along the RV 
septal and RV free wall. These borders were then tracked automatically frame-by-frame 
throughout the cardiac cycle. Manual adjustments were performed when necessary, and regions 
excluded if excessive noise or inadequate tracking were present. RV-FWS was calculated from 
an average of three segmental RV-FWS 
Right heart catheterisation.  RHC studies were undertaken after premedication and local 
anesthesia. A 4-lumen 110 cm 7-Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA) 
was floated to the right heart and resting measurements of right atrial, RV, pulmonary arterial 
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and PCWP were made at end-expiration using a pressure transducer (21BB, ITL Healthcare, 
Chelsea Heights, Australia). The transducer was calibrated to atmospheric pressure at the level 
of the RA and re-checked at intervals to avoid zero drift. CO was determined by thermodilution, 
using an average of four consecutive values that varied <10%. All hemodynamic monitoring 
was recorded using a Horizon SE Hemodynamic System (Mennen Medical Ltd., Yavne, Israel) 
and analysed off-line. 
6.3.2 Functional testing.  
Functional testing.  
A 6MWD test was performed at the time of the echocardiogram, or in close succession to by a research 
nurse in the majority of patients. The test was done in a quiet hospital hallway and followed a 
standardised protocol 110 
Analysis. Statistical analysis was performed using standard software (SPSS version 22, IBM, 
Chicago, IL). RV-FWS was analysed as a positive figure. Changes between baseline and 
follow-up were calculated as baseline subtracted from follow-up. Paired t-tests were used to 
compare baseline with follow-up values, using linear regression to assess clinical features 
associated with 6MWD distance. Multivariable models were selected based on predicted 
clinical markers. Sequential models were employed to assess the incremental and independent 
benefit of RV function parameters. Change in model chi-square was used to determine whether 
the additional markers had an incremental benefit over a clinical model. Bivariate logistic 
regression was used to assess associates of patients likely to improve, versus decline 6MWD 
distance. Height and weight was not recorded in a number of patients, with 132 data points 
being imputed with a mean value. A variability analysis has been reported previously by our 
group in this same cohort 118. 
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6.4 Results 
6.4.1 Baseline  
Patients had an age (62±13 years) and female preponderance (73% women) typical of PAH 
(Table 6.1). The 6MWD was low (329±131 m), with reduced RV-FWS (17±6%) and increased 
PVR. In a subgroup of patients before treatment, functional capacity was slightly lower 
(314±128 m), as was RV FWS (15±6%) with very similar PASP (51±23 mmHg). 
Table 6-1. Baseline Characteristics 
 Pre Treatment 
N=90 
All patients  
N=143 
 Pre Treatment 
N=79 
All patients  
N=120 
Age (years) 64±13 62±13 
BMI 30±13 29±13 
Sex (female)   
HR (bpm) 74±15 74±15 
SBP (mmHg) 124±23 125±23 
DBP (mmHg) 73±23 73±11 
 PAH subtype   
 Scleroderma 40(51%) 66(55%) 
 idiopathic 30(38%) 43(36%) 
 CTEPH 3(4%) 5(4%) 
 Eisenmenger 2(3%) 3(3%) 
Other 4(5%) 4(3%) 
 PAH treatment type   
 ERA only 43(54%) 59(49%) 
 PDE5 only 12(15%) 17(14%) 
 Combined ERA and PDE 24(30%) 44(36%) 
BMI, body mass; HR heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAH, pulmonary arterial hypertension; CTEPH, 
chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist; PDE5, phosphodiesterase type 5 inhibitor. 
6.4.2 Follow-up.  
Over a follow up of 21±15 months (n=119) (Table 6.2), there were improvements in 6MWD 
distance (24±74 m, p=0.005) RV-FWS (1.3±5.4%, p=0.01) and estimated PVR (-0.38±1.5 
Wood units, p=0.006). There was a borderline significant improvements in PASP (-2.4±17.6 
mmHg, p=0.07) and LV systolic function (EF 1.5±8.6%, p=0.08). 
In selected patients with matched data before and after initiating treatment (n=79, follow up 
19±15 months) (Table 2), there were improvements in 6MWD distance (31±80, p=0.003), RV-
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FWS (2.5±4.5%, p<0.001), PASP (-2±18 mmHg, p<0.001), or estimated PVR (-0.28±1.5 Wood 
units, p=0.05). There were no significant changes in LV systolic (EF 2.7±18%, p=0.19) or 
diastolic function (e’ -0.4±1.5 cm/s, p =0.12; E/e’ 2.0±7.3; p=0.06). Appendix Figure 6.3-6.5 
shows the variability in parameters from visit 1 to visit 2 in all patients.  
6.4.3 Echocardiographic features independently associated with exercise capacity.  
In patients not on treatment at baseline, RV function markers associated with exercise capacity 
included RV-FWS, RVEDA, FAC, and LV filling pressures (Table 6.3). In all 119 patients 
(Table 6.3) age was associated with exercise capacity, as were RV-FWS, RVEDA, TAPSE, LV 
filling pressures and hemodynamic markers. After long-term follow-up, age, RV-FWS, RV 
end-diastolic area, RV fractional area change, and LV E/e’ were associated with baseline 
6MWD performance. 
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Table 6-2. Baseline and follow  
 All patients   Patients initiating treatment  
 Baseline Follow up Delta P value Baseline Baseline Follow up Delta 
6MWD (metres) 329±131 353±143 24±74 0.005 314±128 346±146 31±80 0.003 
RV free wall (%) 17±6 19±5 1.3±5.4 0.01 15±6 18±6 2.5±4.5 <0.001 
PASP (mmHg) 50±24 47±22 -2.4±17.6 0.07 51±23 48±20 -1.7±17.6 <0.001 
RVEDA (cm2) 22±9 22±10 0.5±8.3 0.50 22±9 22±8 -0.77±5.8 0.18 
FAC (%) 32±14 35±12 2.4±12.3 0.04 31±14 33±12 1.9±12.3 0.19 
RAA ( cm2) 20±8 20±8 0.71±5.8 0.19 19±8 20±8 0.58±5.0 0.32 
PVR (W.u) 3.6±1.9 3.2±1.5 -0.38±1.5 0.006 3.8±1.8 3.4±1.7 -0.28±1.5 0.05 
TAPSE (cm) 1.9±0.5 1.9±0.6 0.03±0.54 0.54 1.8±0.5 1.9±0.5 0.11±0.46 0.04 
PV AT (cm/s) 80±28 80±24 0.06±28.3 0.99 76±25 78±20 1.6±25.7 0.63 
RVOT VTI (cm) 12±3.9 12±3.7 0.62±3.3 0.09 11±3.9 12±4.0 0.68±3.4 0.14 
LVEDV (ml) 87±33 87±33 -0.05±20.9 0.98 86±38 89±35 2.7±18.3 0.29 
EF (%) 61±10 63±9 1.5±8.6 0.08 60±11 62±9 2.7±18.3 0.19 
SV (ml) 51±16 52±15 0.88±15 0.60 49±16 51±16 1.8±16 0.41 
LAV (ml/m2) 32±14 35±14 3.2±11.0 0.02 31±14 34±13 3.2±10.5 0.04 
e’ septal (cm/s) 6±2.2 6±2.2 -0.07±1.7 0.7 6±2.3 5±2.0 -0.35±1.5 0.12 
e/e’ avg  11±6 13±8 1.2±6.7 0.12 11±5.0 13±9 2.0±7.3 0.06 
6MWD, six minute walk distance; RV, right ventricle; PASP, pulmonary artery systolic pressure; RVEDA, right ventricular end diastolic area; FAC, fractional area change; 
RAA, right atrial area; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; PV AT, pulmonary valve acceleration time; RVOT VTI, 
right ventricular outflow tract velocity time integral; LVEDV, left ventricular end diastolic volume; EF, ejection fraction; LAV, left atrial volume 
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Table 6-3  Regression analysis of 6MW distance 
  All baseline patients (n=121) baseline (not on PAH therapy) (n=79) Follow-up (after PAH therapy, all patients) 
  Std β (95% CI) P value Std β (95% CI) Std β (95% CI) Std β (95% CI) P Value 
Age (years) -0.41(-5.7;-2.4) <0.001 -0.26(-5.0;-0.40) 0.02 -0.21(-5.0;0.12) 0.06 
BMI -0.18(-6.6;0.09) 0.06 -0.21(-7.8;0.35) 0.07 -0.16(-7.9;1.4) 0.17 
HR (bpm) -0.09(-2.4;0.86) 0.35 -0.16(-3.3;0.60) 0.17 -0.14(-3.6;0.86) 0.22 
RV FWS (%) 0.36(3.7;10.6) <0.001 0.34(2.8;12.6) 0.003 0.36(3.6;14.7) 0.001 
RVEDA (cm2) -0.30(-7.5;-2.0) 0.001 -0.26(-6.9;-0.49) 0.03 -0.29(-8.4;-1.1) 0.01 
FAC (%) 0.25(0.73;4.2) 0.006 0.25(0.19;4.2) 0.03 0.23(0.06;4.7) 0.05 
TAPSE (cm) 0.21(7.1;104.6) 0.03 0.20(-7.2;110.2) 0.09 0.16(-19.2;1113.7) 0.16 
PASP (mmHg) -0.28(-2.5;-0.56) 0.002 -0.20(-2.4;0.20) 0.10 -0.26(-3.0;-0.18) 0.03 
PVR (w.u) -0.29(-35.9;-7.0) 0.004 -0.22(-35.4;2.4) 0.09 -0.29(-45;-3.2) 0.02 
PV AT (cm/s) 0.22(0.14;1.8) 0.02 0.07(-0.92;1.7) 0.57 0.16(-0.48;2.5) 0.18 
EF (%) 0.07(-1.5;3.4) 0.44 0.11(-1.5;4.1) 0.35 0.11(-1.8;4.7) 0.37 
SV (ml) 1.4(-0.33;3.05) 0.11 0.40(-1.6;2.5) 0.70 0.92(-0.72;2.6) 0.27 
LAV (ml/m2) -0.25(-4.4;-0.44) 0.02 -0.16(-3.9;0.91) 0.22 -0.30(-5.7;-0.51) 0.02 
E/e’ Average -0.33(-13.5;-3.0) 0.003 -0.38(-17.3;-3.1) 0.006 -0.49(-22.3;-7.3) 
 
<0.001 
6MW, six-minute walk distance; RV, right ventricle; PASP, pulmonary artery systolic pressure; RVEDA, right ventricular end diastolic area; FAC, fractional area change; RAA, right atrial area; PVR, 
pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; PV AT, pulmonary valve acceleration time; RVOT VTI, right ventricular outflow tract velocity time integral; LVEDV, 
left ventricular end diastolic volume; EF, ejection fraction; LAV, left atrial volume
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6.4.4 Incremental value of RV function in assessing exercise capacity.  
In a sequential linear regression model, clinical parameters (age and BMI) and PASP 
were associated with 6MWD (R2=0.33, p<0.001) (Figure 1). The addition of FAC was 
borderline in significantly adding to the model (Figure 2) (R2 0.36, p<0.001, F 
change=0.10), and TAPSE was independent, but did not significantly increase the 
power of the model (R2=0.34, p<0.001, F change=0.12). However, RV-FWS added 
incremental prognostic information (Figure 2) (R2=0.38, p<0.001, F change=0.005). 
Appendix 6.6 shows the incremental value of RV-FWS in patients prior treatments, 
with results replicated.  
 Figure 6-1. Sequential linear regression model for baseline visit.. 
 
 
RV free wall strain is the most robust echocardiographic RV function marker in the 
association of functional capacity 
After long-term treatment of pulmonary hypertension patients, age, PASP and BMI 
significantly associated with exercise capacity in a clinical model (R2=0.41, p<0.001) 
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(Figure 6.2). FAC did not add significantly (R2=0.42, p<0.001, F change p=0.19) and 
the association of TAPSE (R2=0.43, p<0.001, F change. p=0.09) with follow-up 
walking distance reached borderline significance (Figure 6.3). Again, however, RV-
FWS showed incremental value in prediction of 6MWD distance (Figure 6.3) (R2 
=0.48, p<0.001, F change p=0.001).  
Figure 6-2. Sequential linear regression model for follow-up in all patients.  
Similar to baseline, after long-term treatment, RV free wall strain was the strongest 
echocardiographic associate of functional capacity in those on long term treatment 
for pulmonary arterial hypertension 
 
6.4.5 Features associated with a change in 6MW.  
Table 6.4 summarises the associations of delta 6MWD with echocardiographic and 
clinical markers. Delta RV-FWS was the only significant RV function marker 
associated with change in 6MWD (std β 0.25(95% CI 0.95 to 6.0) p=0.007), as was 
PASP (std β -0.21 (95% CI -1.7 to -0.10), p=0.03).  Change in delta FAC, delta TAPSE 
and diastolic markers were not significantly associated with a change in 6MWD.  
.  
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Table 6-4. Associations with delta 6MW distance 
RVFWS, right ventricular free wall strain; PASP, pulmonary artery systolic pressure; RVEDA, right ventricular end diastolic 
area; RAA, right atrial area; FAC, fractional area change; TAPSE, tricuspid annular plane systolic excursion; LAV left atrial 
volume; BSA, body surface area; EF, ejection fraction.   
To distinguish “responders” vs. “non-responders” to pulmonary vasodilator therapy, 
patients were split into those who increased 6MWD distance (n=45), versus those 
whom 6MWD distance declined (n=17). There was no significant difference in 
baseline demographics or RV systolic function. PASP was significantly higher in the 
group who declined 6MWD distance (p=0.004), as was PV acceleration time (p=0.03) 
(Table 6.5). Logistic regression showed that baseline PASP was the only significant 
univariable association of those who decline in 6MWD distance (OR -0.25 (95% CI -
1.7 to -0.09), p=0.03) (Table 6.6); baseline RV-FWS was not significant (OR 
0.95(95% CI 0.94 to 1.03), p=0.39).   
 Treatment only group Follow-up all patients 
 Std β (95%CI) P value Std β (95%CI) P value 
Sex -0.15(-64.6;13.5) 0.20 -0.06(-39.4;20.7) 0.54 
Baseline Age -0.02(-1.6;1.3) 0.85 -0.01(-1.1;0.94) 0.88 
Delta RV FWS (%) 0.27(0.82;8.8) 0.02 0.25(0.95;6.0) 0.007 
Delta PASP (mmHg) -0.12(-1.6;0.52) 0.31 -0.21(-1.7;-0.10) 0.03 
Delta RVEDA (cm2) -0.05(-3.9;2.5) 0.66 -0.14(-2.9;0.47) 0.16 
Delta RAA (cm2) -0.15(-6.0;1.3) 0.20 -0.09(-3.6;1.2) 0.33 
Delta FAC (%) 0.14(-0.62;2.4) 0.24 0.03(-0.99;1.3) 0.78 
Delta TAPSE (cm) 0.09(-25.6;55.3) 0.47 0.11(-10.3;40.6) 0.24 
Delta LAV/BSA (ml/m2)  0.18(-0.75;3.5) 0.20 0.23(0.001;3.1) 0.05 
Delta EF (%) 0.04(-1.8;2.5) 0.76 0.02(-1.5;1.8) 0.85 
Delta E/e’ average 0.23(-0.71;5.7) 0.12 0.12(-1.3;3.9) 0.33 
Delta e’ sep (cm/s) -0.10(-20.7;10.1) 0.49 -0.01(-11.1;9.9) 0.91 
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Table 6-5. 6MW responders versus non responders 
6MW, six-minute walk; RV  right ventricle; RVEDA, right ventricle end diastolic end diastolic area; RAA, right atrial area; 
FAC, fractional area change; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance; PV AT 
pulmonary valve acceleration time; LVEDV, left ventricular end diastolic volume; EF, ejection fraction.  
 
Table 6-6.  Bivariate logistic regression for improved versus decline 6MW 
RV, right ventricle; RVEDA, right ventricular end diastolic area; FAC, fractional area change; PASP, pulmonary artery systolic 
pressure; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; EF, ejection fraction.  
 
Variability analysis. In short, the intraobserver variability of RV-FWS showed an 
intra-class correlation coefficient of 0.73 (95% CI, 0.44–0.88; P < .001) and a mean 
difference of 1.3±3.2%. Inter-observer variability showed an intra-class correlation 
coefficient of 0.62 (95% CI, 0.26–0.83; P < .001) and a mean difference of 4.5±4.7%.  





Age (years) 65±13 62±13 0.42 
6MW (m) 311±133 343±79 0.26 
RV free wall strain 
(%) 
16.5±5.7 15±5.8 0.39 
RVEDA (cm2) 20±9.5 24±7.8 0.17 
RAA (cm2) 17.4±7.5 20.1±7.5 0.22 
FAC (%) 36±13.2 30±12.2 0.10 
PASP (mmHg) 41±20 58±18.9 0.004 
PVR (w.u) 3.0±1.4 3.3±1.4 0.29 
PV AT (cm/s) 85±25.8 68±17.8 0.03 
LVEDV (ml) 86±44 82±22 0.78 
EF (%) 60±10 60±12 0.88 
 OR (95%CI) P value 
Sex 0.41(0.12;1.3) 0.14 
Age at Baseline 0.98(0.94;1.03) 0.42 
RV free wall strain (%) 0.95(0.86;1.06) 0.39 
RVEDA (cm2) -0.19(-3.7;0.32) 0.10 
FAC (%) 0.71(-1.03;1.5) 0.71 
PASP (mmHg) -0.25(-1.7;-0.09) 0.03 
PVR (w.u) 1.4(0.91;2.1) 0.13 
TAPSE (cm) 0.55(0.14;2.1) 0.39 
EF (%) 1.005(0.95;1.06) 0.87 
E/e’ 1.03(0.91;1.2) 0.68 
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6.5 Discussion. 
The guidelines propose that a 6MWD distance of <300m and TAPSE <1.5cm 10 are 
useful predictors of outcome. Although baseline TAPSE and 6MWD showed a 
significant association, changes in TAPSE over time did not associate with 6MWD, in 
contrast with a significant association with RV-FWS. This study supports recent work 
emphasising the prognostic power of RV-FWS (2) by showing that RV-FWS 
associates with exercise performance before and after long-term treatment of PAH. 
We have looked at patients’ naïve to treatment, and have also separately included a 
cohort of patients on long-term treatment. Our work has shown that changes over time 
in the 6MWD distance are associated changes in RV free wall strain, with no other RV 
parameters showing this association. In this respect, RV-FWS was the most robust 
echocardiographic marker of RV function, independent and incremental to clinical 
variables in the association of exercise capacity. Importantly, this was true throughout 
the whole time course of PAH treatment. Changes in exercise capacity were strongly 
related to changes in RV free wall strain, but not to other RV echocardiographic 
parameters. Interestingly, patients who were more likely to decline 6MWD distance 
showed higher PASP levels at baseline.   
Despite the strong mortality benefits of pulmonary vasodilators 189, the degree of 
change of clinical parameters is less well documented. A wide range of responses to 
pulmonary vasodilator therapy is shown in this and other studies 190. A number of 
pivotal studies have shown small, but significant improvements in hemodynamics – 
for example, 1.6-2.7 mmHg improvements in pulmonary pressure have been reported 
after treatment 5. A meta-analysis of intervention trials showed a mean decrease in 
mPAP of -2.86 mmHg 185 using invasive measures - a magnitude of change is similar 
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to our findings. However, assessing treatment based on pulmonary pressure does not 
account for all of the survival benefits from therapy 191. Accounting for the role of the 
RV adds to pulmonary pressure for predicting change in exercise capacity.   
RV free wall strain.  
Although RV function is a more important predictor of outcome, in patients with PAH, 
much effort is directed towards follow up of PASP. Nonetheless, support for RV-FWS 
in the most recent guidelines is constrained by lack of evidence (12). RV-FWS 
measures longitudinal function, which accounts for the predominant aspect of RV 
contraction 192. The RV free wall is regarded as superior to RV 6-segment strain for 
assessing systolic RV function. When compared with controls, the RV septum was not 
significantly different 193, with this generally lower than the RV free wall (due to 
tethering associated with the mitral annulus). RV-FWS has been shown to have 
excellent intra- and inter-observer variation 194,195, with use of the three segment RV-
FWS producing more favourable results over segmental analysis that includes the 
septum. 
The association of RV-FWS with exercise capacity is an essential component of the 
validation of this test. Previously published data 193 involve fewer numbers of patients 
and lack of information on treatment response. One of the strengths of RV-FWS is that 
it avoids the pitfalls of translational rocking, as TAPSE can become pseudonormal 
through translational movement caused by hyperdynamic LV function 196,197. Previous 
outcome studies have shown events in treated PAH to be associated with failure to 
significantly augment RV-FWS 198.   
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6.6 Limitations.  
The gold standard of exercise capacity is maximal cardiopulmonary exercise testing 
(CPET) was not performed in this study. However, 6MWD distance is widely used in 
PAH follow-up, and submaximal testing is a useful marker of daily functional 
capacity. Likewise, the reference standard for RV systolic function is invasive 
pressure-volume loop assessment 199. The latter is difficult to perform in a clinical 
setting and requires specialised equipment. Thus, echocardiography is primarily used 
for follow up.  
This study has used 2D cardiac ultrasound to assess cardiac size and function. Due to 
the non-geometric nature of the RV, the RV size is often underestimated. 3D volumes 
have a promising place within the echocardiographic follow up of PAH 108, with better 
correlations with MRI than are achievable with 2D volumes 81. The use of 3D right 
ventricular strain is limited by the technical aspects of achieving adequate frame rate, 
with studies also shown that there is a steep learning curve for this technique 92.  Some 
of the most robust echocardiographic markers of mortality in PAH and pericardial 
effusion, and right atrial size. Both of these are signs of end-stage disease, and thus 
may not be suitable markers to identify early patient decline. As this was a 
retrospective analysis of prospectively acquired data, there were some limitations of 
study design – for example, the times between follow-up studies were variable. 
Changes in echocardiographic protocols meant that RVS’ data has only been collected 
in recent studies. Patients were excluded if 6MWD was not performed, possibly, these 
patients could have represented a more advanced cohort, altering outcomes.  
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6.7 Conclusion.  
RV free wall strain is a robust predictor of functional capacity in the standard clinical 
follow-up assessment of PAH, further supporting the use of this parameter for 
assessment of RV function in PAH. More studies need to assess the association of 
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6.8 Postscript 
In this chapter, we have used a surrogate of peak exercise performance, the 6MW test, 
to determine the association between echocardiographic measures of RV systolic 
function and patient clinical status. RVFWS independently associated with 6MW 
distance, incremental to other physiologic predictors.  
There has been difficulty in determining a follow-up measure that tracks patient 
progression in PAH. Although there are some established markers of prognostic 
significance, outcome measures appear to underestimate treatment benefit.  The 6MW 
test is an example of this. In a recent meta-analysis of 23 trials involving PAH 
pharmacotherapy, the 6MW distance was the primary or combination endpoint in 
17185. In PAH, increases in the 6MW distance of > 38 meters 200 are required to have 
an impact on patient clinical status. Changes to this degree are rarely seen, with some 
studies showing a difference in the follow-up of > 2 meters able to distinguish 
survivors, from non-survivors 201. The change is also less than the re-test reliability of 
the 6MW test in a stable PAH cohort 182. The meaningful clinical difference required 
is also higher than that observed from a recent meta-analysis of improvements in 6MW 
distance following therapy 202. Ceiling effects can also be witnessed, with stronger 
outcome affecting those whom functional capacity is severely reduced 94. 
Unfortunately, invasive assessment of pressures also underestimates the survival 
benefits seen in trials 191.  Newer methods of tracking outcome in patients need to be 
assessed to determine association with outcome. Of these, measurements of right 
ventricular size and function may be predictive of outcome throughout follow-up.  
RVFWS is influenced by the chronicity of disease, and minimally by the severity of 
PHT, with RVFWS possibly better than 6MWD for determining functional status. 
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Speckle tracking can also provide additional information about the LV status, which 
could play a role in PH. 
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Figure 6-3 Appendix. Variation in the degree of change in 6MW distance at baseline 
and follow up 
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Figure 6-4 Appendix. Variation in the degree of change in RV free wall Strain at 
baseline and follow up 
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Figure 6-5 Appendix. Variation in the degree of change in Pulmonary artery systolic 
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Figure 6-6 Appendix. The incremental predictive ability of RV function markers over 
clinical parameters before treatment (baseline) 











Article published as “Mechanics and Prognostic Value of Left and Right 
Ventricular Dysfunction in Patients with Systemic Sclerosis” accepted 
for publication in Aug 2017 
 
Journal of the American College of Cardiology; Cardiovascular 
Imaging 2017 
Makoto Saito*, Leah Wright *, Kazuaki Negishi, Nathan Dwyer, Thomas H Marwick 
*Joint first authors 
  
Chapter 7.  Left and Right Ventricular Function in Systemic Sclerosis   142 
 
7 Left and right ventricular function in systemic 
sclerosis; Tools for advanced imaging and prediction 
of outcome 
 
7.1 Preface; Myocardial imaging for differential diagnosis 
Systemic sclerosis (SSC) is an interesting model of PH as identification of patients can 
occur early in the course of PH. However, these patients are also susceptible to left 
heart disease - SSC patients are at risk of developing heart failure with preserved EF 
at higher rates than the general population (ranges of 20-45% are proposed) 203,204. 
Incremental to this, the risk of myocardial infarction is increased 205, plus worse 
survival rates following diagnosis of heart failure preserved EF 206. 
A number of different techniques exist to measure fibrosis; the gold standard, invasive 
cardiac biopsy, is not a viable option for screening patients. CMR is viable 207, but due 
to expense, it is not a practical option for early disease screening. Increased stiffness 
in the myocardium is mediated through collagen regulation, with speckle tracking 
imaging able to detect early changes in the myocardium 208. 
Echocardiography is well positioned to be a successful screening tool, with many 
imaging techniques available. Traditional measures, such as the EF, may not be ideal 
methods to detect early disease. In SSC, there is a large proportion of focal fibrosis 209, 
with global measures not detecting such disease patterns. Tissue Doppler utilises the 
velocity of the myocardium and is particularly useful for detecting abnormalities in 
myocardial structure210. A caveat to this is that measures a traditionally performed in 
the longitudinal plane, likewise angle dependency may affect results.  
Historically, research and clinical interests have focused on LV fibrosis 
characterisation. However, the RV is also prone to fibrotic infiltration, which can is 
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associated with increased RV loading conditions211, but, not entirely. There have been 
interesting patterns noted in late gadolinium enhancement on MRI in the RV in SSC 
patients. Studies have shown enhancement at the RV insertion points211, with a patchy 
distribution, not linked to classical coronary artery territory supply212. Fibrosis patterns 
support the concept that myocardial disease in SSC is due to microvascular disease as 
opposed to primary afterload increases due to increased pulmonary artery pressures. 
Focusing on a patients’ haemodynamic profile, as opposed to myocardial 
characteristics, limits the clinical interpretation of progression of cardiac disease.  
Speckle tracking imaging enables measurements of the myocardium not only in the 
longitudinal plane, but circumferentially213, and radially214, with all the different 



















Background: Impairment of myocardial function is a significant potential 
complication of SSc and associated with poor prognosis. The detection of subclinical 
LV and RV dysfunction may permit therapeutic intervention. We sought to investigate 
the prognostic value of both LV and RV deformation in patients with SSc. 
Methods and Results: Speckle tracking LV strain parameters (global longitudinal 
strain (GLS) and global circumferential strain (GCS)) and tricuspid annular peak 
systolic velocity (Ts’) were measured in 112 patients with SSc and 112 age- and 
gender-matched controls. Subjects were followed for a median of 1.9 years for all-
cause admission or death, and the association of the study parameters with outcome 
was assessed using Cox proportional hazards models. GLS, GCS, and Ts’ were 
significantly impaired in patients with SSc, even without PH, compared to controls. 
GCS (r2=0.06, p=0.03) but not GLS (r2=0.04, p=0.11) was associated with systolic 
pulmonary artery pressure. During follow-up, comparable numbers of SSc patients 
(n=45, 40%) and controls (n=38, 34%) had events (p=0.33). In SSc patients, GCS (but 
not GLS), Ts’, and 6MWD were significantly associated with outcome. A model based 
on age, gender and 6MWD was significantly improved by adding GCS (p=0.03) and 
additionally by adding Ts’ (p=0.03). However, 6MWD and Ts’ (but not GCS) were 
independently associated with outcome.  
Conclusion: RV dysfunction was associated with adverse outcome, independent of 
and incremental to clinical and LV deformation parameters in SSc. Subclinical LV 
dysfunction appears to have less prognostic relevance than RV dysfunction. 
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7.3 Background 
SSc is a systemic CTD characterised by inflammation, widespread vascular lesions 
and fibrosis involving various organs including the lungs, skin, gastrointestinal tract, 
kidneys, and heart 215. In particular, cardiopulmonary involvement in SSc associates 
with an unfavourable prognosis 215,216 - particularly PH 217-224. Although pathologic 
observations at necropsy have demonstrated myocardial involvement in around 50-
80% of patients with SSc 212,225,226, clinical evidence of myocardial dysfunction using 
conventional diagnostic modalities has not been widely recognised 215,227,228. New 
techniques for the assessment of myocardial deformation has proven to be more 
sensitive than conventional echocardiography for the prediction of outcomes 229. 
Several strain studies have demonstrated not only right ventricular (RV) but also left 
ventricular (LV) dysfunction in SSc, although the severity of LV dysfunction was 
relatively mild 230, even with the use of sophisticated methods 220-222,224. The prognostic 
impact of this observation is unclear, as is its independence from RV dysfunction 
associated with pulmonary vascular disease, mainly as the LV and RV share several 
anatomical structures 231,232.  
The purpose of this study was to investigate the mechanism of subclinical LV 
dysfunction, and its prognostic value compared to RV function in patients with SSc.  
7.4 Methods 
7.4.1 Study design.  
We identified 116 consecutive patients with SSc without significant ischemic and 
valvular heart disease, who underwent echocardiography between July 2005 to June 
2014. In patients with multiple echocardiograms, the first report on the system was 
selected as the baseline. The diagnosis of SSc was based on the American Rheumatism 
Association’s criteria and confirmed by medical records 233. After the exclusion of 4 
patients due to inadequate echocardiographic image quality, 112 age- and gender-
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matched control patients without significant cardiac disease (e.g. routine studies before 
non-cardiac surgery) were identified, then clinical details were confirmed by viewing 
each medical record. The Tasmanian Health Research Ethics Committee approved the 
study as a low-risk protocol based on data linkage without the need for individual 
consent. 
7.4.2 Clinical data. 
 Clinical parameters (comorbidities, medications, vital signs, serum markers) at the 
time of echocardiography were comprehensively assessed by reviewing each medical 
record. The data of 6MWD and lung function test at the date closest to the 
echocardiogram were also collected in patients with SSc. 
7.4.3 Echocardiography.  
The earliest data stored in the echocardiography database was used for analysis. 
Transthoracic echocardiography was performed by experienced sonographers using a 
commercially available ultrasound machine (Vivid 7, Vivid 9, or Vivid I; GE 
Vingmed, Horten, Norway). Echocardiographic images were digitally recorded and 
downloaded to an imaging server for offline analysis. All echocardiographic 
parameters including strain were analysed by a single core reader, blinded to the other 
data.  
Conventional echocardiographic parameters were measured according to the 
recommendations of the ASE 234,235. LV volumes and LV ejection fraction (EF) were 
calculated by the modified Simpson method using 2-dimensional images, and LV 
volumes were indexed to BSA. LV mass was calculated according to the ASE formula 
and normalised to BSA. LAV was calculated by the modified Simpson’s method using 
2-dimensional images and indexed to BSA. The transmitral early diastolic velocity (E) 
was acquired in the apical 4-chamber view using pulsed-wave Doppler at the level of 
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the mitral valve tips during diastole. The early diastolic mitral annular tissue velocity 
(e’) was measured in the apical 4-chamber view with the sample volume positioned at 
both the septal and lateral mitral annulus with the average of these two values 
calculated. The combined assessment of E and e’ was used to calculate E/e’. The peak 
pressure gradient between RV and RA (TRPG) was measured on the continuous-wave 
spectral Doppler signal of tricuspid regurgitation. Systolic pulmonary artery pressure 
(SPAP) was estimated from TRPG and the maximum IVC diameter and its 
collapsibility 44. In addition, PVR was also calculated from peak tricuspid regurgitant 
velocity and RV outflow tract velocity time integral 47.  
7.4.4 LV strain and tricuspid annular velocity.   
We measured the two global strain parameters (global longitudinal strain (GLS) and 
global circumferential strain (GCS)) using standard methodologies for speckle 
tracking (Research Arena, Tomtec, Germany) 236. After manual tracing of the LV 
endocardial border, the dedicated software automatically tracked the myocardium 
throughout the cardiac cycle. Peak values of segmental longitudinal strain were 
obtained from grayscale–recorded images in the apical 4-chamber, 2-chamber, and 
long-axis views and GLS was obtained by averaging these peak values 89. The peak 
values of the six segmental circumferential strain curves were obtained from the short-
axis view at the papillary muscle level and averaged to provide GCS. Similarly, using 
speckle tracking, tricuspid annular peak systolic and early diastolic velocities (Ts’ and 
Te’) were measured from the RV apical 4-chamber view. The mean frame rate was 
54±21 frames/s. In the patients with AF, strain parameters were measured if the 
preceding and pre-preceding intervals were equal 237.  
Chapter 7.  Left and Right Ventricular Function in Systemic Sclerosis   148 
 
7.4.5 Follow-up.   
The primary outcome was unplanned all-cause admission or death after the index 
echocardiogram. The secondary outcome was heart failure (HF)-specific admission or 
death. The outcome was confirmed from each medical record. Patients were censored 
at the time of outcome or the end of study follow-up. 
7.4.6 Statistical analysis.   
Data were expressed as mean±SD or median (interquartile range). Overall, <5% of 
observations were missing, with the exception of Ts’ and Te’ (14%), and lung function 
parameters (48%). Missing Ts’ and e’ were imputed from propensity models using 
parameters without missing data (age, gender, body mass index, systolic blood 
pressure, HR, LV mass index, e’, E/e’, LA volume index, GLS, SPAP, diabetes 
mellitus, serum creatinine, AF, hemoglobin). Other continuous variables (<5%) were 
imputed using the corresponding mean value. The significance of differences between 
the groups was assessed using Student’s t-test or Mann-Whitney U-test according to 
the distribution of the study parameters. For categorical variables, the chi-square test 
or Fisher exact test were used, as appropriate. Univariable linear regression analysis 
was performed to assess the association between carbon monoxide diffusing capacity 
of the lungs (%DLCO) and cardiac function parameters. Univariable quadratic 
regression analysis was used to evaluate the associations between LV strain parameters 
and SPAP because it had better fit than a simple linear regression model.  
Univariable and multivariable Cox proportional-hazards models were used to 
determine the features associated with the outcomes. The optimal model was selected 
based on the significant variables in the univariable analysis and clinically relevant 
parameters. The incremental value of GCS and Ts’ were also assessed in 3 modelling 
steps, using nested models. The first step consisted of fitting a multivariable model of 
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age, gender, and 6MWD. Then, GCS was included in the second step. Finally, Ts’ was 
included in the third step. The change in overall log-likelihood ratio chi-square was 
used to assess the increase in predictive power after the addition of GCS and Ts’, and 
Harrell’s C statistic was used to evaluate model performance. The receiver operating 
characteristic (ROC) curve was used to determine the optimal cut-off values of GCS, 
Ts’, and 6MWD for predicting the outcomes. Comparisons of AUC in each parameter 
were performed with the method proposed by Delong et al.238 Reclassification was 
evaluated to assess the incremental benefit of adding Ts’ to the model based on age, 
gender, 6MWD and GCS with continuous net reclassification improvement (NRI) 
methods and integrated diagnostic improvement (IDI) 239,240.   
Inter- and intraobserver variabilities were examined for GLS, GCS, and Ts’ using the 
intraclass and interclass correlation coefficients. Measurements were performed in a 
group of 10 randomly selected subjects by one observer, then repeated on 14 separate 
days by two observers. Statistical analysis was performed using standard statistical 
software packages (SPSS software 20.0, SPSS Inc., Chicago, IL and R software 
ver.3.0.2 (http://cran.r-project.org/)), and statistical significance was defined by 
p<0.05. 
7.5 Results 
7.5.1 Clinical characteristics.  
Table 7.1 summarises the clinical characteristics of the patients with SSc and controls. 
Patients with SSc had significantly higher HR and prevalence of chronic lung disease, 
and lower blood pressure and less use of anti-hypertensive agents. About half of the 
SSc patients were treated with pulmonary vasodilators. The performance of lung 
function testing was incomplete in SSc patients, but their %DLCO appeared to be more 
impaired rather than forced vital capacity and forced expiratory volume in one second.  
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Table 7-1. Baseline characteristics in patients with systemic sclerosis and controls 
Variables 
Systemic sclerosis 
(n = 112) 
Control 
(n = 112) 
p Value 
Age (yrs) 64 (57-71) 64 (57-71) 1.00 
Male sex, n (%) 27 (24) 27 (24) 1.00 
Body mass index (kg/m2) 26.9 (23.7-28.4) 27.6 (24.8-29.4) 0.14 
Systolic blood pressure (mmHg) 121 (110-135) 128 (118-142) 0.01 
Diastolic blood pressure (mmHg) 73 (65-79) 75 (70-82) 0.01 
Heart rate (/min) 74 ± 13 69 ± 12 <0.01 
Comorbidities    
Hypertension, n (%) 31 (28) 39 (35) 0.31 
Diabetes , n (%) 12 (11) 15 (13) 0.53 
Atrial fibrillation, n (%) 9 (8) 6 (5) 0.42 
Chronic lung disease, n (%) 34 (30) 20 (18) 0.03 
Serum markers    
Blood urea nitrogen (mmol) 5.8 (4.6-6.7) 5.8 (4.3-6.5) 0.42 
Creatinine (mmol/L) 75 (63-86) 75 (64-81) 0.74 
Sodium (mmol/L) 139 (137-140) 139 (137-140) 0.95 
Hemoglobin (g/L) 133 ± 17 135 ± 15 0.49 
Medications    
β blockers, n (%) 7 (6) 9 (8) 0.60 
ACEi/ARB, n (%) 13 (12) 28 (25) 0.02 
Diuretics (loop or thiazide), n (%) 14 (13) 9 (8) 0.20 
Endothelin receptor antagonist, n (%) 54 (48) 0 (0) <0.01 
PDE5 inhibitor, n (%) 5 (4) 0 (0) <0.01 
6-minute walk test    
6 minute walk distance (m) 451 (386-498) - NA 
Lung function test (n = 58)    
% FVC 98 (81-110) - NA 
% FEV1 77 (69-81) - NA 
% DLco 63 (46-80) - NA 
Data are expressed as mean±SD or as number (percentage) or median (interquartile range).ACEi 
indicates Angiotensin-converting enzyme inhibitors; ARB, Angiotensin receptor blockers; PDE5, 
Phosphodiesterase type 5; %FVC, percent forced vital capacity; % FEV1, percent FEV; % DLco, 
percent predicted diffusing capacity of the lung for carbon monoxide. 
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7.5.2 Echocardiographic characteristic  
Table 7.2 shows a comparison of echocardiographic parameters, most of which were 
within the normal range. Although LV volume, EF, and diastolic parameters were not 
significantly different between the groups, pulmonary haemodynamics, RV function 
and LV strain parameters were significantly worse in patients with SSc compared to 
controls. These results were consistent even in SSc patients with SPAP <40mmHg and 
no administration of drugs for PH (n=44, Appendix Table 7.4). Both longitudinal and 
circumferential peak strain in the mid-septal segment were significantly more impaired 
in SSc patients than in controls (longitudinal: -16.5% [IQR -13.0--20.0] vs -19.0% 
[IQR -16.0--22.0], p<0.01, circumferential: -29.0% [IQR -23.5--36.0] vs -32.0% [IQR 
26.5--40.0], p=0.04) (Figure 1). 
Figure 7-1. Bull’s-eye diagram of a percent difference of left ventricular segmental 
strain (Longitudinal strain: 18 segments; Circumferential strain: 6 segments) between 
patients with SSC and controls ((strain in SSc/strain in control) x 100 (%)). Blue 
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Table 7-2. Echocardiographic characteristics in patients with systemic sclerosis and 
controls 
Data are expressed as mean ± SD or median (interquartile range).LA indicates left atrial; LV, left 
ventricular; PVR, pulmonary vascular resistance; RV, right ventricular; SPAP, systolic pulmonary 






(n = 112) 
Control 
(n = 112) 
p Value 
LV end-diastolic volume index 
(ml/m2) 
49 ± 13 48 ± 12 0.55 
LV end-systolic volume index 
(ml/m2)  
15 (10-20) 14 (11-17) 0.53 
LV ejection fraction (%)  69 ± 9 70 ± 7 0.76 
LV mass index (g/m2) 82 (68-95) 81 (70-97) 0.86 
LA volume index (ml/m2) 32 (27-41) 32 (26-36) 0.27 
E/A 1.04 (0.84-1.30) 1.04 (0.85-1.26) 0.84 
E velocity deceleration time (ms) 200 (167-232) 196 (166-229) 0.97 
e’ (cm/s) 8.6 (7.0-10.5) 8.5 (6.5-9.5) 0.07 
E/e’  9.1 (7.3-10.6) 9.0 (7.6-10.7) 0.55 
TRPG (mmHg) 23 (19-32) 19 (6-25) <0.01 
SPAP (mmHg) 27 (22-35) 24 (11-28) <0.01 
PVR (Wood units) 1.5 (1.2-1.9) 1.2 (0.9-1.5) <0.01 
LV global longitudinal strain (%) -18.3 ± 3.0 -19.5 ± 2.6 <0.01 
LV global circumferential strain (%) -26.9 ± 5.3 -29.5 ± 5.3 <0.01 
Ts’ (cm/s) 6.3 ± 1.9 6.8 ± 1.6 0.02 
TAe’ (cm/s) -5.4 (-4.1--6.5) -5.7 (-4.9--6.9) 0.03 
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There were weak but significant associations of diffusion capacity with SPAP 
(r2=0.07, p=0.04), but not PVR (r2=0.06, p=0.06), Ts’ (r2=0.05, p=0.08), GCS 
(r2=0.05, p=0.09), and GLS (r2=0.01, p=0.46).  
In SSc, a quadratic regression demonstrated a significant relationship between GCS 
and SPAP (r2=0.06, p=0.03) (Figure 7.2). No significant relationship could be defined 
between GLS and SPAP (r2=0.04, p=0.11). 
7.5.3 Events.   
During follow-up (median 1.9 years [IQR 1.1-3.8]), unplanned all-cause readmission 
or death occurred in 45 SSc patients (40%) and 38 controls (34%, p=0.33). In the case 
of SSc patients without PH (n=44), only one patient had an event. 
SSc patients (n=20, 18%) were slightly more likely to develop HF-specific 
readmission or death (secondary outcome) compared to controls (n=11, 10%, p=0.08). 
In patients with SSc, the common reasons for admission other than HF (n=11) were 
lung disease (n=5), renal disease (n=3), and ischemic heart disease (n=3). 
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Figure 7-2. The relationships between global longitudinal strain (7.2a), global 
circumferential strain (7.2b), and systolic pulmonary artery pressure in patients with 
SSC. The dotted line shows 95% confidence interval 
 
7.5.4 Associations of outcomes.  
Table 7.3 shows the univariable Cox regression analyses of the primary outcome in 
patients with SSc. All-cause admission or death was significantly associated with 
lower sodium, diuretic use, shorter 6MWD, impaired lung function, LV mass index, 
SPAP and PVR, GCS and Ts’. LV diastolic function parameters and GLS were not 
significantly associated with outcome. Similarly, HF-specific admission or death was 
also associated with the same variables and lower systolic blood pressure (Appendix 
Table 7.5). In the ROC analysis for predicting the primary outcome, the discriminative 
ability of 6MWD (AUC=0.79) was significantly larger than that of GCS (AUC=0.65, 
p=0.04), but not Ts’ (AUC=0.68, p=0.09) (Figure 7.3A). There was no significant 
difference of AUCs between Ts’ and GCS (p=0.80). The optimal cut-point for GCS 
was -25.8% (sensitivity 64%, specificity 67%), for Ts’ 6.9 cm/s (sensitivity 84%, 
specificity 47%), and for 6MWD 433 m (sensitivity 80%, specificity 67%). 
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Table 7-3.  Univariable Cox regression analysis for the association of all-cause 





Age (yrs)  1.02 (0.99-1.04) 0.26 
Male sex, n (%) 1.73 (0.90-3.33) 0.10 
Body mass index (kg/m2)  1.02 (0.96-1.08) 0.55 
Systolic blood pressure (mmHg) 0.98 (0.97-1.00) 0.06 
Diastolic blood pressure (mmHg) 0.98 (0.95-1.01) 0.21 
Heart rate (/min) 1.02 (1.00-1.04) 0.051 
Comorbidities 
  
Hypertension, n (%) 1.12 (0.62-2.03) 0.70 
Diabetes , n (%) 0.97 (0.38-2.46) 0.97 
Atrial fibrillation, n (%) 1.88 (0.79-4.47) 0.16 
Chronic lung disease, n (%) 1.61 (0.88-2.93) 0.12 
Serum markers  
  
Blood urea nitrogen (mmol) 1.01 (0.85-1.20) 0.90 
Creatinine (mmol/L)  1.01 (1.00-1.02) 0.18 
Sodium (mmol/L) 0.88 (0.80-0.97) <0.01 
Hemoglobin (g/L) 1.01 (1.00-1.02) 0.17 
Medications 
  
β blockers, n (%) 0.89 (0.12-6.73) 0.91 
ACEi/ARB, n (%) 1.43 (0.41-4.98) 0.58 
Diuretics (loop or thiazide), n (%) 2.96 (1.48-5.91) <0.01 
Endothelin receptor antagonist, n (%) 0.67 (0.37-1.23) 0.20 
PDE5 inhibitor, n (%) 2.83 (0.86-9.33) 0.09 
6-minute walk test 
  
6 minute walk distance (m) 0.99 (0.99-1.00) <0.01 
Lung function test (n = 58)   
% FVC 0.98 (0.97-1.00) 0.03 
% FEV1 0.97 (0.94-1.00) 0.09 
% DLco 0.96 (0.94-0.99) <0.01 
Echocardiographic parameters 
  
LV end-diastolic volume index (ml/m2) 0.98 (0.95-1.01) 0.13 
LV end-systolic volume index (ml/m2)  1.00 (0.94-1.06) 0.92 
LV ejection fraction (%)  0.98 (0.95-1.01) 0.24 
LV mass index (g/m2) 1.02 (1.01-1.03) <0.01 
LA volume index (ml/m2) 0.98 (0.96-1.02) 0.99 
E/A 0.65 (0.30-1.45) 0.30 
E velocity deceleration time (ms) 1.00 (0.99-1.01) 0.95 
e’ (cm/s) 0.92 (0.81-1.04) 0.18 
E/e’  1.07 (0.96-1.19) 0.21 
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TRPG (mmHg) 1.02 (1.01-1.03) <0.01 
SPAP (mmHg) 1.02 (1.01-1.03) <0.01 
PVR (Wood units) 1.69 (1.32-2.16) <0.01 
LV global longitudinal strain (%) 1.02 (0.91-1.13) 0.75 
LV global circumferential strain (%) 1.09 (1.03-1.16) <0.01 
Ts’ (cm/s) 0.75 (0.63-0.89) <0.01 
TAe’ (cm/s) 1.15 (0.97-1.37) 0.11 
ACEi; angiotensin-converting-enzyme inhibitor; ARB, Angiotension receptor blockade; PDE5, 
phosphodiesterase type 5 inhibitor; %FVC, percent forced vital capacity; % FEV1, percent FEV; % 
DLco, percent predicted diffusing capacity of the lung for carbon monoxide  LA indicates left atrial; 
LV, left ventricular; PVR, pulmonary vascular resistance; RV, right ventricular; SPAP, systolic 
pulmonary artery pressure;TRPG, tricuspid regurgitation pressure gradient; Ts’, tricuspid annular peak 
systolic velocity; TAe', tricuspid annular peak early diastolic velocity.  
ROC analysis for predicting the secondary outcome also showed similar results 
(Figure 3B). There was a significant difference of AUCs between 6MWD and GCS 
(p=0.03), but other AUC comparisons were not significant. Addition of Ts’ into the 
model reduced the impact of GCS. In the final model, 6MWD and Ts’ were 





Figure 7-3. ROC curves for predicting all-cause admission or death (7.3a) and HF-specific 
admission or death (7.3b) in patients with SSC. GCS indicates global circumferential 
strain; Ts’, tricuspid annular peak systolic velocity; 6MWD, 6-minute walk distance; 
95%CI, 95% confidence interval 
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7.5.5 Incremental value and independence of RV and LV function for 
outcome.   
In sequential Cox models for predicting all-cause readmission or death in patients with 
SSc, the model based on age, gender, and 6MWD was significantly improved by the 
addition of GCS and further improved by adding Ts’ (Figure 7.4). Moreover, the 
addition of Ts’ to the model based on age, gender, 6MWD, and GCS led to a further 
significant reclassification improvement in the overall group (Continuous NRI: 0.63, 
p<0.01). However, IDI (0.02) was not significant (p=0.32).  
 
Figure 7-4.  Incremental value of Ts’ over clinical parameters and GCS as a correlate 
of all-cause readmission or death in patients with SSC. GCS indicates global 
circumferential strain; Ts’, tricuspid annular peak systolic velocity 
 
7.5.6 Reproducibility.   
The intraclass and interclass correlation coefficients were, 0.93 (95%CI 0.72 to 0.98) 
and 0.92 (95%CI 0.67 to 0.98) for GLS, 0.91 (95%CI 0.67 to 0.98) and 0.93 (95%CI 
0.70 to 0.99) for GCS, and 0.86 (95%CI 0.44 to 0.97) and 0.85 (95%CI 0.32 to 0.97) 
for Ts’. All reproducibility and agreement therefore fell into the good to excellent 
ranges.   
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7.6 Discussion 
The present study demonstrates the relative prognostic value of RV and LV 
dysfunction in SSc patients, and points towards a mechanism for linking these features. 
Similar to previous reports, LV deformation in SSc – while reduced compared with 
controls - was within the normal range. GCS appeared to be more affected by increased 
systolic RV pressure and associated with adverse outcome than GLS. The 
measurement of GCS had an incremental benefit over 6-minute walk test for predicting 
outcome. However, the association between GCS and outcome appeared to be 
mediated by RV function, and RV systolic function and 6MWD showed the only 
independent association with outcome in SSc.  
7.6.1 Mechanism of LV dysfunction in SSc.   
SSc is a systemic CTD characterised by inflammation and fibrosis involving distinct 
target organs 215. Histological studies have shown myocardial fibrosis in up to 80% of 
patients with SSc 212, and myocardial fibrosis has been considered as the primary 
mechanism of LV dysfunction. In the present study, a mild deterioration of LV 
longitudinal and the circumferential strain was observed compared to controls 219-222, 
consistent with previous observations of impaired LV longitudinal strain in SSc, and 
thought to be associated with subendocardial myocardial fibrosis 219-222,224,241.  
The deterioration of segmental strain in the septal segments, likely affected by both 
LV and RV function, appeared to contribute to the impairment of global strain. Also, 
GCS was weakly associated with increased SPAP and reduced diffusion capacity. 
These results suggest that LV dysfunction could be affected by not only LV 
myocardial fibrosis but also by RV dysfunction and pulmonary haemodynamics, 
reflecting ventricular interdependence in patients with SSc. In addition to its 
association with RV longitudinal systolic deformation, RV pressure overload 
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influences the IVS and LV geometry. An altercation of the geometry impairs LV 
torsion and segmental longitudinal and circumferential strain, more for the septum than 
for the free wall of the LV 231. These findings are supportive of our observations; in 
the present study, SSc patients had significantly higher PVR, and half of the patients 
were treated pulmonary vasodilators, which could minimise the effects of chronic RV 
pressure overload. 
7.6.2 Prognostic value of LV dysfunction in SSc.   
RV dysfunction, usually caused by vascular and interstitial lung disease resulting in 
PH, has frequently been reported, and strongly associated with adverse outcomes in 
SSc patients 87,215,216,242. The present study also demonstrated that RV dysfunction 
associated with adverse outcome, independent of and incremental to functional 
capacity and LV deformation parameters in SSc. However, LV dysfunction was not 
independently associated with outcome, implying that RV dysfunction mediated its 
univariable association. Also, there was only one adverse event in SSc patients without 
PH. Above all, these results suggest that the predictive power of LV dysfunction seems 
to be weaker than RV dysfunction in SSc, although this could depend on the severity 
of PH in the study cohort.   
7.7 Study limitations.  
 Our data should be interpreted in the context of their limitations. First, our 
observational study carries the risk of unmeasured confounders. However, the 
prevalence of SSc (50 to 300 cases per 1 million persons) 215 makes a prospective 
design difficult, and the present study sample was among the largest reported to date 
87,219-222. Second, in this study, half of the patients were already on pulmonary 
vasodilator therapy, implying that the prognostic impact of RV dysfunction might be 
attenuated. However, the association with adverse outcome was similar even in SSc 
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patients without PH. Finally, we did not measure RV global strain, which requires the 
whole RV to be visible throughout the cardiac cycle. As a surrogate, we measured 
tricuspid annular velocity using speckle tracking, which is angle-independent and has 
good reproducibility 44. In the multivariable analysis, the majority of predictors 
displayed weak strength of contribution. The inclusion of parameters together could 
lead to an overstatement of contribution of each parameter in the model.  
7.8 Conclusion.  
Subclinical LV dysfunction, as well as RV dysfunction, is observed in SSc. The 
impairment of LV circumferential deformation was associated with adverse outcome 
and had an incremental benefit over functional capacity for predicting outcome. 
However, this association was related to RV dysfunction; consequently, RV 
dysfunction and functional capacity were more strongly associated with clinical 
events.
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7.9 Appendix 
Appendix Table 7-4. Echocardiographic characteristics in patients with systemic 







(n = 44) 
Control 
(n = 44) 
p 
Age (yrs)  60 (52-64) 60 (52-64) 1.00 
Male sex, n (%) 11 (25) 11 (25) 1.00 
LV end-diastolic volume index 
(ml/m2) 
48 ± 10 50 ± 13 0.33 
LV end-systolic volume index 
(ml/m2)  
14 (11-20) 15 (11-18) 0.93 
LV ejection fraction (%)  68 ± 9 70 ± 7 0.47 
LV mass index (g/m2) 80 (65-94) 78 (68-94) 0.70 
LA volume index (ml/m2) 30 (25-39) 31 (25-36) 0.78 
E/A 1.12 (0.92-1.31) 1.15 (0.89-1.43) 0.52 
E velocity deceleration time (ms) 181 (156-218) 200 (167-230) 0.20 
e’ (cm/s) 8.6 (7.4-10.5) 8.6 (7.3-10.7) 0.79 
E/e’  8.2 (7.3-10.4) 8.8 (7.3-9.8) 0.92 
TRPG (mmHg) 22 (18-25) 16 (5-23) <0.01 
SPAP (mmHg) 26 (22-28) 21 (9-26) <0.01 
PVR (Wood units) 1.4 (1.2-1.7) 1.1 (0.9-1.4) <0.01 
LV global longitudinal strain (%) -18.6 ± 3.0 -20.0 ± 3.0 0.03 
LV global circumferential strain (%) -27.8 ± 5.4 -30.5 ± 5.8 0.02 
Ts’ (cm/s) 6.2 ± 1.6 7.2 ± 1.7 <0.01 
TAe’ (cm/s) -5.4 (-4.3--6.4) -6.1 (-5.5--7.3) 0.03 
 
Chapter 7.  Left and Right Ventricular Function in Systemic Sclerosis   162 
 
Appendix Table 7-5. Association of HF-specific admission or death in patients with 





Age (yrs)  1.02 (0.98-1.06) 0.37 
Male sex, n (%) 2.05 (0.78-5.38) 0.14 
Body mass index (kg/m2)  1.00 (0.92-1.09) 0.99 
Systolic blood pressure (mmHg) 0.96 (0.93-1.00) 0.01 
Diastolic blood pressure (mmHg) 0.96 (0.91-1.00) 0.058 
Heart rate (/min) 1.01 (0.98-1.05) 0.46 
Comorbidities 
  
Hypertension, n (%) 0.82 (0.33-2.03) 0.67 
Diabetes , n (%) 1.75 (0.51-6.04) 0.38 
Atrial fibrillation, n (%) 2.12 (0.62-7.30) 0.23 
Chronic lung disease, n (%) 2.63 (1.09-6.37) 0.03 
Serum markers  
  
Blood urea nitrogen (mmol) 0.91 (0.69-1.20) 0.49 
Creatinine (mmol/L)  1.00 (0.97-1.03) 0.98 
Sodium (mmol/L) 0.90 (0.78-1.03) 0.12 
Hemoglobin (g/L) 1.01 (0.98-1.04) 0.58 
Medications 
  
β blockers, n (%) 0.70 (0.09-5.24) 0.73 
ACEi/ARB, n (%) 1.77 (0.59-5.34) 0.31 
Diuretics (loop or thiazide), n (%) 5.90 (2.41-14.47) <0.01 
Endothelin receptor antagonist, n (%) 1.16 (0.47-2.87) 0.75 
PDE5 inhibitor, n (%) 2.67 (0.77-9.33) 0.09 
6-minute walk test 
  
6 minute walk distance (m) 0.99 (0.99-1.00) <0.01 
Lung function test (n = 58)   
% FVC 0.96 (0.94-0.99) <0.01 
% FEV1 1.02 (0.97-1.08) 0.50 
% DLco 0.94 (0.90-0.98) <0.01 
Echocardiographic parameters 
  
LV end-diastolic volume index (ml/m2) 0.98 (0.94-1.01) 0.12 
LV end-systolic volume index (ml/m2)  1.01 (0.94-1.08) 0.85 
LV ejection fraction (%)  0.97 (0.92-1.02) 0.19 
LV mass index (g/m2) 1.02 (1.00-1.04) 0.02 
LA volume index (ml/m2) 1.00 (0.97-1.04) 0.90 
E/A 0.76 (0.24-2.43) 0.65 
E velocity deceleration time (ms) 1.00 (0.99-1.01) 1.00 
e’ (cm/s) 0.85 (0.70-1.03) 0.10 
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E/e’  1.11 (0.97-1.28) 0.14 
TRPG (mmHg) 1.03 (1.02-1.05) <0.01 
SPAP (mmHg) 1.03 (1.02-1.05) <0.01 
PVR (Wood units) 1.52 (1.24-1.85) <0.01 
LV global longitudinal strain (%) 1.03 (0.89-1.20) 0.68 
LV global circumferential strain (%) 1.10 (1.01-1.20) 0.04 
Ts’ (cm/s) 0.68 (0.51-0.90) <0.01 
TAe’ (cm/s) 1.26 (0.97-1.65) 0.09 
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7.10 Postscript.  
The previous chapter shows that LV function is a reliable outcome marker in SSC 
patients. However, this association was confounded by RV dysfunction; consequently, 
RV dysfunction and functional capacity were more strongly associated with clinical 
events. RV dysfunction can manifest through a number of markers – but due to the 
arrangement of RV fibres, contraction of the RV is comprehensively reflected from 
EF. Haemodynamic markers are often measured, but the infiltrative process could 
provoke RV dysfunction despite normal pulmonary pressures. Speckle tracking plays 
an essential role in this, but other aspects of the echocardiographic exam may be 
abnormal. No single parameter should be considered in isolation.  
As mentioned previously, SSC patients are a unique group in which there is an 
interplay of left and right heart disease. The distinction between pre versus post 
capillary hypertension in these patients can often make for complex clinical analysis. 
The diagnosis of diastolic dysfunction combines tissue Doppler, haemodynamics, and 
structural changes. Eventually, downstream effects of increased LA pressure will lead 
to structural abnormalities within the RV. The clear differentiation of left versus right 
heart disease is difficult in the SSC cohort.   
In the forthcoming chapter, we look into how current clinical guidelines work in a 
population at risk for PHT, and further investigate the use of speckle tracking as a 
novel tool in preclinical disease differentiation.  
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8 PAH differential diagnosis; Echocardiography for the 
Differential diagnosis of pre versus postcapillary pulmonary 
arterial hypertension 
8.1 Preface; Differential diagnosis of pre versus postcapillary 
pulmonary hypertension 
Previously the strength of LV versus RV markers for prediction of outcome in SSC 
was assessed. As mentioned, the pressure is routinely used within this cohort to screen 
for the presence of pulmonary vascular disease. The importance of determining the 
cause of raised PA pressure has a substantial impact on clinical follow-up.  
PH is divided into Group 1 (increased pulmonary artery resistance) and Group 2 (PH 
due to left heart disease leading to raised left atrial pressure). Overall, left ventricular 
related PH is the predominant cause of raised pressures within the general population7. 
The clinical sonographer is faced with the dilemma of determining the 
pathophysiological basis of raised pulmonary pressures.  
Diastolic dysfunction refers to the impaired filling of the heart due to increases in 
ventricular stiffness. Increased pressures within the left atrium lead to congestion 
within the pulmonary circulation, creating an increase in pulmonary artery pressure. 
Guidelines have been published regarding the echocardiographic diagnosis of diastolic 
dysfunction 243. The gold standard is through the invasive measurement of the LV 
relaxation time constant (tau), and PCWP to determine invasive pressures). Guidelines 
suggest four categories of diastolic dysfunction severity, with the determination based 
on four criteria; left atrial size, tricuspid jet velocity, tissue velocities, and estimation 
of LV filling pressures with E/e’ ratio 243.   
In a PH cohort, the diagnostic accuracy of this algorithm may be altered. Current 
diagnostic guidelines also do not allude to the diagnostic strength of parameters. This 
chapter aims to compare strain and other echocardiographic parameters in 
Chapter 8.  PH Differential Diagnosis    167 
differentiating PH type. If diastolic dysfunction criteria are not sufficient, perhaps LV 
GLS could be helpful in distinguishing pathology.   
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8.2 Abstract 
Background. Treatment selections for PH are dependent on etiology. We sought 
whether recently published recommendations for non-invasive assessment of PCWP 
could facilitate the recognition of pulmonary venous hypertension in dyspneic patients 
undergoing right RHC for evaluation of suspected PH.  
Methods. We recruited 157 consecutive patients undergoing RHC with 
echocardiographic EF >50% (median interval 1 day) for investigation of dyspnea. The 
proposed algorithm included tricuspid regurgitant maximum velocity (TRV max), 
tissue Doppler annular velocities (e’), average E/e’ and LAV ml/m2. Bivariate logistic 
regression, including receiver-operating characteristic (ROC) curves, were used to 
assess predictive ability using the area under the receiver operator curve (AUC).  
Results. Patients with preserved EF and raised PCWP showed significantly increased 
LAV ml/m2 and E/e’, but not TRV max or average e’. Bivariate logistic regression 
showed E/e’ (OR 0.15 95% CI 0.06-0.38, p<0.001) and LAV ml/m2 (OR 0.43 95% CI 
(0.22-0.84), p=0.01) associated with raised PCWP, and LAV and E/e’ showed only 
modest predictive ability for determining raised wedge pressure (AUC=0.64 and 0.69). 
Only 45% of patients with PCWP>15 mmHg had >2 abnormal parameters. Alternative 
markers of post-capillary PH were increased LV mass (AUC=0.60), LV end-diastolic 
volume (AUC=0.64), impaired GLS (AUC=0.47) and pulmonary to left atrial ratio 
(ePLAR; AUC=0.73).  
Conclusions. The detection of post-capillary PH appears to be better predicted with 
LV markers than recently recommended algorithms for detecting raised PCWP.   
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8.3 Background 
Echocardiographic assessment of pulmonary artery pressure and LV dysfunction are 
central to the investigation of dyspnoea 244,245. PH may be due to changes in the 
pulmonary arterial bed (pre-capillary PH) 10, or due to increased left atrial pressure 
(LAP) (post-capillary PH) 10,246. Elevation of pulmonary venous pressure leads to 
elevations in right heart pressures; 44-80% of patients with diastolic dysfunction (DD) 
develop PH 247 in referral and community-based cohorts 248. The distinction has 
significant implications, particularly for pulmonary vasodilator therapy 249 that are 
relatively contraindicated in Group 2 PH  
The predictive ability of echocardiographic methods for the differentiation of normal 
from abnormal filling pressures in heart failure with preserved EF remains 
controversial 250. However, new combinations of measurements have been proposed 
to characterise abnormal LV function. Recent recommendations have proposed that 
DD may be diagnosed in most patients with a normal EF, by a majority of abnormal 
average E/e’, annular velocities (e’), tricuspid regurgitation velocity (TRV max) and 
left atrial volume (LAV) index 243. In patients with impaired EF or myocardial disease, 
increased LV filling pressure may be recognized if the E/A ratio is >2, or E/A ratio is 
0.8-2 (or E/A<0.8 with a peak E velocity of >50 cm/sec) if there is a majority of 
abnormal average E/e’, tricuspid regurgitation velocity (TRV max) and left atrial 
volume (LAV) index. In our practice, RHC is performed to identify the cause of 
unexplained dyspnea when this has therapeutic implications, especially in relation to 
the use of pulmonary vasodilator therapy. Accordingly, we sought whether the 
accuracy of this new diagnostic algorithm for recognition of raised filling pressures 
was superior to LV parameters in dyspneic patients undergoing RHC.  
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8.4 Methods 
8.4.1 Patient selection.  
Consecutive patients were included if they underwent RHC and echocardiography 
(median interval 1 day) between July 2003 to April 2015. Patients were retrospectively 
recruited from the cardiac catheterisation laboratories of the Royal Hobart Hospital 
(Hobart, Australia) and the Princess Alexandra Hospital (Brisbane, Australia). Patient 
exclusions are shown in Figure appendix 8.4.  Approval was obtained from the 
Tasmanian Human Research Ethics committee (H0013333) and Metro South Human 
Research Ethics Committee (HREC 16/QPAH/008). 
8.4.2 Echocardiography.  
Echocardiography was performed using commercial equipment (Vivid 7, Vivid i and 
Vivid e9, General Electric Medical Systems, Milwaukee, WI; ie33, Philips, Andover. 
MA).  A single reader performed all LV and RV measurements according to ASE 
guidelines 101. LV EF was measured from the apical 4- and 2-chamber views 
(Simpson’s biplane method) 101. LV mass was calculated from the parasternal long 
axis (ASE method) 101. RVEDA and RVESA were calculated from the apical RV 
focused view; FAC was calculated as the percentage change in RVEDA and RVESA 
101 . PASP was measured from the peak TR velocity using the modified Bernoulli 
equation 29. RAP was derived from the IVC dimension response to inspiration from 
the subcostal view 44.  
Peak velocities of the early (E) and late (A) diastolic filling were derived from 
transmitral inflow. Peak diastolic early velocity (e’) of the lateral and septal mitral 
annulus was recorded from the apical 4-chamber view (Pulsed-wave tissue Doppler 
imaging). E/e’ was calculated from early transmitral E wave divided by the average e’ 
to infer LV filling pressures (LVFP) 243. LAV measurements were performed from the 
apical 2- and 4- chambers (area-length method) 101. Recommended parameters were 
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dichotomized based on ASE guidelines regarding diastolic evaluation with 
LVEF>50%: 1) Average E/e’ >14, 2) Septal e’ <7 cm/s or lateral <10 cm/s, 3) TR 
velocity >2.8 m/s, 4) LAV 34 ml/m2. DD was defined as >50% positive criteria 
(Figures 8.1, 8.2 and 8.3). To assess the efficacy of the guidelines for assessing DD, 
groups were created 243; Group 1 (E/e’+, e’+, LAV+), Group 2 (E/e’+, e’+, TR+), 
Group 3 (E/e’+, TR+, LAV+), Group 4 (e’+, TR+, LAV+), Group 5 (All markers +), 
Group 6 (2 markers+), Group 7 (1+), Group 8 (no +).  Furthermore, patients were 
categorised based on the classification of DD regardless of EF: 1) Normal LAP with 
grade 1 DD, 2) Indeterminate, 3) Increased LAP and grade 2 DD, 4) Increased LAP, 
grade 3 DD.  Pulmonary to left atrial ratio (ePLAR) was calculated from the peak TR 
velocity divided by the transmitral E/e’ (TR V max/E/e’) 251. 
Wall motion tracking software that accepted DICOM images (Image-Arena, TomTec 
Gmbh, Unterschleissheim, Germany,) was used to analyse the apical 4-, 2- and 3-
chamber LV views, which were averaged to produce LV global strain (LV GLS). 
Optimal LV cavity views were selected, with the LV end-diastolic endocardial border 
manually traced along the myocardium (borders were automatically tracked frame-by-
frame). Manual adjustments were performed when necessary, and regions excluded as 
required (e.g. inadequate tracking). RVFWS was performed from the RV focused view 
(basal, mid and apical segments averaged).  
8.4.3 Right heart catheterisation.   
RHC studies were undertaken after premedication and local anesthesia. A 4-lumen 110 
cm 7-Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA) was floated to the 
right heart, and resting measurements of right atrial, right ventricular, pulmonary 
arterial and PCWP were made at end-expiration using a pressure transducer (21BB, 
ITL Healthcare, Chelsea Heights, Australia). The transducer was calibrated to 
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atmospheric pressure at the level of the RA and re-checked at intervals to avoid zero 
drift. CO was determined by thermodilution, using an average of four consecutive 
values that varied <10%. Electrocardiographic (ECG) leads were connected to both 
arms and the left leg, allowing three ECG channels for the timing of signals. All 
haemodynamic monitoring was recorded using a Horizon SE Haemodynamic System 
(Mennen Medical Ltd., Yavne, Israel) and subsequently analysed off-line. 
Figure 8-1. Diastolic dysfunction interpretation and comparisons with invasive 
pressure assessment 
 
8.1 patient correctly identified as having normal PCWP through echocardiography. 
Tissue Doppler velocities reduced, although, E/e’, LAV indexed and TR v max are all 
within normal ranges. Diagnosis confirmed with invasive pressure assessment. 
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Figure 8-2. Incorrect identification of normal PASP 
 
Incorrect echo identification of normal PCWP and normal PASP. Reduced tissue 
Doppler velocities in the presence of normal E/e’, normal LAV indexed and TR V max. 
The patient shows both raised wedge pressure, and mean pulmonary artery pressure 
on invasive examination. 
8.4.4 Statistical analysis.  
Statistical analysis was performed using standard software (SPSS 20.0, IBM, Chicago, IL) 
Data are presented as mean and standard deviations. Data that were not normally distributed 
are presented as medians and inter-quartile range. In patients with missing BSA, the group 
mean was substituted (1.73 in women and 1.96 in men). Student T-test was used to compare 
parametric data, and the Mann-Whitney U-test used to compare significance, with statistical 
significance set to p<0.05. Bivariate logistic regression was used to compare groups.  Receiver 
operator characteristic (ROC), area under the curve (AUC) was performed with MedCalc 
Statistical software version 16.8.4 (MedCalc Software bvba, Ostend, Belgium). Youden Index 
was calculated as sensitivity + specificity. 
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Figure 8-3. Incorrect identification of normal PCWP, with elevated pulmonary 
pressures identified. 
 
Incorrect identification of normal PCWP, with elevated PASP, correctly identified. 
Septal tissue Doppler velocities are reduced, increased LAV indexed, with raised TR 
v max. After the invasive assessment, the subject was found to have normal wedge 
pressure, with increased mean pulmonary artery pressure 
8.5 Results 
8.5.1 Patient characteristics.  
Of 190 consecutive patients with invasive PCWP and echocardiography (Figure 8.1), 
157 had EF >50% (60 with PCWP>15 mmHg, and 97 with PCWP<15 mmHg). AF 
was present in 3 patients in each PCWP group, and TR v max was not measureable in 
8. The 33 patients with EF<50% (Appendix Table 8.4) had significantly greater PCWP 
(p<0.001), LAV (p=0.001), E/e’ septal (p=0.03), and e’ septal (p=0.001).  
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Age 62(13.8) 63(55-63) 59(16.0) 65 (11.8) 0.01 
Sex (female) 72%(172)  80 (78) 41 (68) 0.07 
SBP 126±27 125 (112-134) 123(18) 126 (33) 0.58 
DBP 72±10 70 (65-80) 72 (9) 68 (19) 0.38 
HR 76±14 75 (66-85) 77 (15) 73 (13) 0.07 
BSA 1.8±0.21 1.8 (1.8-1.8) 1.8 (0.15) 1.8 (0.16) 0.03 
Invasive      
 PAPs (mmHg) 49±21.5 41 (35-60) 46.6(20.3) 50(20.6) 0.38 
 PAPm (mmHg) 33.0±9.5 31 (26-45) 34.1(14.6) 38.0(12.6) 0.08 
 PCWP (mmHg) 12.8±4.0 14 (10-16) 10.0(3.0) 18.4(4.0) <0.001 
 Cardiac output 4.8±1.2 4.7 (3.9-6.1) 5.2 (1.5) 5.4 (2.3) 0.59 
Echocardiography      
 LV Mass (gm) 160±64.1 148(112-188) 138.6(50.8) 164.3(62.6
) 
0.009 
 LV Mass 
(gm/m2) 
88.4±34.5 83(64-104) 77.4(26.1) 89.5(34.1) 0.02 
 LVEDV (ml) 89.8±45.5 81 (63-97) 75.4(26.2) 90.6(35.1) 0.005 
 LVESV (ml) 40.7±34.7 32 (23-43) 29.3(12.0) 34.2(15.6) 0.04 
 SV (ml) 50±19.1 46 (38-56) 46(18.0) 52(20) 0.02 
 EF (%) 58±12.5 61 (52-66) 62(7.1) 63(7.8) 0.60 
 LVGLS (%) 17±4.5 18 (15-20) 19(3.4) 18(3.9) 0.27 
Diastology      
 e’ septal (cm/s) 5.8±2.2 5 (4-7) 6.1(2.5) 5.8(2.5) 0.44 
 e’ lat (cm/s) 8.8±3.0 8(6-10) 9.0(3.3) 8.4(2.5) 0.24 
 e’ average 
(cm/s) 
7.4±2.4 7 (6-9) 8.0(3.3) 7.4(2.9) 0.30 
 E/e’ septal 13.0±7.8 12 (9-18) 11.1(3.8) 18.1(12.5) <0.001 
 E/e’ lateral 8.5±5.4 8(6-12) 8.0(4.2) 11.3(7.5) 0.006 
 E/e’ avg 10.8±6.4 10(8-14) 9.7(4.2) 15.0(10.9) 0.001 
 LAV ml/m2 33.6±15.7 31 (23-49) 30.3(14.9) 42.3(22.3) <0.001 
 Mitral valve E 
wave 
0.67±0.23 0.70 (0.52-0.89) 0.68(0.25) 0.85(0.31) 0.001 
 Mitral valve A 
wave 
0.68±0.22 0.71(0.54-0.84) 0.71(0.21) 0.71(0.25) 0.87 
 EA ratio 1.1±0.68 0.87 (0.72-1.2) 1.0(0.51) 1.3(0.91) 0.03 
 DT cm/s 234±55.1 223 (185-272) 234(55.2) 232(55.9) 0.81 
Right side      
 RVEDA (cm2) 22.5±8.9 21 (14-27) 21.1(7.9) 21.9(8.2) 0.56 
 FAC (%) 29.5±13.6 32 (23-40) 31.2(13.4) 33.9(11.6) 0.23 
 RV Free wall 
(%) 
16.6±6.1 16(13-21) 17.4(5.9) 17.6(5.5) 0.84 
 PASP echo 
(mmHg) 
57.6±25.4 47 (32-66) 50.9(24.6) 52.2(23.6) 0.77 
 RAA (cm2) 20.4±8.0 19 (14-26) 19.2(7.7) 22.1(8.3) 0.04 
 PVR (w.u) 3.7±1.8 3.2 (2.2-4.5) 3.8(2.0) 3.2(1.2) 0.15 
 Tr Vmax (cm/s) 3.5±0.84 3.1 (2.8-3.9) 3.3(0.80) 3.3(0.79) 0.72 
 SBP- systolic blood pressure, DBP- Diastolic Blood pressure, Pulmonary artery pressure systolic, PAPm- Pulmonary artery 
pressure mean, CO- Cardiac Output, PCWP- pulmonary capillary wedge pressure, LVEDV- left ventricular end diastolic volume, 
LVESV- Left ventricular end-systolic volume, EF – Ejection fraction , LVGLS-left ventricular global longitudinal strain,  DT- 
deceleration time, RVEDA- Right ventricular end-diastolic area, FAC- Fractional area change, RAA- right atrial area, PVR-
Pulmonary vascular resistance.  
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8.5.2 Association of raised PCWP 
Patients with preserved EF (n=157) were divided based on invasive PCWP <15 or >15 
mmHg (Table 8.1). These groups showed differences in E/e’ avg (p=0.001), LAV 
(p<0.001) and LV mass (p=0.02). However, there were no differences between groups 
in e’ (p=0.30), or TR velocity (p=0.72). Table 8.2 shows the strength of the association 
between echo markers and raised PCWP in a bivariate logistic regression. The 
strongest associations were raised E/e’ and LAV.  
Most patients (87%) were categorized as E/A<0.8 and E>50 cm/s or E/A from 0.8-2.0, 
and 73 had normal LAP. We were unable to categorize 27% of patients. Table 8.3 
summarizes patients with normal EF, according to whether PCWP was >15 mmHg or 
not. Significantly more patients with elevated PCWP had dilated LAV (32% vs 53%, 
p=0.01) and increased E/e’ (11% vs 38%, p<0.001). However, there were no 
significant differences in septal e’ (66% vs 73%, p=0.86), TR velocity (75% vs 77%, 
p=0.76), LV mass (16% vs 25%, p=0.13) or LV GLS (59% vs 66%, p=0.40).  
Table 8-2. Echocardiographic parameters associated with elevated PCWP. In this 
logistic regression, the only significant associations were with E/e’ and LA volume 
 
TR Vmax- Tricuspid jet maximum regurgitant velocity, LAV ml/m2- left atrial volume ml/m2, LV mass index – Left ventricular 
mass index gm/m2, LV GLS – left ventricular global longitudinal strain 
8.5.3 Estimation of raised PCWP.  
The discriminant ability of diastolic parameters for PCWP >15 mmHg was assessed 
from ROC curves (Appendix Figure 8.5). Only LAV and average E/e’ showed 
significant but modest predictive ability (AUC 0.61, p=0.03 and AUC 0.64, p=0.007 
 OR (95%CI) p 
e’ lateral >10 cm/s  1.0 (0.47;2.1) 1.0 
e’ septal  >7 cm/s 0.73(0.32;1.6) 0.44 
Any e’ normal  0.85(0.39;1.9) 0.69 
E/e’ average <14 0.15(0.06;0.38) <0.001 
TR vmax ( <2.8 cm/s) 0.76(0.42;1.9) 0.76 
LAV ml/m2  (< 34 ml/m2)  0.43(0.22;0.84) 0.01 
LV mass index  gm/m2 (<115 or 96 gm/m2 by gender) 0.54(0.24;1.2) 0.14 
LV GLS (%) (>19.7%) 0.74(0.37;1.5) 0.40 
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respectively). In patients with EF >50%, an E/e’ >14 had had the highest accuracy 
(94/134, 70%) and the highest specificity (71/80, 89%), but with a lower sensitivity 
(23/54, 43%). In contrast, a peak TR velocity >2.8 m/s has a lower accuracy (70/154, 
45%) and specificity (24/94, 26%) but higher sensitivity (46/60, 77%). The accuracy 
of an indexed LAV >34 ml/m2 was intermediate (93/150, 62%), with a low sensitivity 
(31/59, 53%) but better specificity (71/80, 89%). 
Table 8-3. Echocardiographic features associated with each PCWP group 





PCWP >15 mmHg p 
LAV ml/m2  60 (38%) 29 (32%) 31 (53%) 0.01 
e’ lat  <10 cm/s 80 (64%) 48 (64%) 32 (64%) 1.0 
e’ septal < 7  cm/s 80 (69%) 45 (66%) 35 (73%) 0.44 
Any e’ abnormal  100 (74%) 59 (73%) 41 (76%) 0.49 
E/e’ avg>14  32 (24%) 9 (11%) 23 (38%) <0.001 
TR vmax >2.8 cm/s 116 (75%) 70 (75%) 46 (77%) 0.76 
Other echo markers  
LV Mass (>115 or 96 
gm/m2 by gender) 
19 (19%) 15 (16%) 15 (25%) 0.13 
LV GLS (<19.7%) 92 (62%) 55 (59%) 37 (66%) 0.40 
No patients categorised into group 3. LAV ml/m2 – left atrial volume indexed, TR Vmax- Tricuspid valve maximum regurgitant 
velocity, LV Mass gm/m2- Left ventricular mass index, LV GLS – left ventricular global longitudinal strain. 
 
The diastolic guidelines correctly identified 106 patients with normal wedge pressure 
(65% of all 162 patients, regardless of EF), 75 of whom (71%) had PCWP <15 mmHg. 
They identified 17 patients with increased LAP, of whom 11 (65%) had PCWP >15 
mmHg. The remaining 39 patients (n=24%) could not be determined using the 
guidelines (either because of difficulties with attributing an E/A ratio due to AF or E/A 
fusion), and 20 of these had PCWP >15 mmHg. 
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Pre versus postcapillary pulmonary arterial hypertension. Patients (irrespective of 
EF) were divided into pre-capillary (PAPm >25 mmHg with PCWP <15 mmHg, n=89) 
versus post-capillary PH (PAPm >25 mmHg with PCWP >15 mmHg, n=79)) 
(Appendix Table 8.5). Post-capillary PH patients were significantly older (p=0.02), 
otherwise clinical variables were similar. LV mass (p=0.001), EDV (p<0.001) and E/e’ 
(p<0.001) were significantly greater in the post-capillary group, and EF (p=0.01) and 
LV-GLS were lower (p=0.001), but there no differences in tissue Doppler velocities. 
The post-capillary group showed a significantly larger RA area (p=0.008). ePLAR was 
significantly different between groups (Appendix Figure 8.6) (p<0.001), and showed 
modest discrimination (AUC=0.73, p<0.001) (Appendix Figure 8.7); a cut-off of 0.21 
m/s (derived from the Youden index) derived showed good sensitivity (92%) and 
modest specificity (57%). Alternative markers of post-capillary PH were increased LV 
mass (AUC=0.68, p<0.001), LV EDV (AUC=0.71, p=0.0001), impaired LVGLS 
(AUC=0.64, p=0.007). Comparison of the AUC showed ePLAR had similar 
discrimination to LVGLS (p=0.15), LV mass index (p=0.37) and EDV (p=0.75). There 
were no significant differences between LVGLS and EDV (p=0.23), or LV mass BSA 
(p=0.50).  
Discussion 
In this population of dyspneic patients undergoing RHC with preserved EF, non-
invasive markers of LVFP (E/e’ and LAV) were moderately useful, but other markers 
proposed in the diastolic function recommendations were non-contributory. Among 
those with PAH, the recognition of pulmonary venous hypertension was challenging, 
with LV parameters more effective than estimated LVFP. 
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Echocardiographic markers of LV filling pressure. The results of this study 
emphasise the ongoing difficulties associated with the assessment of diastolic function 
by echocardiography. LV filling is characterised by untwisting and suction, LV 
relaxation and LV compliance, but the assessment of all of these components are 
influenced by left atrial pressure 252. Previous work has shown that an array of 
parameters have associations with invasive PCWP  (isovolumetric relaxation time, 
atrial filling fraction, deceleration time, and E/A ratio), with the combinations being 
stronger than individual markers 253. When assessing reader concordance in the 
grading of DD, perceived weights given to different markers by reading cardiologists 
is an important driver of variation. In particular, pseudonormal and restrictive patterns 
display lower levels of agreement among readers 254. In response to the complexity of 
categorising patients, especially in patients with discordant criteria, recommendations 
have been updated 243. Previous recommendations suggested e’ as a starting point for 
diastolic assessment, as normal values are unlikely in patients with DD 255. However, 
we found no significant difference in e’ when comparing the elevated versus normal 
PCWP groups. Low E/e’ values (<8) or high values (>15) seem to be adequate in 
correctly identifying LVFP, but a significant proportion of patients fall between these 
categories, requiring additional indices 250.  
The accuracy of E/e’ is lower in those with normal EF 256, unfortunately, this group is 
one where the diagnostic challenge of defining LVFP is most important 257-259.  Our 
results are similar to those derived from meta-analysis 250 and research cohorts 260 that 
estimate between 24-44% of patients with elevated LVFP had increased E/e’. We 
found 32% of patients with raised PCWP had increased E/e’, while 11% of patients 
with normal PCWP showed elevated E/e’. A caveat of this is the quality control 
Chapter 8.  PH Differential Diagnosis    180 
required when performing Doppler echocardiography, specifically the acquisition of 
traces at gentle end expiration (as is performed during RHC readings).  
Left atrial measurements are a good indicator of chronically elevated left atrial 
pressures. However, a dilated left atrium may be a legacy of previously elevated LVFP, 
or changes may be accelerated in disease conditions such as diabetes mellitus 261 and 
obesity 262. The finding that markers of LVFP (E/e’ and LAV) displayed the strongest 
predictive ability in determining raised PCWP is contrary to the equal weightings of 
LAV, E/e’ and TR maximum velocity proposed in recent recommendations. However, 
E/e’ and LAV have only modest predictive ability for determining elevated PCWP. 
The new process of evaluation of diastolic parameters does not appear to have 
improved the identification of raised PCWP – at least in patients captures in our 
practice of RHC - with a significant proportion of patients still categorised as 
“indeterminate”. 
The distinction of pre- and post-capillary pulmonary hypertension. There is no 
evidence to support the use of pulmonary vasodilator therapy in HFpEF 10,263, so the 
distinction between pre and post-capillary PH is vital for therapeutic decision-making. 
Invasively, this is performed through assessing PCWP, combined with the mean 
pulmonary arterial pressure and cardiac output 10. PH occurs in DD due to passive 
transmission of LAP. ePLAR has been proposed as a new method in which 
echocardiography can aid in the non-invasive distinction between pre and 
postcapillary PH 251. Although there were significant differences between pre- versus 
post-capillary PH in our group, the AUC demonstrated only modest discrimination, 
with significant overlap between cases.  
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Limitations. While concerns about the new guidelines may be raised about their 
application in all echocardiograms, this study pertains specifically to individuals 
undergoing RHC. This test is not performed routinely at our institutions in most 
patients with dyspnoea. Our centres are referral centres for PAH, and RHC is generally 
performed in those with suspected PH. Nonetheless, the non-invasive recognition of 
pulmonary venous hypertension is an important topic in this group.  
Second, velocity vector imaging was used to measure strain on archived images at a 
frame-rate of 30 frames/second. While this approach has been validated, the results for 
strain may have been different with the use of different software on raw data.  
Conclusion. Individual diastolic markers do not have the same predictive ability in 
determining raised PCWP. LV GLS did not appear to add significantly to 
discrimination of raised PWCP. Markers of elevated left atrial pressure have modest 
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8.6 Conclusion 
A combined echocardiographic approach offers significant improvement in diagnostic 
accuracy over single echocardiographic markers. Interestingly, studies have found that 
RV dilation and dysfunction can occur early in an “at risk cohort”, even in the presence 
of normal pulmonary pressures 264. 
8.7 Postscript 
Patients within this cohort are considered to have the progressive disease already; once 
filling pressure has increased, substantial myocardial dysfunction is already present. 
However, the detection of raised pulmonary pressure by echocardiography is 
constrained by errors and inconsistencies with TR assessment 31, and the assessment 
of RAP is a potential source of inaccuracy. RAP is a reliable marker of outcome, and 
is a highly significant risk stratification marker 42. There may be a role for speckle 
tracking to assess changes in PAP throughout the cardiac cycle. Functional assessment 
of the left atrium with speckle tracking imaging has shown progressive dysfunction as 
diastolic function progresses 265, highlighting its ability to track the progression of the 
disease. Potentially, underestimation of patients who present with falsely normal 
pressure could be identified with speckle tracking. The next chapter addresses whether 
RA strain can help with one of the other conundrums of PH assessment measurement 
of RA pressure.  
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8.8 Appendix 
Table 8-4 Appendix. Baseline measurements in all 190 patients, divided by groups 
with EF<50% and >50%. 
 All patients 
(n=190) 
Mean (SD) 







Age 62(13.8) 63(55-63) 65(14.4) 61(14.8) 0.18 
Sex (female) 72%(172)  47%(16) 76%(142) <0.001 
SBP 126±27 125 (112-134) 133(14) 124(24) 0.24 
DBP 72±10 70 (65-80) 76(11.5) 70(13) 0.19 
HR 76±14 75 (66-85) 78(17) 75(21) 0.54 
BSA 1.8±0.21 1.8 (1.8-1.8) 1.8(0.10) 1.8(0.15) 0.32 
Invasive      
 PAPs (mmHg) 49±21.5 41 (35-60) 39(19) 40 (20) 0.98 
 PAPm 
(mmHg) 
33.0±9.5 31 (26-45) 27 (9.0) 30 (18.3) 0.35 
 PCWP 
(mmHg) 
12.8±4.0 14 (10-16) 16 (8.0) 13.0 (6.0) <0.001 
 Cardiac output 4.8±1.2 4.7 (3.9-6.1) 4.1 (1.4) 5.3 (2.2) <0.001 
Echocardiography      
 LV Mass (gm) 160±64.1 148 (112-188) 217 (72) 148 (56.7) <0.001 
 LV Mass 
(gm/m2) 
88.4±34.5 83(64-104) 122 (38.8) 82(30) <0.001 
 LVEDV (ml) 89.8±45.5 81 (63-97) 135 (74) 81 (30.7) <0.001 
 LVESV (ml) 40.7±34.7 32 (23-43) 89.5 (59.5) 31 (13.6) <0.001 
 EF (%) 58±12.5 61 (52-66) 36.8 (11.6) 62 (7.3) <0.001 
 LVGLS (%) 17.3±4.5 18 (15-20) 12.2 (5.3) 18.3 (3.6) <0.001 
Diastology      
 e’ septal (cm/s) 5.8±2.2 5 (4-7) 4.4 (1.9) 6.0 (2.5) 0.001 
 e’ lat (cm/s) 8.8±3.0 8(6-10) 8.1 (3.4) 8.8 (3.0) 0.36 
 e’ average 
(cm/s) 
7.4±2.4 7 (6-9) 7.4 (4.2) 7.8(3.2) 0.56 
 E/e’ septal 13.0±7.8 12 (9-18) 19.9(11.5) 14.0 (9.2) 0.03 
 E/e’ lateral 8.5±5.4 8(6-12) 10.9 (5.6) 9.4 (5.9) 0.22 
 E/e’ avg 10.8±6.4 10(8-14) 14.5 (7.9) 11.8 (8.0) 0.10 
 LAV ml/m2 33.6±15.7 31 (23-49) 63.4 (44.4) 35 (19.1) 0.001 
 Mitral valve E 
wave 
0.67±0.23 0.70 (0.52-0.89) 0.74(0.24) 0.75(0.29) 0.91 
 Mitral valve A 
wave 
0.68±0.22 0.71(0.54-0.84) 0.63(0.25) 0.71(0.23) 0.17 
 EA ratio 1.1±0.68 0.87 (0.72-1.2) 1.2 (0.21) 1.1 (0.70) 0.47 
 DT cm/s 234±55.1 223 (185-272) 212 (69) 233 (55) 0.13 
Right side      
 RVEDA (cm2) 22.5±8.9 21 (14-27) 22.8(9.7) 21.4 (8.0) 0.40 
 FAC (%) 29.5±13.6 32 (23-40) 30.2 (11.2) 32.2 (12.7) 0.43 
 RV Free wall 
(%) 
16.6±6.1 16(13-21) 15.7(7.0) 17.5 (5.7) 0.13 
 PASP echo 
(mmHg) 
57.6±25.4 47 (32-66) 48.3 (17.1) 51.4 (24.1) 0.51 
 RAA (cm2) 20.4±8.0 19 (14-26) 26.1 (12.4) 20.3 (8.0) 0.02 
 PVR (w.u) 3.7±1.8 3.2 (2.2-4.5) 3.6 (2.1) 3.6 (1.8) 0.94 
 Tr Vmax 
(cm/s) 
3.5±0.84 3.1 (2.8-3.9) 3.1 (0.64) 3.3 (0.80) 0.21 
 SBP- systolic blood pressure, DBP- Diastolic Blood pressure, Pulmonary artery pressure systolic, PAPm- Pulmonary artery 
pressure mean, CO- Cardiac Output, PCWP- pulmonary capillary wedge pressure, LVEDV- left ventricular end diastolic 
volume, LVESV- Left ventricular end-systolic volume, EF – Ejection fraction , LVGLS-left ventricular global longitudinal 
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strain,  DT- deceleration time, RVEDA- Right ventricular end-diastolic area, FAC- Fractional area change, RAA- right atrial 
area, PVR-Pulmonary vascular resistance 








Age (years) 60(15.3) 65(11.7) 0.02 
HR (bpm) 78(15.3) 74(12.7) 0.08 
SBP (mmHg) 123(18.2) 127(30) 0.66 
DBP (mmHg) 72(9.0) 70(18.7) 0.53 
PAPs (mmHg) 53(18.5) 51.5(19.9) 0.69 
PAPm (mmHg) 38.2(12.6) 37.9(11.7) 0.90 
PCWP (mmHg) 10.5(3.0) 18.9(4.5) <0.001 
 LV Mass (gm) 138(52.9) 178.9(69.6) <0.001 
 LVMI  77.4(27.7) 97.8(38.2) <0.001 
 LVEDV (ml) 73.6(25.0) 103.2(55.3) <0.001 
 LVESV (ml) 29.8(13.1) 51.5(47.2) <0.001 
 EF (%) 60(8.9) 55(15.8) 0.01 
 LVGLS (%) 18.1(3.4) 15.6(5.4) 0.001 
 e’ med (cm/s) 5.8(2.5) 5.2(2.4) 0.17 
 e’ lat (cm/s) 8.7(3.1) 8.0(2.6) 0.18 
 e’ average (cm/s) 7.9(3.2) 7.4(3.7) 0.45 
 E/e’ medial 11.3(4.0) 19.6(12.8) <0.001 
 E/e’ lateral 7.7(3.2) 11.6(7.1) <0.001 
 E/e’ avg 9.5(3.6) 15.7(10.5) <0.001 
 LA 4 ch (ml) 52.9(21.4) 92.2(66.2) <0.001 
 LA 2 ch (ml) 52.1(21.4) 93.0(64.2) <0.001 
 LAV avg (ml) 52.3(24.5) 91.2(62.2) <0.001 
 LAV ml/m2 28.6(13.4) 50.1(34.2) <0.001 
 EA ratio 0.89(0.38) 1.3(0.87) 0.002 
 DT cm/s 237(56.7) 227(63.3) 0.28 
 RVEDA (cm2) 22.4(8.8) 22.9(9.1) 0.68 
 FAC (%) 29.7(13.3) 30.9(11.8) 0.56 
 RV Free wall (%) 16.8(6.2) 16.2(5.8) 0.53 
 PASP echo (mmHg) 55.5(25.0) 53.6(22.4) 0.62 
 RAA (cm2) 20.1(8.3) 24.0(10.0) 0.008 
 PVR (w.u) 3.8(2.0) 3.4(0.76) 0.29 
 TR Vmax (cm/s) 3.4(0.8) 3.4(0.76) 0.56 
 ePLAR 0.35(0.17) 0.24(0.15) <0.001 
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAPs, pulmonary artery pressure systolic; PAPm. 
Pulmonary artery pressure mean; PCWP, pulmonary capillary wedge pressure; LVMI, left ventricular mass index; LVEDV, left 
ventricular end diastolic volume; LVESV, left ventricular end systolic volume; EF, ejection fraction; LVGLS, left ventricular 
global longitudinal strain; LA, left atrial; LAV, left atrial volume; DT, deceleration time. RVEDA, right ventricular end 
diastolic area; FAC, fractional area change; PASP, pulmonary artery systolic pressure; RAA, right atrial area; PVR, pulmonary 
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Figure 8-4 Appendix. Study flow chart 
  
Figure 8-5 Appendix. Discrimination of raised PCWP (> or < 15 mmHg) by 
echocardiographic markers  
 
 
Chapter 8 Differential Diagnosis of PAH   186 
 
Figure 8-6. Boxplot with median and 95% ranges for normal, precapillary and 
postcapillary PH ePLAR ranges 
 
Figure 8-7. Receiver-operating characteristic curves area under the curve using 
ePLAR to differentiate pre versus postcapillary PH 
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9 Right atrial pressure estimation with echocardiography 
9.1 Preface; Right atrial pressure estimation with echocardiography 
Previously thought of as a passive structure, the function of the RA has a direct impact 
on ventricular filling164.  RAP pressure-volume loop analysis involving a micro-
manometer tipped catheter266 gives a precise measure of changes in volumes and size 
throughout cardiac contraction (in animals). Changes are intrinsically linked pressures 
at that specific time point.  
RAP assessment with echocardiography plays a fundamental role in clinical risk 
stratification. A variety of methods can be used to estimate RAP assessment, these 
range from providing a discrete value from regression equations to the estimation of 
categorical ranges of values. Assessment protocols are published in standard 
echocardiography guidelines 101, but the accuracy of these measures is limited. The 
diagnostic accuracy of echocardiography has been reviewed by a number of authors267, 
with sensitivity (the ability of the test to correctly identify disease) and specificity (the 
ability of the test to correctly identify those without the disease) acceptable for 
predicting > or < 10 mmHg. Calculation with this method still leaves a large 
percentage of patients in whom increased RAP may be over or underdiagnosed. 
Review of RAP techniques in a large validation cohort was only accurate in 34% of 
cases268. IVC diameter varies significantly between RAP invasive ranges, with 
inadequate visualisation in 19% of patients 268. A restrictive filling profile, TV E/e’ 
and systolic filling fraction are secondary markers but have not shown to improve RAP 
estimation accuracy 268, with under-estimation the predominant error. Predictors of this 
inaccuracy (the difference between echocardiography and invasive RAP) are not  
defined. Weak, but significant associations include RA EF. RA size, RV function, or 
BSA did not show a significant association with bias. Novel markers of RA assessment 
have shown 3DE to be valuable in defining elevated RAP 269, but are not endorsed for 
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use in recent guidelines. 2D speckle tracking does not require any additional images 
to be acquired and gives an in-depth view of RA function.  
Whether markers of RA function are independent of RV systolic function has been 
questioned, as close correlations often exist between RA and RV longitudinal strain 
270. The afterload dependence of strain could be used to advantage in the RA, as it 
influences speckle tracking. Measures of RA elastance have been shown to improve 
in a chronic pressure overload state, with increases in reservoir function,  and declines 
in conduit function as shown 271. The incremental value of RA function above standard 
clinical assessment is not established.   
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9.2 Abstract 
Background. Echocardiographic assessment of RAP from inferior vena cava 
(RAPIVC) dimension may underestimate catheter-derived pressure (RAPC). As RA 
deformation, measured by speckle tracking, is preload-dependent, we hypothesised 
that RA strain might improve estimation of RAPC. 
Methods. Right atrial strain components (RA reservoir function (ƐR), peak RA ƐCT 
and RA ƐCD were measured in 125 of 175 patients who had echocardiography and 
invasive measures of RAP (median difference 1 day). To determine the ability of RA 
strain measures to differentiate incorrect RAPIVC assessment, categories with RAPIVC 
values <3, 8 and >15 mmHg were compared with RAPC groups <3, 4-7, 8-10, 11-14 
and >15 mmHg.   
Results. Non-invasively determined RAP was significantly lower (p=0.001) than 
invasively determined RAPC, with a weak correlation (r=0.35, p<0.001). RA strain 
components were associated with RA size, RV function and IVC size. In those with 
invasive RAP >15 mmHg, over half of patients were categorised into the 
echocardiographic prediction of RAP <10 mmHg. There were no significant 
differences in RA characteristics that differentiated patients in whom 
echocardiographic estimation of RAP was inaccurate. 
Conclusion. Right atrial strain was significantly different between those with normal 
versus raised pressure, but it did not identify those with an incorrect echocardiographic 
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9.3 Background 
Echocardiographic quantification of right atrial pressure (RAP) is primarily performed 
through interrogation of inferior vena cava (IVC) size and distensibility 272-274. The 
IVC is a compliant vessel and is highly responsive to changes in central venous 
pressure and volume, as well as changes in intra-thoracic pressure. Consequently, 
guidelines are based on 3 values (Figure 1); normal IVC size of <2.1 cm defines a RAP 
of <3 mmHg, RAP >2.1 cm with ≥50% collapsibility suggests RAP of 8 mmHg; 
patients with IVC >2.1 cm with <50% collapsibility have RAP of 15 mmHg 101.  
Although measurement of RA pressure has been removed from recent PAH 
guidelines15 due to the level of inaccuracy of echocardiographic assessment, RAP is 
still a strong prognostic marker 
Velocity vector imaging is based upon tracking of individual speckles from frame to 
frame, and the use of this technique for assessment of myocardial deformation has 
been validated in numerous studies. While some methods of myocardial strain 
measurement are vendor-specific, this approach has been used for the analysis of 
DICOM data from differing ultrasound machines and is, therefore, vendor 
independent. Velocity vector imaging has been used to assess RA function, with 
normal ranges published in small cohorts 275. A number of previous studies have shown 
that RA strain is reduced in PAH276, adding to the growing number of markers 
associated with increased pulmonary artery pressures. RA strain can be broken down 
into 3 phases (Figure 2); RA ƐR refers to the deformation which occurs from filling of 
the RA from the venous system. RA ƐCT, measured as the peak deformation post RA 
contraction. RA ƐCD is the difference between the RA ƐR and RA ƐCT. Timing 
relative to the QRS is used to conduct measurements, using either P-P or R-R intervals. 
As RA strain is preload-dependent, increased deformation of the RA during the 
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reservoir phase could be indicative of increased venous pressure.  The aim was to 
determine whether measures of right atrial strain would aid in the identification of 
incorrect RAP assessment with echocardiography (RAPIVC). We hypothesised that RA 
strain would increase before IVC size, and therefore identify those with potential 
underestimation of RAP.  
9.4 Methods. 
9.4.1 Patient selection.   
Between July 2003 to April 2015, 175 consecutive patients underwent RHC and 
echocardiography (median difference -1, IQR 26 days. Patients were prospectively 
recruited from the Royal Hobart Hospital Cardiac Catheterization laboratory (Hobart, 
Australia) and the Princess Alexandra Hospital Cardiac Catheterization laboratory 
(Brisbane, Australia). Of these, all right atrial strain components could be measured in 
125 patients - 14 patients were excluded due to AF, 1 due to heart block, and the 
remainder due to insufficient echo images. Institutional Review Board approval was 
obtained from the Human Research Ethics committee (Tasmania) Network (approval 
number H0013333) and the Metro South Human Research Ethics Committee (HREC 
16/QPAH/008). 
9.4.2 Conventional echocardiography  
Echocardiography was performed using standard commercial equipment (Vivid 7, 
Vivid i and Vivid e9, General Electric Medical Systems, Milwaukee, WI; ie33, Philips, 
Andover. MA).  LV and RV measurements were performed according to ASE 
guidelines 101 by a single reader. LV EF was measured from the Simpson’s biplane 
method from the apical 4- and 2-chamber views 101. LV mass was calculated from the 
parasternal long axis linear method, using the ASE method 101. RVEDA and RVESA 
were calculated from an apical RV focused view. FAC was calculated as the 
percentage change between the RVEDA and RVESA 101. PASP was measured from 
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the peak tricuspid regurgitation velocity using the modified Bernoulli equation 29. RAP 
was derived from the IVC dimension and distensibility from the subcostal view 44. 
RAP was given a value of 3 mmHg if IVC size was <2.1cm, the intermediate value of 
8 mmHg was given if IVC size was >21 cm, with >50% change during respiration. 
RAP >15 mmHg was given to patients with IVC>2.1 cm with a change in respiration 
<50%. (Figure 9.1). Peak velocities of the early (E) and late (A) diastolic filling were 
derived from the transmitral inflow pattern. Tissue Doppler imaging was used to 
determine the peak diastolic early velocity (e’) of the lateral and septal mitral annulus 
from the apical 4-chamber view. E/e’ was calculated from early mitral inflow divided 
by the average annular velocity to infer LV filling pressures 243. LAV measurements 
were performed from the apical 2 and 4 chamber views, using the area-length method 
101.  
Figure 9-1. Echocardiographic assessment of right atrial pressure RAP 
 
Figure 9.1a, Normal IVC (IVC<2.1cm) and collapsible, RAP= 3mmHg.  Figure 9.1b, 
IVC dilated (>2.1 cm), with >50% collapsibility with inspiration, RAP=8 
mmHg.Figure 9.1c, dilated IVC (>2.1cm), with no respiratory collapse, RAP=15 
mmHg. 
 
9.4.3 Strain.  
Velocity vector imaging was performed with wall motion tracking software (Image-
Arena, TomTec Gmbh, Unterschleissheim, Germany). The LV package was used to 
measure the RA as no specific atrial packages were available.  
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For each chamber analysed, manual adjustments were performed when necessary, and 
regions excluded if excessive noise or inadequate tracking was present. For RA strain, 
P-P gating was used from the RV apical-focused view. RA measurement points 
(Figure 9.2), peak RA ƐR, was measured as the mean peak of 6 segments of the RA, 
RA contraction (ƐCT) was measured as 6 segments at peak RA contraction. RA ƐCD 
was calculated as the difference between RA ƐR and RA ƐCD. LV global longitudinal 
strain (LVGLS) was performed from the apical 4, 3 and 2 chamber views. The right 
ventricular free wall (RVWFS) was performed from the RV apical focused view, as 
the average of the basal, mid and apical segments.  
 
Figure 9-2. Echocardiographic measure of right atrial strain. Speckle tracking right 
atrial strain measurements 
 
RAƐ Reservoir ( RA Ɛ R) function was measured as the peak phase of RA 
deformation. RAƐ contraction (RAƐ CT) is the peak right atrial deformation point 
after atrial contraction ( p wave). Right atrial conduit function (RAƐ CD) is the 
difference between RAƐ R and RAƐ CT 
9.4.4 Right heart catheterisation.   
RHC studies were undertaken after premedication and local anesthesia. A 4-lumen 110 
cm 7-Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA) was floated to the 
right heart, and resting measurements of right atrial, right ventricular, pulmonary 
arterial and PCWP were made at end-expiration using a pressure transducer (21BB, 
ITL Healthcare, Chelsea Heights, Australia). The transducer was calibrated to 
atmospheric pressure at the level of the RA and re-checked at intervals to avoid zero 
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drift. CO was determined by thermodilution, using an average of four consecutive 
values that varied <10%. Electrocardiographic (ECG) leads were connected to both 
arms and the left leg, allowing three ECG channels for the timing of signals. All 
haemodynamic monitoring was recorded using a Horizon SE Haemodynamic System 
(Mennen Medical Ltd., Yavne, Israel) and subsequently analysed off-line. 
9.4.5 Statistics.  
Statistical analysis was performed using standard software (SPSS 20.0, IBM, Chicago, 
IL) Data that were not normally distributed are presented as medians and inter-quartile 
range. Receiver operator characteristic curves were used to evaluate the strengths of 
atrial strain for predicting under-estimation of RAP by echocardiography. Bivariate 
logistic regression was used to compare groups.  The Mann-Whitney U-test was used 
to compare significance, with statistical significance set to p<0.05. To categorise under 
versus overestimation of RAP with echo, groups were split into the 3 
echocardiographic RAP estimation ranges (3, 8 and 15 mmHg). Using invasive RAP 
measures, groups were then categorised into several subgroups; RAP 4-7, RAP 8-10, 
RAP 11-14 or RAP>15 mmHg. 
9.5 Results 
9.5.1 Patient characteristics (Table 9.1).  
The 175 patients (median age 64 years, 64% female) included in the study had mild 
increases in pulmonary pressures and borderline reduced RV function. The RA size 
was mildly increased, and median RAPC was 8 mmHg, with RAPIVC was only 3 mmHg 
(p<0.001); the mean difference between invasive and non-invasive measures was 3±5 
mmHg. RA strain parameters showed RA ƐR 31±20%, RA ƐCT 12±11% and RA ƐCD 
16±14%.  
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9.5.2 Associations with invasively determined RAP.  
There was a weak association between RAPC and RAPIVC (r=0.35, p<0.001) (Table 
9.2). Demographic features such as BSA and sex were associated with RAPC (Table 
9.3). RAPIVC was associated with RA size, RVEDA (β 0.30(0.09; 0.26), p<0.001), RV 
pressure and RVFWS (β-0.21(-0.30;-0.04), p=0.009). Table 9.3 shows that RA 
deformation parameters were associated with RAV, RAPIVC but not RAPC. RA strain 
parameters were associated with some indices of RV function.  
9.5.3 Comparison of echocardiographic and invasive RAP.  
Table 9.4 summarises the association between RAPC values and RAPIVC ranges. In 
those with echocardiographic RAP 3 mmHg, only 13% RAPC <3 mmHg. In the 
RAPIVC 8 mmHg group, echocardiography overestimated 43%. In those with RAPIVC 
>15 mmHg, half of the patients were categorised into RAP <10 mmHg.  
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Table 9-1. Baseline demographics 
Clinical variables Median (IQR) (n=175) 
 Age (years) 64 (18.2) 
 Sex (female) 112(64%) 
 SBP (mmHg) 127 (30) 
 DBP (mmHg) 77 (11) 
 Heart rate (bpm) 70 (17) 
 BMI 27.2 (9.6) 
Invasive measures  
 Right atrial pressure (mmHg) 8 (6) 
 Right ventricular systolic pressure (mmHg) 53 (40) 
 Mean pulmonary artery pressure (mmHg) 33 (20) 
 Pulmonary artery systolic pressure (mmHg) 40.5(32) 
RA size and function (n=125)  
 IVC (cm) 1.9(0.8) 
 RA ƐR (%) 30.9 (20.4) 
 RA ƐCT (%) 12.4 (10.8) 
 RA ƐCD (%) 16.1 (13.9) 
 Right atrial area (cm2) 21.1 (12.5) 
 Right atrial volume/ BSA (ml/m2) 34.5 (32.5) 
Right ventricular size and function  
 Right ventricular end diastolic area (cm2) 22.0 (12.0) 
 Right ventricular end systolic area (cm2) 15.4 (10.6) 
 FAC (%) 32.6 (17.8) 
 TAPSE (cm) 1.8 (0.80) 
 RVS’ (cm/s) 9.0 (3.0) 
 RV free wall strain (%)  16.8 (8.6) 
 Right ventricular systolic pressure echo (mmHg) 44.0 (35.8) 
 Right atrial pressure echo (mmHg) 3.0 (5) 
 Pulmonary vascular resistance (w.u, Abbas 
method)) 
3.2 (2.2) 
Left ventricular size and function  
 Left ventricular mass (gm) 151.2 (80.7) 
 Left ventricular  Mass/ BSA (gm/m2) 89.0 (34.2) 
 LVEDV (ml) 85.0 (43.5) 
 LVESV (ml) 32.0 (23.3) 
 Ejection fraction (%) 61 (14) 
 Left atrial volume/BSA (ml) 42 (28) 
 MV E (cm/s) 0.71 (0.42) 
 MV A (cm/s) 0.69 (0.31) 
 MV DT (s) 217 (76) 
 e’ average (cm/s) 7.0 (3.5) 
 e/e’ sep 12.1 (9.0) 
 e/e’ lat 7.9 (6.0) 
 E/e’ avg 10.2 (7.2) 
 LV global longitudinal strain (%) 18.3 (5.4) 
SBP, Systolic blood pressure; DBP, diastolic blood pressure;; BMI, body mass index; IVC, inferior vena cava; RA ƐR, right 
atrial reservoir function; RA ƐCT, right atrial contraction; RA ƐCD, right atrial conduit function; FAC, fractional area change; 
TAPSE, tricuspid annular plane systolic excursion; RVS’, LVEDV, left ventricular end diastolic volume; LVESV, left 
ventricular end systolic volume; MV E, mitral valve inflow; MV A, Mitral valve atrial contraction inflow;   
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Table 9-2. Factors associated with invasive right atrial pressure (n=125) 
  Std B (95% CI) p 
Clinical features Age (years) 0.06(-0.03;0.07) 0.45 
 HR (bpm) 0.02(-0.05;0.06) 0.76 
 BSA 0.22(2.4;11.5) 0.003 
 Sex  0.20(0.58;3.7) 0.007 
RA size and function RAP echocardiography 0.35 (0.25;0.58) <0.001 
 RA ƐR (%) -0.13(-0.09;0.01) 0.13 
 RA ƐCT (%) -0.13(-0.17;0.03) 0.15 
 RA ƐCD(%) -0.10(-0.12;0.03) 0.26 
 RAA (cm2) 0.29(0.08;0.25) <0.001 
 RAV/BSA (ml/m2) 0.24(0.02;0.07) 0.002 
 IVC (cm) 0.36(1.8;4.3) <0.001 
RV size and function RVEDA (cm2) 0.30(0.09;0.26) <0.001 
 FAC (%) -0.19(-0.13;-0.02) 0.01 
 TAPSE (cm) -0.13(-2.6;0.17) 0.08 
 RVSP (mmHg) 0.18(0.006;0.07) 0.02 
 RV free wall strain (%) -0.21(-0.30;-0.04) 0.009 
HR, heart rate; BSA, body surface area; RAP, right atrial pressure; RA ƐR, right atrial reservoir function; RA ƐCT, right atrial 
contraction; RA ƐCD, right atrial conduit; RAA, right atrial area; RAV, right atrial volume; IVC, inferior vena cava; RVEDA, 
right ventricular end diastolic area; FAC, fractional area change; TAPSE, tricuspid annular plane systolic excursion; RVSP, right 
ventricular systolic pressure 
To determine whether RA strain measures differentiated patients with correct vs 
incorrect non-invasive RAP assessment, groups were first split based on 3 distinct 
RAPIVC values (<3, 8  or >15 mmHg, Table 5). Patients were then categorized based 
on 5 invasive RAPC groups (RAP<3 mmHg, 4-7 mmHg, 8-10 mmHg, RAP 11-14 
mmHg and >15 mmHg (Table 9.5). Within the RAP 3 group, there were no significant 
differences in over- vs under-estimated groups in RA size and function, or RV size 
and function. Similar results were seen in the RAP 8 group, with no significant 
differences in RA and RV structure and function parameters. There were much smaller 
numbers present in the RAP>15 mmHg group, but again the groups showed no 
significant differences. 
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Table 9-3. Associations with right atrial strain parameters 
  RA ƐR p value RA ƐCT p values RA ƐCD p value 
RA parameters RAP invasive -0.13 (-1.6;0.15)  0.13 -0.13 (-0.62;0.10) 0.15 -0.10 (-0.75;0.20) 0.26 
 RAP echo -0.46(-2.6;-1.34)  <0.001 -0.40 (-1.3;-0.53) <0.001 -0.37 (-1.6;-0.60) <0.001 
 RAV (ml2) -0.46(-0.23;-0.11) 
 
<0.001 -0.39(-0.11;-0.05) <0.001 -0.40(-0.14;-0.06) <0.001 
 RAA (cm2) -0.46 (-1.3;-0.65) 
 
<0.001 -0.41(-0.63;-0.27) <0.001 -0.40(-0.81;-0.34) <0.001 
 IVC size (cm) -0.41 (-17.6;-7.6) <0.001 -0.41(-9.1;-3.7) <0.001 -0.30(-10.5;-2.5) 0.002 
 RAV/BSA (ml/m2) -0.46 (-0.42;-0.21) 
 
<0.001 -0.39(-0.20;-0.08) <0.001 -0.40(-0.26;-0.11) <0.001 
RV parameters RVSP echo -0.21 (-0.28;0.03) 0.02 -0.09 (-0.10;0.04) 0.35 -0.26(-0.22;-0.04) 0.004 
 RVEDA (cm2) -0.25(-0.80;-0.15) 
 
0.004 -0.15(-0.34;0.04) 0.11 -0.27(-0.60;-0.13) 0.002 
 FAC (%) 0.35(0.24;0.65) 
 
<0.001 0.29(0.08;0.32) 0.001 0.31(0.12;0.43) 0.001 
 RVFWS (%) 0.53(1.02;1.8) 
 
<0.001 0.40(0.34;0.86) <0.001 0.48(0.58;1.2) <0.001 
 RVSP invasive -0.23(-0.30;-0.03)  0.02 -0.01 (-0.08;0.071) 0.96 -0.34(-0.27;-0.08) 0.001 
 HR (bpm) -0.20(-0.47;-0.04) 
 
0.02 -0.15(-0.23;0.02) 0.09 -0.17(-0.32;0.004) 0.06 
RAP, right atrial pressure; RAV, right atrial volume; RAA, right atrial area; IVC, inferior vena cava ; RAV/BSA, right atrial volume/body surface area; RVSP, 
right ventricular systolic pressure; RVEDA, right  ventricular end diastolic area;; FAC, fractional area change; RVFWS, right ventricular free wall strain; HR, heart 
rate.
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Table 9-4. Echocardiographic as compared to invasive RAP groupings 
RAP, right atrial pressure, IVC, inferior vena cava 
9.5.4 Between reader variability.  
Variability measures were performed on 10 patients, and 20 patients for intra-observer 
variation. For RA ƐR there was a modest, significant association between readers (r=0.68, 
p=0.03). The same was true for RA ƐCT contraction, with a modest, significant associations 
(r=0.66, p=0.04), and RA ƐCD (r=0.65, p=0.04). Bland-Altman analysis revealed that scatter 
increased as mean values increased for all RA strain parameters (Figure 4). ICC analysis 
revealed there were modest correlations between reads of RA reservoir (ICC 0.68 (0.12-0.91), 
p=0.01), RA contraction (ICC=0.65(0.08-0.90) p=0.02), and RA conduit function 
(ICC=0.65(0.08-0.90), p=0.02). Intra-observer correlations were better for RA reservoir 
(r=0.92, p<0.001) and contractile function (r=0.83, p<0.001). The ICC for intra observer 
variability was higher than between reader values; with RA ƐR (ICC 0.91 (0.80-0.97) p<0.001), 
similar to RA ƐCT (0.83(0.62-0.93), p<0.001) and conduit function (0.78(0.52-0.91), p<0.001). 
The respective mean differences were small (0.24±5.1%, -0.24±4.1% and 0.47±4.9%). 
 
 RAPIVC 3 mmHg RAPIVC 8 mmHg RAPIVC >15 mmHg 
RAP <3 mmHg 14(12.8%) 1 (2.5%) 0 (0%) 
RAP 4-7 mmHg 43 (39.4%) 13(32.5%) 4 (15.4%) 
RAP 8-10 mmHg 27 (24.8%) 9 (22.5%) 9 (34.6%) 
RAP 11-14 mmHg 17 (15.6%) 8 (20%) 5 (19.2%) 
RAP>15 mmHg 8 (7.3%) 9 (22.5%) 8 (30.8%) 
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Table 9-5. Non-Invasive RAP as compared to invasive RAP readings and differences in RA strain values 
 
RAP, right atrial pressure; RA ƐR, right atrial reservoir function; RA ƐCT, right atrial contraction; RA ƐCD, right atrial conduit function 
RAP = 3 on echo 
 RAP < 3 mmHg (n=12) RAP 4-7 (n=37) RAP 8-10 (n=24) RAP 11-14 (n=12) RAP>15 (n=7) 6 missing P value 
RA ƐR 32.8(±12.0) 42.0(±17.7) 35.8(±15.0) 43.7(±19.6) 28.1(±10.7) 0.72 
RA ƐCT 14.2(±5.3) 19.5(±10.6) 13.7(±7.5) 19.8(±7.3) 13.6(±7.7) 0.84 
RA ƐCD  17.3(±8.7) 23.6(±11.5) 22.7(±12.5) 23.9(±14.7) 12.2(±5.1) 0.88 
RAP =8 on echo 
 RAP < 3 mmHg (n=1) RAP 4-7  (n=9) RAP 8-10 (n=7) RAP 11-14 (n=6) RAP>15 (n=5)  P value 
RA ƐR 18.1 30.2(±16.8) 28.1(±22.0) 32.7(±5.5) 21.1(±9.7) 0.10 
RA ƐCT 5.5 14.2(±10.4) 11.0(±11.9) 12.7(±6.3) 9.1(±5.7) 0.07 
RA ƐCD  12.6 16.0(±9.7) 17.1(±20.1) 20.1(±9.5) 12.0(±5.6) 0.15 
RAP= 15 mmHg on echo 
 No patients RAP 4-7  (n=4) RAP 8-10 (n=6) RAP 11-14 (n=4) RAP>15 (n=2)  P value 
RA ƐR  15.2(±5.4) 15.3(±6.0) 13.9(±7.5) 12.1(±5.4) 0.92 
RA ƐCT  6.2(±5.5) 6.4(±3.0) 7.8(±6.9) 3.5(±0.28) 0.80 
RA ƐCD   8.9(±8.0) 10.3(±5.0) 6.1(±2.2) 8.6(±5.1) 0.73 
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Figure 9-3. Between reader Pearson’s correlation for right atrial strain components. 
Table 9.3a shows correlation between RA ƐR for 2 readers (r=0.68, p=0.03), 9.3b 
shows RA ƐCT between readers (r=0.66, p=0.04), with similar results for 9.3c RA 
ƐCD (r=0.65, p=0. 04)
 
Figure 9-4. 9.4a shows Bland-Altman plot between reader RA ƐR (ICC 0.68 (0.12; 
0.91), p=0.01), with a mean difference of -2.6% (±10.5). Table 9.4b shows the RA 
ƐCT plots (ICC 0.65(0.08; 0.90), p=0.02), with a mean difference of -1.5 %( 
±6.8).Table 9.4c displaying RA ƐCD shows a similar result (ICC 0.65(0.08; 0.90), 




Overall, although there were significant correlations between invasive and non-
invasive RAP, there are still a large number of people in which echocardiography 
underestimates RAP. Overall, RA strain values do not add to the clinical ability to 
determine underestimation of invasive RAP. Right atrial strain was associated with 
RV function and non-invasively derived RAP, although associations with invasively 
derived RAP were lacking. Variability measures for RA deformation appear 
acceptable for both intra- and inter-variability analysis.  
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We have found associations with pressures were present, but this did not add to the 
ability to predict RA pressure. Other studies have replicated the associations with RV 
invasive pressures and right strain, this adds to the current evidence, but how its 
superior or additive to current processes’ in pulmonary hypertension management are 
not known. Other work has shown a strong association with right atrial strain in 
functional capacity and has shown strong associations with PVR and cardiac output 
276.  
9.6.1 Echocardiographic assessment of RA pressure.  
Classical drivers of the miscalculation of RAP using echocardiography can come from 
patient body size, athletic training (through increased venous return) 277, prominent 
Eustachian valve, or patients on mechanical ventilation 278. We excluded patients on 
mechanical ventilation, and although did not screen for athletic training, this would 
have been highly unlikely in this cohort. Correcting IVC dimensions for BSA 279 has 
previously been suggested, although is not routinely performed in clinical practice, and 
was not used in our cohort. The use of 3D ultrasound could have been combined with 
strain markers to formulate a composite value for RAP calculation. 3D RAV has been 
shown to be feasible in healthy control patients 280, and 3D RA volume has been used 
in conjunction with IVC size to predict RAP, specifically >10 mmHg, in acutely 
decompensated heart failure patients 269.  
9.6.2 Right atrial function within the cardiac cycle.  
The RA promotes RV filling, while also minimising pressure within the central venous 
circulation 266. As the pulmonary pressure increases, the RV undergoes hypertrophy to 
adapt to increased afterload, and RV filling becomes increasingly dependent on right 
atrial contraction. Animal models have demonstrated that the RA can alter its 
functionality to act as a reservoir or a conduit 281. It also provides a buffer to 
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irregularities in atrial filling, and help to prevent acute elevations in RV diastolic 
pressure, as well as being able to actively respond to an acute increase in pulmonary 
pressure by increasing RA contractile force. All these findings further justify the need 
to consider the RA as more than just a static entity in the cardiac cycle. Remodelling 
occurs within the RA tissue in response to chronic increases in afterload, RA tissue in 
PAH been shown to have significantly reduced contractile force as compared to 
controls, with this possibly independent of RV function 282. RA size itself is a strong 
predictor of outcome in PAH. Whether or not RA function could be an early 
determinant or RA size increases is not yet known. Within our cohort, RA size seemed 
to be a significant driver of RA strain. 
9.6.3 Right atrial deformation  
RA strain has previously been reported using LV strain packages, with studies showing 
a reduction of RA strain compared to controls in a variety of disease cohorts 270. The 
results of our study contrast with previous work showing a significant negative 
correlation between peak RA strain and RAP 283, as well as the association of RV 
invasive pressures and right atrial strain in treatment-naïve patients, in whom RA strain 
was associated negatively with PVR (r = -0.46; p<0.05), functional capacity, and 
cardiac output 276. It is possible that this heterogeneity relates to the duration of 
pulmonary hypertension – the development of atrial fibrosis as a consequence of 
sustained pressure overload may add a vital confounder to the association between 
atrial strain and pulmonary pressure – but this requires further study.   
An interesting group is that of the elite athlete cohort, with studies showing 
significantly lower RA reservoir function phase, and RA contraction phase against 
matched controls 284. The difficulty comes in determining how this value will add in 
clinical settings.  The importance of the association with RA strain and RV free wall 
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strain should not be overstated. As the RV acts as a “mirror”, this association likely 
due to tethering effects, with other cohorts also showing associations with RV 
decompensation 270. Similar associations have been found with mRAP285 and PASP276.  
9.7 Limitations.  
Data were acquired in different echocardiographic machines, although TomTec is 
vendor independent software. Although having the measures performed on same 
machines would be optimal, this is often not feasible in a busy echocardiographic lab. 
All efforts were made to perform the echocardiographic measures in close succession, 
but the median time difference was 1 day. We acknowledge that changes in patient 
volumetric status would have occurred during this period.   
9.8 Conclusion.  
Right atrial strain measures appear to differentiate between patients with PH and 
associated with markers of RV failure. RAP is an essential diagnostic parameter in 
PAH.  However, right atrial strain parameters did not appear to identify those in which 
non-invasive techniques are incorrect.  
 
9.9 Postscript 
Right atrial size and pressure are markers associated with PHT and right heart 
failure. Whether this can be used as an early disease marker to track the progression 
of PAH is unknown. The previous chapter presented our experience in the 
performance of right atrial deformation in a clinical cohort and its clinical utility in 
the prediction of RAP.  
Strong correlations exist between IVC collapsibility and RHC assessment of RAP274, 
but it is pertinent to remember that a highly significant association can still be seen 
even if individual data points disagree 286. Other studies have attempted to use other 
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methods to adjust inaccuracies present, including tricuspid E/e’ ratio and diastolic 
flow predominance in the hepatic veins46, but these have had a modest effect on 
accuracy. Precaution should be used when utilising the IVC to estimate the pressure 
in athletes 277 and ventilated patients287. Other clinical and echocardiographic 
predictors of inaccuracies have not been identified268. 
Chapter 9 shows that right atrial strain appears to be a possible measurement in a 
PAH cohort. However, although significant associations exist with RAP, this does 
not differentiate over versus underestimation of RAP. Whether RA strain can 
facilitate understanding of the clinical progression of PAH, and early detection of 
clinical decompensation warrants more study.  
Patients with SSC constitute a challenging group, as screening for PH is undertaken 
to identify patients with early disease 288. Historically, SSC patients have been 
screened using the echocardiographic measurement of PASP. As previously 
mentioned, following PASP is not an optimal method of PAH follow-up. At least 
50% of pulmonary circulation must be obstructed before a rise in resting PAP is 
detected288. RV strain may be helpful in the pursuit of early diagnosis; before the 
persistent elevation of PASP, there may be temporal fluctuations that leave a 
“fingerprint” of myocardial damage. Alternatively, provocative tests are used to 
identify whether there is some compromise of the pulmonary vascular reserve. The 
next chapter will investigate whether provocative testing and RV strain provide 
different information about the preclinical disease.  
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10 RV and PASP response to provocative testing 
10.1 Preface; Early detection of myocardial disease in systemic 
sclerosis.  
Although the majority of Group 1 PAH is idiopathic, rarer causes such as congenital 
heart disease and CTD may provide insights into the temporal progression of RV 
failure. As mentioned previously, the SSC cohort is of particular interest. Routine 
screening is recommended with echocardiography, to facilitate early detection of PAH 
(using haemodynamic markers).  
PH is one of the most significant causes of morbidity in CTD 289, with high rates of 
right heart failure.  The SSC cohort is characterised by fibrosis and thickening of the 
central and peripheral organs and can manifest in the cardiac pathophysiology through 
LV diastolic dysfunction290. Both of these conditions present with raised TR jet 
velocity.  
The detection of a ”pre-clinical” phase of cardiovascular fibrosis in SSC could help 
with early detection of either right and left-sided heart disease. Elevations in pressure 
due to left versus right heart disease requires substantially different clinical 
management. Mortality benefits seen through pulmonary artery vasodilator treatment 
are not witnessed in pulmonary venous hypertension, with no changes in functional 
status or outcomes seen 291-293. Echocardiographic markers of myocardial deformation 
could aid in the early differentiation of pulmonary venous or PAH. When suspicion of 
disease is high (symptoms combined with risk factors), the treating team may proceed 
directly to RHC. Further to this, “stress testing” by volume loading used to elucidate 
raised pressures during invasive assessment can aid in early diagnosis294.  
A combination of a “stress test” with subsequent myocardial imaging may give further 
insight into temporal progression of disease in an at-risk population.   
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10.2 Abstract 
Background- Early detection of PH in SSC may improve outcomes. “Stress testing” 
during RHC with a volume challenge is thought to differentiate those with latent 
cardiac disease. Speckle tracking with echocardiography could identify SSC patients 
who raise cardiac pressures post stress. We seek to define LV and RV characteristics 
that are predictive of a pathological response to fluid loading. We hypothesised that 
speckle tracking of the myocardium would identify SSC patients presenting with 
raised pressures after stress. 
Method. 231 patients were identified who had RHC performed in close succession to 
echocardiography (median 0 days (-132;-7). 43 symptomatic SSC (age 59±13, 91% 
women) with no overt PH (PASP 30±6 mmHg with echo) underwent fluid loading 
(670±320 ml). Echocardiography was performed in close succession to RHC. 
Associations of abnormal responses was sought and significance set to p<0.05.  
Results.  SSC who underwent fluid loading were significantly younger than the 
remainder, with less evidence of LV diastolic or LV/RV systolic dysfunction as 
compared to post- and pre-capillary PH groups. PCWP increased to >15mmHg in 17 
patients after fluid loading, and LV mass was the only echocardiographic marker to 
predict change in PCWP. TAPSE was a weak, borderline significant association of 
increased mean pulmonary artery pressure.  
Conclusion. LV markers associated with changes in PCWP after fluid loading. RV 
function showed a weak association with raises in PAPm. Myocardial deformation did 
not associate with increases in filling pressure after fluid loading.    
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10.3 Background 
Cardiac fibrosis, as determined via biopsy, has shown to be present in a large number 
of SSC patients. Two critical cardiac sequelae of this are the development of PAH 
and diastolic dysfunction, and shortness of breath in SSC patients could be 
attributable to either of these entities. The diagnosis of elevated pulmonary artery 
pressure is confirmed with RHC, with PCWP measurements used to differentiate the 
pathological source of elevation. PAH has a substantial mortality risk, thus early 
detection and intervention with novel treatments can improve patient outcomes and 
quality of life substantially.  
The echocardiographic differentiation between pre versus postcapillary PH is 
dependent on the integration of measurements of LV diastolic and systolic function, 
pulmonary haemodynamics and right ventricular assessment. Myocardial 
deformation imaging could be used to elucidate early progression of the disease.   
In SSC patients who present with shortness of breath, the echocardiographic 
sensitivity to detect early disease is not known. The presence of mild symptoms may 
already herald advanced obliterative disease. The DETECT algorithm 295 
recommends SSC patients with suggestive markers (serum markers, telangiectasia, 
reduced FVC%/DLCO%, right axis deviation on ECG) should undergo 
echocardiography. The recommended echocardiographic parameters to raise PAH 
suspicion are TR V max and RAA. TR V max is in current echocardiographic 
guidelines for the diagnosis of post-capillary PH243. A higher TRV max threshold has 
been suggested for PAH patients, with a velocity of >3.4 m/s. The use of novel 
imaging markers using speckle tracking imaging could identify patients most likely 
to respond to fluid loading. 
Chapter 10. RV and PASP response to provocative testing   211 
Physicians may decide to proceed directly to invasive assessment if clinical suspicion 
is high. Before catheterisation, patients have generally been in a fasting state for ~12 
hours, which can lead to a depletion of intravascular volume, and possible 
underestimation of LV filling pressures296. Fluid loading during RHC has been 
proposed as a method to “unmask” latent PAH. The aims for this chapter are to 
define LV and RV characteristics that predict a pathological response to fluid loading 
during RHC.  
10.4 Methods.  
10.4.1 Patient recruitment.  
Consecutive patients undergoing RHC from 2003 to 2013 to investigate dyspnoea or 
fatigue were studied at the Royal Hobart Hospital and Princess Alexandra Hospital 
(Queensland, Australia). 236 patients were identified who had RHC performed in 
close succession to echocardiography (median 0(-132;-7) (figure 1). PAH was 
defined as PAPm ≥ 25 mm Hg and PCWP of ≤ 15 mm Hg in both groups, as per 
local Australian prescribing guidelines at the time. Of these, 43 patients (age 59±13, 
91% women) with SSC, but no overt PAH (PASP 30±6 mmHg with echo) 
underwent fluid loading (670±320 ml). We used previously published detection 
scores from the DETECT algorithm for PAH detection in SSC. 
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Figure 10-1. Patient flow chart 
 
10.4.2 Fluid loading.  
Up to 1 litre of normal saline was administered via the venous sheath, usually over a 
20-minute period. Haemodynamics were reassessed with every 250 mL volume. The 
bolus was ceased if the criteria for PH were reached; PCWP > 15 mm Hg, or if the 
patient became symptomatic.  
10.4.3 Echocardiography.   
Echocardiography was performed using standard commercial equipment (GE Vivid 7, 
Vivid i and Vivid e9, Horten, Norway; Philips ie33, Bothell, WA). All measurements 
were performed by a single reader, using standard views. 
Standard measurements. LV and RV measurements were performed according to ASE 
guidelines 101 by a single reader for both studies. The measurement technique for the 
systolic and diastolic function has been described previously in the methods chapter.  
10.4.4 Statistical analysis  
Statistical analysis was performed using SPSS (IBM, version 21). An independent 
samples t-test was used to compare groups. A paired-sample t-test was used to 
compare patients before and after fluid loading during RHC. Univariable logistic 
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regression was used to assess association with raised invasive PCWP. Patients were 
split based on raised PCWP post fluid >15 mmHg. Associations of increased PCWP 
were sought using binary logistic regression. The significance level was set to 
p<0.05.  
10.5 Results.  
10.5.1 Baseline data 
Echocardiographic data are shown in Table 10.1. The 43 patients with SSC who 
underwent fluid loading were significantly younger than the remainder, with less 
evidence of LV diastolic dysfunction. Left ventricular systolic markers were not 
significantly different. The post-capillary PH group showed evidence of impaired 
right ventricular function with standard RV function measures and RVFWS.  
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Table 10-1. Baseline clinical and echocardiographic values of fluid load PAH 
 
10.5.2 Fluid loading response 
Fluid loading significantly increased PCWP, PADP, PAPm, and PCWP (Table 10.2). 
Figure 10.2 shows the individual response to fluid loading. Although the mean 
 
Fluid PAH (n=43) Post cap PH (n=40) P value 
Age (years) 58(16.0) 68 (19.7) 0.04 
PAPs (mmHg) 26 (4.6) 45 (29.5) 0.004 
PAPm (mmHg) 17 (3.5) 30 (18.5) <0.001 
PCWP (mm 7 (2.9) 19(8.3) <0.001 
6MWD (meters) 398 (152) NA  
HR (bpm) 70 (17) 75 (20) 0.01 
LV Mass (gm) 132 (46.1) 199 (113.6) 0.47 
LV EDV (ml) 75 (23) 110 (86.8) 0.66 
LV ESV (ml) 31 (12) 47(69.5) 0.82 
SV (ml) 47 (13) 60 (28) 0.13 
EF (%) 61 (11) 56 (28) 0.55 
MV EA ratio 1.0 (0.47) 1.2 (1.5) 0.59 
MV DT (cm/s) 238 (87) 186 (66) 0.63 
e septal (cm/s) 7.0 (4) 5.0(4.8) <0.001 
e lat (cm/s) 10 (6.5) 8(4.8) 0.006 
E/e med 9 (4.7) 19(12.1) 0.001 
E/e lat 7 (4.4) 12(7.5) 0.03 
LAV (ml) 44.3 (16.5) 111(85.4) 0.04 
LV GLS % 19.2 (3.6) 15.0(12.3) 0.30 
TAPSE (cm) 2.1 (0.70) 1.5(1.2) 0.006 
RV EDA (cm2) 14.0 (5.0) 21.2(8.1) <0.001 
RVSP (mmHg) 26 (7.3) 40 (28.8) <0.001 
RAA (cm2) 14 (4.5) 24(10.0) <0.001 
RVFWS % 21.9 (9.2) 17.1(10.1) 0.002 
RV FAC % 39 (16) 28 (15.7) 0.19 
PAPs, pulmonary artery systolic pressure; PAPm, pulmonary artery pressure mean; PCWP, pulmonary capillary wedge pressure; 
6MWD, six-minute walk distance; HR, heart rate; LV, left ventricle; LVEDV, left ventricular end diastolic volume; LVESV, left 
ventricular end systolic volume; EF, ejection fraction; MV EA, mitral valve early to atrial inflow ratio; MV DT, mitral valve 
deceleration time;  LAV, left atrial volume, LV GLS, left ventricular global longitudinal strain; TAPSE, tricuspid annular plane 
systolic excursion; RVEDA, right ventricular end diastolic area; RVSP, right ventricular systolic pressure; RAA, right atrial area; 
RVFWS, right ventricular free wall strain; FAC, fractional area change.  
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pressures all significantly increased, there was a significant amount of individual 
variation present. 17 patients elevated PCWP>15 mmHg.  
Table 10-2. Invasive haemodynamic response to fluid loading 
  Pre fluid Post fluid Delta P value 
PAPs (mmHg) 26.1 (±4.6) 37.2 (±4.6) 11.0 (±4.0) <0.001 
PAPd (mmHg) 9.2 (±3.3) 18.3 (±3.1) 9.1 (±4.2) <0.001 
PAPm (mmHg) 16.8 (±3.5) 26.4 (±4.0) 10.2 (±3.4) <0.001 
PCWP (mmHg) 7.1 (±2.9) 13.9 (±2.7) 6.9 (±3.1) <0.001 
PAPs, pulmonary artery pressure systolic;  PAPd, Pulmonary artery diastolic pressure; PAPm, pulmonary artery 
pressure; PCWP, pulmonary capillary wedge pressure.   
 
Figure 10-2.  Individual variation in response to fluid load for PAPm, PAPs, 
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10.5.3 Echocardiographic characteristics of fluid response group 
 Groups were split based on PCWP elevations of  >15 mmHg (Table 10.3). Systolic 
function measures did not show any significance. Similarly, diastolic function was not 
different. LV GLS was not different, with LA strain parameters also not significant.  
Right ventricular markers were also not statically significant between the two groups.  
Table 10-3. Echocardiographic comparison of  PCWP response to fluid loading 
PAPs, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PAPm, pulmonary artery mean 
pressure; LV, left ventricle; LVEDV, left ventricle end diastolic volume; EF, ejection fraction; MV E, mitral valve early inflow; 
MV A, mitral valve atrial contraction; MV DT, mitral valve deceleration time; LAV, left atrial volume; LA, left atrium; GLS, 
global longitudinal strain; FAC, fraction area change; PASP, pulmonary artery systolic pressure; RAA, right atrial area; 
RVEDA, right ventricular end diastolic area; RVFWS, right ventricular free wall strain.  
 PCWP < 15 mmHg after 
fluid 
PCWP>15 mmHg after 
fluid 
P value 
 Mean (SD) Mean (SD)  
PAPs (mmHg) 26(±3.7) 27(±5.8) 0.43 
PCWP (mmHg) 6(±2.3) 8(±3.3) 0.08 
PAPm (mmHg) 16(±2.8) 17 (±4.2) 0.42 
Age (years) 59(±10.6) 57(±16.3) 0.70 
LV Mass (gm) 130.3(±32.6) 132.4(±26.7) 0.83 
LV EDV (ml) 76.2(±16.0) 81.3(±22.6) 0.41 
LV EF (%) 58(±10.3) 61(±7.3) 0.22 
SV (ml) 43.5(±10.2) 49.7(±13.7) 0.11 
MV E (cm/s) 0.65(±0.13) 0.74(±0.19) 0.10 
MV A (cm/s) 0.66(±0.20) 0.66(±0.18) 0.95 
MV DT (cm/s) 237(±48.8) 245(±43.2) 0.62 
e’ septal (cm/s) 8.3(±3.2) 8.2(±2.8) 0.98 
e’ lateral (cm/s) 10.5(±4.0) 10.8(±3.9) 0.89 
e’ avg (cm/s) 9.6(±3.7) 10.0(±3.7) 0.78 
E/e’ med 8.5(±2.8) 9.9(±2.3) 0.25 
E/e’ lat 7.0(±4.0) 7.6(±2.7) 0.69 
E/e avg 7.7(±3.6) 8.3(±2.6) 0.57 
LAV (ml) 46.3(±11.5) 48.4(±16.7) 0.66 
LA reservoir (%) 30.8(±10.0) 32.4(±7.7) 0.58 
LA contraction 
(%) 
12.9(±4.8) 13.0(±3.2) 0.95 
LA conduit (%) 17.9(±7.6) 19.4(±6.4) 0.51 
LV GLS (%) 18.0(±2.7) 19.2(±3.3) 0.23 
RV FAC (%) 36.4(±10.5) 41.2(±7.3) 0.11 
PASP echo 30.4(±7.2) 28.4(±4.0) 0.34 
RAA (cm2) 14.6(±3.0) 14.4(±3.4) 0.80 
RVEDA (cm2) 14.5(±3.6) 13.9(±3.3) 0.63 
RVFWS (%) 20.6(±5.8) 23.2(±5.7) 0.17 
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10.5.4 Univariate associates of changes in pulmonary haemodynamics 
after fluid load.  
Data were assessed as continuous variables, with the pre-measure subtracted from post 
fluid values for PCWP, PADP and PAPm. LV mass associated with increased delta 
PCWP and delta PAPm. TAPSE was of borderline significance for association with 
raised PAPm. PADP did not show any significant associations with echocardiographic 
makers. Patients were then split into groups based on whether post fluid PCWP 
increased > 15 mmHg. Bivariate logistic regression showed similar results, with no 
baseline invasive or echocardiographic variables predicting those who increased 
PCWP > 15 mmHg (Table 10.4).   
10.5.4.1 Detection of Pulmonary Arterial hypertension based on 
DETECT guidelines 
Current PAH detection algorithms in SSC suggest the use of right atrial size and TR 
jet velocity for detection of PAH.  The categorisation of DETECT parameters (TR V 
max >2.8 or RAA> 16 cm2) and association with increases in PAPm (as a continuous 
variable) was assessed. The degree of change in PAPm did not show a significant 
relationship with baseline TR Vmax >2.8 (Std β -0.08(-4.4; 2.9) p=0.68), or with 
RAA >16 cm2 (Std β -0.18(-3.6; 1.1) p=0.30). RV dysfunction value of <20% was 
also not a significant predictor or delta PAPm (Std β 0.04(-2.3;2.8)p=0.83).  
Echocardiographic measures of increased LV filling pressures (septal e’, LAV and 
E/e’) were ineffective for predicting raised PCWP, but measures of structural change 
showed significant univariable associations with LVEDV and LV mass. Patients 
were then split into groups based on whether post fluid PCWP increased to >15 
mmHg. Bivariable logistic regression showed no baseline invasive or 
echocardiographic variables predicting those who increased PCWP >15 mmHg 
(Table 10.4).   
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10.5.5 ROC characteristics for pre versus post capillary pulmonary 
hypertension 
We compared three groups; SSC-PAH, SSC-symptomatic (normal resting 
haemodynamics but elevated pressure after fluid load) and post-capillary PH. In the 
symptomatic SSC and SSC PAH, LAV was a significant discriminator (AUC 0.63 
(0.51; 0.74) p=0.04), with the SSC PAH group showing significantly larger LA 
volume. TR Vmax (AUC 0.80(0.70; 0.89) p<0.001) and RAA (AUC 0.76(0.66; 0.85) 
p<0.001) also had significant discriminatory ability. RVFWS had modest predictive 
ability (AUC 0.69(0.58; 0.80) p=0.002), but LV GLS was not significant (AUC 
0.44(0.32; 0.55) p=0.30). 
The SSC symptomatic group was difficult to distinguish from the post-capillary PH 
group, RV FWS (AUC 0.65(0.55;0.75), p=0.007) discriminated disease type, but not 
LV GLS (AUC 0.57(0.47;0.68), p=0.18). RAA (AUC 0.41(0.31; 0.51) p=0.09), TR 
V max (AUC 0.66(0.56; 0.75) p=0.003) and LAV were not significant (AUC0.54 
(0.43; 0.65) p=0.48).  
Finally, the pre versus capillary pulmonary hypertension groups were compared for 
the ability for echocardiography to discriminate cause of raised pulmonary pressure. 
TR Vmax was not significant in predicting pre from post-capillary PH (AUC 
0.50(0.39; 0.62), p=0.95), RAA was significant, but this trended towards the post-
capillary group having larger RAA (AUC 0.71 (0.61;0.82), p<0.001), RV free wall 
was not significant (AUC 0.42(0.29;0.55), p=0.22). LV GLS showed significant but 
modest predictive ability (AUC 0.64 (0.51;0.77), p=0.02), and LA volume was a 
strong discriminatory marker (AUC 0.83(0.74;0.92), p<0.001). 
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Table 10-4 Echocardiographic associates of delta invasive haemodynamic pressures 
 
Delta PAPm Delta PCWP Delta PADP 
 
Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value 
Age (years) -0.10(-0.11;0.06) 0.57 0.19(-0.04;0.12) 0.30 -0.19(-0.18;0.06) 0.30 
LAV (mls) -0.18(-0.13;0.045) 0.32 -0.20(-0.12;0.04) 0.30 -0.25(-0.19;0.04) 0.19 
LV mass (gm) -0.34(-0.08;-0.002) 0.04 -0.41(-0.08;-0.009) 0.02 -0.28(-0.09;0.01) 0.11 
e’ avg (cm/s) -0.10(-0.44;0.28) 0.64 -0.35(-0.58;0.07) 0.12 0.08(-0.72;0.94) 0.78 
E/e’ avg -0.03(-0.53;0.46) 0.88 0.24(-0.24;0.66) 0.33 -0.23(-1.0;0.37) 0.35 
E/e’ lat -0.04(-0.44;0.38) 0.88 0.16(-0.33;0.64) 0.51 -0.26(-0.94;0.27) 0.26 
LV GLS (%) -0.26(-0.63;0.08) 0.13 -0.11(-0.47;0.27) 0.57 0.01(-0.48;0.52) 0.94 
LVEDV  -0.24(-0.10;0.02) 0.15 -0.36(-0.11;-0.003) 0.04 -0.21(-0.13;0.03) 0.25 
EF (%) 0.07(-0.10;0.15) 0.70 0.15(-0.07;0.17) 0.41 0.03(-0.15;0.18) 0.87 
RAV 0.004(-0.09;0.10) 0.98 0.01(-0.09;0.10) 0.94 -0.17(-0.18;0.07) 0.35 
TAPSE (cm) -0.29(-5.0;0.28) 0.08 -0.22(-4.1;0.93) 0.21 -0.10(-4.4;2.5) 0.59 
RVEDA (cm2) -0.26(-0.63;0.07) 0.12 -0.23(-0.52;0.11) 0.20 -0.22(-0.70;0.16) 0.21 
RVSP (mmHg) -0.05(-0.24;0.18) 0.80 -0.09(-0.26;0.16) 0.64 -0.16(-0.40;0.17) 0.41 
RV FAC (%) 0.006(-0.12;0.12) 0.97 0.08(-0.09;0.15) 0.66 0.11(-0.12;0.21) 0.56 
RV free wall  -0.19(0.31;0.09) 0.28 -0.21(-0.31;0.09) 0.26 -0.10(-0.33;0.19) 0.60 
PAPm, pulmonary artery pressure mean; PCWP, pulmonary capillary wedge pressure; PADP, pulmonary artery diastolic pressure; LAV, left atrial volume; LV, left ventricle; GLS, global longitudinal strain; EDV, end 
diastolic volume; EF, ejection fraction; RAV, right atrial volume; TAPSE, tricuspid annular plane systolic excursion; RV, right ventricle; EDA, end diastolic area; FAC, fractional area change;   
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10.6 Discussion.  
SSC patients are a unique group who have a high chance of presenting with latent 
pulmonary vascular disease. Echocardiographic markers did not have a strong 
association with the prediction of post fluid loaded elevations in RHC. LV mass was 
the only echocardiographic marker to show significance for predicting PCWP 
increases, with right heart function also bordering on significance for detecting 
increased PAPm. SSC specific baseline detection algorithms variables (TR V max, 
and RAA) did not predict patients who elevated PAPm post fluid.   
Prior work on fluid loading has been done in a number of settings, with the clinical 
applicability of this technique still being defined. Some reasons for this could are 
postulated. Firstly, correct protocols for this procedure are still to be defined, and the 
response of “normal” patients to fluid loading is unclear. Fujimoto and colleagues 297 
used a fluid challenge of 2 litres in healthy individuals. Interestingly, they found both 
age and sex associated with increased PCWP response. Another study suggested that 
infusion of 500 ml of fluid over 5-10 minutes 298 is sufficient, and suggested 
increasing upper limits of normal after saline infusion to include PCWP >18 mmHg.  
Recent guidelines state 130 that although fluid loading of 400 ml over 5 to 10 minutes 
is safe, and can help to distinguish PAH from LV diastolic dysfunction, 
standardisation is required before its use in clinical practice can be endorsed. Our 
study limited the amount of fluid given to ~ 1 litre, which is in line with previous 
studies.  
Recent guideline reviews 130 suggests the SSC population to be a specific group in 
which the term “borderline” may be helpful, as this could identify a subgroup of 
patients likely to progress to PAPm> 25mm Hg. “Borderline” PH has not been added 
to the guidelines, as evidence that this term would be helpful in the left heart sided 
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PH population is lacking. Unfortunately, in our sample, echocardiography did not 
have a strong association with elevations of PASP/EDP after fluid challenge. 
Echocardiographic guidelines now recommend echocardiographic values be indexed 
for body surface area. Measures were not  routinely performed when the majority of 
these studies were undertaken hence values have not been indexed due to lack of 
data. 
Higher survival rates have been shown in SSC-PAH patients diagnosed through a 
detection program 299, highlighting the importance of early detection and 
intervention.  Echocardiographic components of these algorithms are related to 
haemodynamic markers (TR v max), and dilation of the RA. Diastolic guidelines 
highlight the importance of TR v max in post-capillary PH.  In our SSC group, TR v 
max was not a significant discriminator between the PAH vs PH post capillary 
groups, with RAA significantly trending towards being larger in the post capillary 
PH group. Both markers had significant discriminatory ability in SSC PAH 
compared to the SSC fluid loaded group, with RV strain showing modest 
discriminatory ability. We feel some of these contradictions highlight issues with 
simplifying the diagnostic pathway to simple echocardiographic haemodynamic 
markers. If early detection is such a strong outcome marker, echocardiographic 
markers which differentiate pathological basis of pressure changes should be 
incorporated.  
Exercise is also a popular stressor used in during RHC. Although exercise pressures 
are not in current guidelines for PAH diagnosis, exercise echocardiography has been 
used to screen for potential diastolic dysfunction300. The predictive ability of 
echocardiography for predicting exercise-induced PH could also be assessed in the 
SSC cohort.  
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Screening of SSC patients offers a chance to detect early onset of PH. Structural 
changes of the myocardium (LV mass) associated with an increment of filling 
pressure after fluid loading, but myocardial deformation did not aid in the 
differentiation of this cohort. Strain did not appear useful to identify to the preclinical 
phase of SSC related heart disease.  
10.7 Conclusion 
Early detection of PH through fluid loading can be performed safely in an SSC cohort, 
but the ability of echocardiographic parameters to detect responders has not been 
shown. Whether early disease treatment should be established based on fluid loading 
response also is not known. Likewise, the prognostic significance of a fluid loading 
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10.8 Postscript 
Echocardiography permits assessment of myocardial function along with 
haemodynamics. In SSC, changes are not only due to pressure elevations, but also to 
intrinsic fibrotic changes in the myocardium. Early pharmaceutical intervention can 
improve patient symptom status, but physicians must also consider side effect risk to 
patients 301.  
Although echocardiography was not predictive of fluid response, exercise could be a 
more appropriate stressor of the pulmonary vasculature in regards to PAH symptom 
development. The up triation of treatment is primarily guided by changes in functional 
class 10. In SSC, there is increased risk of developing left heart disease thus 
echocardiography can reveal the underlying pathology that might provoke disease.  
There are other tools which may be better for tracking outcome. Increased pressure 
depends on pulmonary vascular properties; impaired vascular function could detect 
early changes in the SSC population. The next chapter will evaluate the value of 
vascular function.  
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11 Early detection – microvascular function and 
pulmonary vascular disease 
11.1 Preface 
SSC is an interesting model of PH because it provides an opportunity to observe a 
phase when pulmonary pressures are healthy, despite pulmonary vascular changes. 
Echocardiography is a widely used non-invasive screening tool in SSC, and vital in 
patient risk stratification. As discussed, conventional echocardiographic markers are 
primarily indicators of late-stage disease. Other non-invasive methods exist which 
could be used to assess disease status.  
Screening with echocardiography is recommended if patients present 
symptomatically, the presence of TR velocity > 2.5 m/s is used to refer patients for 
invasive measures 302. This elevation in PA pressure only occurs after a significant 
amount of the pulmonary vascular bed is destroyed. Algorithms for early detection 
have also included right atrial size 295, although this is a marker of end-stage disease 
progression.   
Histological samples suggest small vessel associated disease in the connective disease 
cohort 303. Although direct assessment of the pulmonary vasculature is possible with 
MRI, this has limited feasibility for clinical follow-up. Other methods include single-
photon emission computed tomography which measures lung perfusion, and absolute 
quantification of pulmonary blood flow, but due to radiation dosage, repeated use for 
clinical follow-up is not recommended. Direct measurement of vascular function is a 
practical way in which patients with vascular disease are identified.  
A number of different peripheral measures of vascular dysfunction exist. Assessment 
can be split into micro or macrovascular function (cut off 100 microns). Vascular 
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function has been used in the association of left-sided heart disease, but limited work 
has been done with microvascular function and right-sided echocardiographic 
parameters. 




Background. SSC is a multi-organ disease that presents with sclerodactyly, digital 
ulceration and exercise impairment related to interstitial lung disease, pulmonary 
vascular disease as well as systolic and diastolic heart failure. We sought to 
characterise associations between central and peripheral dysfunction in SSC, with the 
hypothesis that macrovascular disease would be more closely related to traditional 
CVD endpoints, while microvascular disease would be related to subclinical cardiac 
dysfunction. 
Methods. We identified 88 patients diagnosed with SSC - 21 with diffuse disease 
(26%), and 35 (38%) on treatment for PAH. Assessment of microvascular function 
was performed with brachial flow-mediated dilatation (FMD), peripheral artery 
tonometry (PAT) and laser Doppler flowmetry (LDF) in response to a 5 minute period 
of occlusive hyperaemia. Echocardiography assessed pulmonary artery pressure, LV 
and RV function. 
Results. Traditional CVD risk factors did not show associations with macrovascular 
disease, with microvascular function having modest correlations with disease duration. 
Macrovascular function appeared associated with LV mass and RV size, and in the 
PAH group, the microvascular function associated with RV function. 
Conclusion. Microvascular disease appears related to RV function in PAH. The 
macrovascular disease appears to relate to traditional heart disease factors such as LV 
mass. Endothelial function markers do not appear to be interchangeable in assessing 
patient outcome.  
  




SSC is a multisystem autoimmune disease which invariably leads to vascular damage 
and fibrosis in heart, lungs and other internal organs. Vascular disease can manifest as 
ischemia of the peripheral extremities, PAH, and secondary Raynaud’s phenomenon. 
Although a rare disease (~242 cases per million adults) 304, this presents a significant 
burden; 1 and 3 year survival rates in CTD-related PAH are significantly lower than 
in idiopathic PAH 305. SSC patients have repeated follow-up visits involving multiple 
specialists, and SSC associated with serious adverse events during PAH treatment 306.  
Peripheral disease subtypes include limited cutaneous (features on the face, forearms 
and lower legs), or the less common diffuse cutaneous sclerosis (upper arms, thighs 
and trunks). Peripheral digit amputation is needed in ~15% 307. Vascular damage 
occurs at a micro and macro-vascular level, both peripherally and centrally. The cause 
of death is predominantly heart and lung disease related 308. Nonfatal outcomes are 
based on peripheral diseases, such as ulcer rates and amputations, or central CVD 
outcomes such as PAH development, and LV dysfunction. This combination of 
peripheral and central disease creates a complex disease phenotype, and the disease 
trajectory is highly individualised. However, better characterisation of the underlying 
disease processes might facilitate interventions to improve mortality rates, which have 
been unchanged over the past few decades 308. We hypothesise that microvascular and 
macrovascular disease will be associated with left-sided cardiac function, while 
microvascular will be associated with peripheral disease, and right-sided function.  
11.4 Methods 
11.4.1 Study group.  
We recruited 88 patients from the Tasmanian scleroderma database. Written informed 
consent was provided, and the Human Research Ethics Committee (Tasmania) 
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Network approved the study (H14301). Studies were performed at two sites, Menzies 
Institute of Medical Research (Hobart) and Launceston General Hospital 
(Launceston). Patients were asked to refrain from caffeine and nicotine for at least 6 
hours before testing and had no heavy meals before testing (a light breakfast was 
allowed 4 hours before testing).  Patients were tested in a climate controlled room (~ 
24 ºC) after patients had been lying supine for >15 minutes. Patients with PAH were 
diagnosed with invasive RHC and had been stable on PAH therapy for at least 1 year 
(n=34). Patients treated with vasodilator therapy (mean duration 7.1±3.3 years) did not 
refrain from PH medication before the studies.  
We excluded patients with acute myocardial infarction within 3 months but did not 
selectively exclude patients with diabetes mellitus, CAD, hypercholesterolemia, 
hypertension or history of valve repair.  
11.4.2 Total skin scores.  
Rodnan’s skin scores were performed by a specialist rheumatology physician or nurse 
309. By skin involvement, diffuse cutaneous sclerosis was classified as skin 
involvement proximal to the elbows and skin. Limited cutaneous sclerosis included 
skin involvement distal to the elbow and knees.   
11.4.3 Brachial flow-mediated dilatation.   
Studies were performed according to published guidelines 103, using standard 
equipment (Philips iu22, Phillips Healthcare, Bothell, WA and Vivid I, General 
Electric Medical Systems, Milwaukee, WI). A single expert sonographer performed 
all studies.  A cuff was placed on the forearm; an ECG tracing was obtained with 3 
beat acquisitions used. Full methods detailed in chapter 2 methodology. 
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11.4.4 Finger plethysmography.  
Peripheral artery tonometry (PAT) measurements were obtained with 
plethysmography (Endopat 2000, Haifa, Israel). All jewellery was removed before 
testing. Testing followed recommend guidelines 104, and hyperemic measurements 
were performed simultaneously with brachial FMD measurements.  The index finger 
was used for the majority of testing (94%); if this finger was not available (due to digit 
amputation, or open wounds), the next finger with no open wounds was used-usually 
the ring finger (3.4%), with the 3rd and 5th digit for use for 1 patient each. Full methods 
detailed in chapter 2. 
11.4.5 Laser Doppler Flow-mediated dilatation:  
Laser Doppler probes (CP1, Moor Instruments, UK) were placed on the subcutaneous 
tissues on the dorsal side of the forearm. The skin was shaved and wiped with alcohol. 
Probes were fixed lightly with medical tape to the same arm as was used for brachial 
FMD and Endopat-2000. Measurement of data was performed according to the 
methodology of Roustit et al. 106. The full methodology is detailed in chapter 2.  
11.5 Echocardiography.  
Echocardiograms were obtained in the closest possible temporal proximity to the 
vascular studies and measurements were performed according to guidelines101  Left 
ventricular free wall strain (LV GLS; Velocity vector imaging, Tomtec GmbH, 
Unterschlessheim, Germany) was performed in 3 apical images; right ventricular (RV) 
strain was performed on the RV free wall. PASP was measured from the tricuspid jet 
regurgitation signal, plus RAP (determined from IVC distensibility). Peak velocities 
of the early (E) and late (A) diastolic filling were derived from spectral Doppler of 
transmitral inflow. Tissue Doppler imaging was used to determine the peak diastolic 
early velocity (e’) of the lateral and septal mitral annulus from the apical 4-chamber 
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view. Standard ranges of echocardiographic parameters 101 were used to identify 
studies as normal or abnormal. 
11.5.1 Statistical analysis.  
Sample size calculations were powered for the primary hypothesis that FMD and 
PAT ratio was higher in patients treated than untreated. Work will be the first 
observational trial to characterise the difference in endothelial function in SSc 
patients with and without pulmonary hypertension treatments, so the effect sizes are 
estimated from previous observations of a PAT ratio difference of 0.4 (between SSc 
controls and SSc-PAH patients) and a clinically meaningful 7% increase in FMD310. 
With an anticipated effect size of 0.68, a power of 0.8 and a type I error of 5% (two-
tailed) we will need a minimum of 35 patients per group to demonstrate a difference 
in endothelial function. This study is not powered to identify differences in 
endothelial function between types of PAH therapies but will be hypothesis 
generating.  
Data were analysed with standard statistical software (SPSS version 21, IBM, Chicago, 
IL). Baseline data are presented as mean or median and standard deviation or inter-
quartile ranges. Brachial FMD, resting LDF, peak LDF, PASP, E/e’ and LV mass/BSA 
were log-transformed to obtain normality. Mann-Whitney U-test was used to assess 
significance between groups (p-value set to <0.05). Logistic regression was used to 
assess associations, with bivariate regression used for dichotomous variables. 
11.6 Results 
Baseline characteristics. Of 88 patients (median age 63 years, IQR 55-68), 21 (26%) 
had diffuse SSC (Table 11.1). The median time since diagnosis of SSC was 11 years 
(IQR6-18), and the median Rodnan’s skin score was 6 (IQR 2-12). Although 25 
patients had previous or active skin ulceration (28%), only 4 patients had previous 
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digit amputation (5%). Dyslipidemia was the most prominent cardiovascular risk 
factor (20%), with small numbers with a history of CAD (10%), and diabetes (7%). 
PAH had previously been diagnosed in 34 (38%), although most of these patients 
(92%) showed normal PASP by echocardiography (25 mmHg). Most of these patients 
were treated with endothelin receptor antagonists (30%), or phosphodiesterase type 5 
inhibitors (8%). Groups showed standard medians for vascular and echocardiographic 
markers (Table 11.2). 
LV and RV dysfunction (Table 11.3) were present in a minority of patients - 28% 
displayed reduced RV radial contraction (RV FAC <35%), with 12% of patients 
showing reduced RV longitudinal function (RV free wall strain <16%).   
There were low levels of overt LV systolic dysfunction (2 patients displayed LV EF 
<50%), although 40% of patients displayed reduced global longitudinal strain (LV 
GLS <19.7%). Stroke volume of <60 ml was present in 75% of patients.  
A similar proportion of patients displayed markers of diastolic dysfunction; 48% 
showed increased LV filling pressures (E/e’>8), and 37% showed increased LA size 
(LAV indexed > 34 ml/m2). 
Table 11-1. Patient baseline demographics 
 
Group (N=88) 
Age (years) 63(55-68) 
Disease Duration (years) 11 (8.0) 
Sex (female) 76%(68) 
SSC limited (vs. Diffuse) 75%(67) 
SBP (mmHg) 128 (21) 
HR (bpm) 71 (13) 
Diagnosed PAH 35(38%) 
Medications  
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- Any ERA 27(30%) 
- Any PDE5 7(8%) 
Statin 19(78%) 






Coronary Disease 10%(9) 
Dyslipidaemia 20%(18) 
DBP (mmHg) 72 (14) 
BMI  26.4 (6.3) 
Skin Score 4.5 (7) 
Abbreviations. BMI, body mass index; BSA, body surface area; ERA, endothelin receptor antagonists; 
PDE5, phosphodiesterase type 5 inhibitor; DBP, diastolic blood pressure; SBP, systolic blood pressure; 
HR, heart rate; SSc, systemic sclerosis; TCP02, transcutaneous tissue oximetry 
 
Table 11-2. Vascular and echocardiographic function 
Vascular function (n=88) Median (IQR)    
 Baseline LDF (PU) 42.5(48.6)   
 Peak LDF (PU) 147.6(82.5)   
 Peak-Baseline LDF (PU) 91.4(68.9)   
 FMD (%) 2.9 (4.9)   
 Log Reactive Hyperaemia  0.51(0.75)   
Echocardiography (n=75) Median (IQR) Normal Abnormal 
 PASPe(mmHg) 25.2 (9.4) 65(91.5%) 6 (8.5%) 
 LV Mass/BSA (gm/m2) 111.9(43.1) 61(69%) 12 (14%) 
 SV (ml) 53 (21) 18 (25%) 53 (75%) 
 LVEF (%) 60(13) 71(97%) 2(3%) 
 LAV/BSA (ml/m2) 32.7(11.5) 46(52%) 27(30%) 
 e’ septal (cm/s)  6.0(4) 30(43%) 40 (57%) 
 E/e’ average  8.4(3.2) 38(55%) 31(45%) 
 LV GLS (%) 20.3(2.9) 44(49%) 29(40%) 
 RVEDA/BSA (cm2/m2) 9.1(2.1) 68(92%) 6 (8%) 
 RAV/BSA (ml/m2) 22.3(11.9) 49(66%) 25(34%) 
 TAPSE (cm) 2.1(0.53) 65(88%) 9(12%) 
 RVFAC (%) 39.2(11.9) 53(60%) 21(28%) 
 RV free wall strain (%) 23.1(4.9) 62(84%) 12(16%) 
PU, Perfusion units; LAV, left atrial volume; LDF, laser Doppler flow; LV, left ventricular; LVEF, left ventricular ejection 
fraction; LVGLS, left ventricular global longitudinal strain; PASPe, pulmonary artery systolic pressure via echocardiography; 
RV, right ventricular; RVEDA, right ventricular end-diastolic area; RVFAC, right ventricular fractional area change; TAPSE, 
tricuspid annular plane systolic excursion 
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11.6.1 Associations of vascular function.  
Vascular function measures did not have significant associations with SSC 
characteristics such as the presence of PAH, diffuse versus limited SSC and history of 
peripheral ulcers (Table 11.4), although PAT and disease duration did show weak 
associations (std β-0.24(-7.2;0.02), p=0.05). Traditional CVD risk factors did not show 
any significant associations with vascular function makers (Table 11.1, Appendix).  
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Table 11-3. Vascular function markers and SSC disease status 
 
History of ulcers Disease duration Rodnans skin score (log) Diffuse Vs. limited (bivariate) 
  Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value HR (95%CI) P value 
Brachial FMD (log) 1.5(0.47;5.0) 0.48 0.12(-2.2;6.4) 0.33 -0.08(-0.35;0.18) 0.54 0.79(0.24;2.6) 0.69 
PAT (log) 0.83(0.29;2.4) 0.72 -0.24(-7.2;0.02) 0.05 -0.23(-0.34;0.02) 0.09 1.2(0.41;3.7) 0.71 
Baseline LDF (log) 1.5(0.32;7.3) 0.59 0.13(-2.5;9.1) 0.26 0.11(-0.16;0.42) 0.38 0.53(0.10;2.9) 0.47 
Peak LDF (log) 1.9(0.13;28.1) 0.64 0.13(-4.4;15.30 0.27 -0.006(-0.53;0.51) 0.96 1.9(0.11;33.5) 0.65 
Peak-Baseline LDF 1.0(0.99;1.01) 0.995 0.01(-0.04;0.04) 0.92 -0.08(-0.003;0.001) 0.51 1.01(0.99;1.02) 0.41 
Linear regression for vascular and echocardiography 
 LV mass LV GLS E/e’ avg LAV/BSA 
 Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value 
Brachial FMD (log) -0.36(-28.7;-5.8) 0.004 -0.05(-2.0;1.4) 0.73 0.04(-1.6;2.3) 0.75 0.04(-0.46;0.61) 0.78 
PAT (log) -0.14(-15.5;4.5) 0.28 0.09(-0.88;1.8) 0.50 0.26(0.06;3.4) 0.04 -0.09(-6.0;3.0) 0.50 
Baseline LDF (log) 0.03(-15.2;19.9) 0.79 -0.03(-2.4;1.9) 0.83 -0.09(-3.6;1.8) 0.49 0.15(-3.0;12.4) 0.23 
Peak LDF -0.10(-42.4;18.4) 0.43 -0.06(-4.3;2.8) 0.66 -0.21(-8.4;0.63) 0.09 0.02(-12.1;14.6) 0.85 
Baseline-Peak LDF -0.17(-0.21;0.04) 0.18 -0.03(-0.02;0.01) 0.81 -0.25(-0.04;0.00003) 0.05 -0.14(-0.09;0.02) 0.26 
FMD; Flow-mediated dilatation; PAT, peripheral arterial tone;  LDF, laser Doppler flowmetry; LV, left ventricle; GLS, global longitudinal strain; LAV/BSA left atrial volume to body surface area. 
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Table 11-4. Vascular markers and RV function 
 
FAC RV free wall strain RVEDA/BSA RAV/BSA 
  Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value 
Brachial FMD (log) 0.08(-3.2;6.3) 0.51 -0.13(-3.6;1.2) 0.31 -0.27(-2.3;-0.08) 0.04 -0.22(-10.2;0.57) 0.08 
PAT (log) 0.25(0.06;7.3) 0.05 0.13(-1.006;3.1) 0.31 -0.09(-1.1;0.52) 0.47 -0.03(-5.1;4.2) 0.85 
Baseline LDF (log) -0.13(-9.5;2.9) 0.30 0.04(-2.9;4.1) 0.74 -0.03(-2.07;1.7) 0.82 -0.06(-9.5;5.9) 0.64 
Peak LDF (log) -0.14(-16.8;4.7) 0.26 0.03(-5.3;6.8) 0.80 -0.11(-4.7;1.7) 0.36 -0.15(-21.4;5.0) 0.22 
Peak-Baseline LDF -0.15(-0.07;0.02) 0.24 -0.04(-0.03;0.02) 0.77 -.10(-0.02;0.008) 0.41 -0.15(-0.09;0.02) 0.23 
Restricted to PAH treatment group only 
 FAC RV free wall strain RVEDA/BSA RAV/BSA 
 Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value Std β (95%CI) P value 
Brachial FMD (log) -0.09(-0.02;0.01) 0.63 -0.01(-4.1;3.9) 0.96 -0.41(-4.2;0.38) 0.02 -0.22(-17.3;4.3) 0.23 
PAT (log) -0.41(0.003;0.06) 0.03 0.40(0.18;5.6) 0.04 -0.29(-2.3;0.33) 0.14 -0.07(-9.6;6.7) 0.71 
Baseline LDF (log) 0.12(-6.4;12.0) 0.54 0.09(-3.6;5.8) 0.65 -0.23(-6.0;1.5) 0.22 -0.23(-21.4;5.0) 0.21 
Peak LDF (log) 0.17(-6.9;18.5) 0.36 0.21(-2.9;9.9) 0.27 -0.14(-7.1;3.4) 0.47 -0.18(-27.4;9.6) 0.34 
Peak-Baseline LDF 0.12(-0.04;0.08) 0.55 0.11(-0.02;0.04) 0.58 0.02(-0.02;0.03) 0.92 -0.06(-0.10;0.07) 0.76 
FMD; Flow-mediated dilatation; PAT, peripheral arterial tone; LDF, laser Doppler flowmetry; FAC, fractional area change; RVEDA/BSA, right ventricular end diastolic area/ body service area; RAV/BSA, 
right atrial volume/ body service area
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11.6.2 Vascular function and echocardiographic findings.  
Brachial FMD was associated with indexed LV mass (std β-0.36[-28.7;-5.8], p=0.004), 
but not with LVGLS, or diastolic markers (Table 10.3). LV filling pressures showed a 
weakly significant association with microvascular function measures (baseline-peak 
LDF std β-0.25[-0.04;0.00003], p=0.05; PAT std β 0.26[0.06;3.4], p=0.04). RV 
structure showed a mildly significant association with brachial FMD (RVEDA cm/m2 
std β -0.41[-4.2; 0.38], p=0.04). RV radial function as measured with RV FAC showed 
a moderate association with microvascular function (std β-0.25 [0.06;7.3], p=0.05),  
In order to correct for treatment with vasodilators, assessment of RV function 
parameters was restricted to those on active treatment for PAH. This showed a 
moderate, significant association with brachial FMD and PASP (r=0.52, p<0.001), 
RAV/BSA (r=0.40, p=0.02) and RVEDA/BSA (r-0.49, p=0.04). There were 
moderately significant associations with PAT and RV free wall strain (Table 4) 
(r=0.40, p=0.04) and FAC (r=0.41, p=0.03) (Figure 11.1). 
Figure 11-1. Associations with RV function parameters and microvascular function.  
 
PAT shows moderate significant correlation with RVFWS (r=0.40, p=0.04) and FAC 
(r=0.41, p=0.03) 




The results of this study with patients with SSC showed that LV mass and 
macrovascular dysfunction appeared related, whereas microvascular function showed 
only a minor association with diastolic dysfunction. Traditional CVD risk factors did 
not seem strongly associated with the vascular function. Digital microvascular 
function showed moderate associations with RV function in both FAC and RV free 
wall strain.  
11.7.1 Vascular function measures.  
The heterogeneity of systemic SSC creates a wide variation in the description of 
cohorts in the literature. Fibro-proliferative disease in the vasculature, combined with 
underlying risk factors 311, has led to the proposal of the term ‘accelerated 
atherosclerosis’ in SSC. Our groups had small rates of associated chronic disease, but 
groups did seem to have reduced vascular function as compared to normal ranges. We 
did not measure carotid IMT in our cohort (a popular surrogate for CVD risk), although 
there is no consensus about the value of this parameter 312.  
Our findings on the association of brachial FMD and LV mass has been shown in a 
population-based cohort 313. This association was also witnessed in this group of SSC 
patients with multiple risk factors, suggesting trials targeting LV structure might 
include brachial FMD as a surrogate marker of vascular function. Brachial flow-
mediated dilatation (FMD) 102 has been used as a measure of atherosclerotic risk and 
macrovascular disease in SSC in a large number of trials 314. Its previous use in SSc 
315 suggested value in differentiation between diffuse and limited entities 315, although 
this differentiation was not shown in our findings.  
LDF relies on the Doppler shift of the red blood cells in the microvasculature, with 
this expressed in perfusion units, although a variety of different methodologies have 
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been proposed 316,317. Its use is mainly limited to the research domain, with studies into 
the relation of outcome in CVD and SSC not yet performed. We showed weak, 
significant associations with diastolic function and markers. We feel more work should 
be performed in this area before results are extrapolated.  
A primary strength of PAT measures is the relative level of operator independence as 
compared to brachial FMD 104. The prediction of CV events is similar between 
EndoPAT and FMD 318, with prognostic information available in a variety of disease 
cohorts 318. Nonetheless, within the SSC population, we have found this measure to 
have some limitations. Due to the nature of the disease, there are difficulties 
performing measures on the same finger (active ulcers and amputations). If this 
measure is to be used for an SSC cohort, these reproducibility issues should be 
addressed. Interestingly, although brachial FMD and Endo-PAT 2000 measured 
endothelial function, clinical correlates did differ in population-based cohorts 319 and 
did not seem significantly related 320.  
11.7.2 Echocardiography in systemic sclerosis.  
Echocardiography has been adopted as a tool for both clinical and research outcomes 
in SSC. Cardiac involvement in SSC can manifest in a number of mechanisms. 
Fibrosis may present as myocardial damage, fibrosis of the conduction system or 
pericardial disease 217. Clinically, diastolic dysfunction is the most frequently observed 
manifestation of cardiac involvement 321 and present in 17% of patients, with 
significant mortality due to heart disease 322. There was a significant number of patients 
with reduced GLS within our cohort, but impaired systolic function rates were low. 
Diastolic dysfunction showed similar results, with large numbers showing markers of 
raised LV filling pressures. There has been limited work on the association of 
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peripheral and cardiac manifestations of SSC 323. Left-sided cardiac disease (LV GLS) 
has shown an association with brachial FMD in a small number of SSC patients 324.  
The clinical focus has been placed mainly on detection of pulmonary pressures with 
tricuspid regurgitation, but as shown in outcome in PAH trials, RV strain is a strong 
predictor of outcome 77. We are looking to track this cohort over time, to determine if 
RV strain in SSC has similar findings. RV dysfunction in SSC-PAH could occur 
primarily as a response to afterload increases 325, but work with the novel parameter 
isovolumetric acceleration, which is a load-independent marker of RV function, has 
shown this to be impaired in patients without PAH-induced SSC 87.  
11.7.3 Limitations.  
The SSc population in this study was a highly heterogeneous group, with patients 
displaying a wide range of skin and internal organ involvement. Patients also had a 
history of traditional cardiovascular disease risk factors, with a significant proportion 
having diabetes and small numbers with prior myocardial infarction. However, this 
population truly reflects the interplay between different comorbidities in SSc 326. An 
omission from this chapter is the echocardiographic measurement of flow. Brachial 
flow-mediated dilatation with the flow was measured, but evidence shows markers are 
not a robust substitute for cardiac flow327 thus have not been included in the paper. 
Conclusion.  
Vascular function and echocardiography both have an essential role in the 
characterisation of disease status. Micro and macrovascular function in SSC appears 
to have different traditional and echocardiographic associations. PAH and 
microvascular disease appear related to RV function measures, while macrovascular 
disease relates to LV structural heart disease.  




SSC patients with worse PAH have worse outcomes than their idiopathic PAH 
counterparts, even in the presence of less severe haemodynamic profiles 328. It is 
difficult though to decide how accurate early prediction markers are, and whether early 
treatment should be initiated in the presence of impaired vascular function. Vascular 
dysfunction can present as a number of comorbidities associated with SSC, and 
differentiating the cause of dysfunction is not possible.  
Sequential follow-up of patients, as opposed to detection at a single time point is also 
important. There is limited information on the variability of vascular function 
measures over follow-up. Issues with skin thickening and fluctuations in weather 
conditions can drastically change peripheral vascular status. Tests should be replicable 
and disease-specific. Although microvascular tests can be performed non-invasively, 
patient functional status is what physicians use to guide treatment.  
Previously in this thesis, we have attempted to identify early disease markers through 
speckle tracking of the myocardium. However, we have not shown a clear marker for 
early cardiac disease in this cohort. It is likely that early detection and screening for 
PH offers substantial benefits, novel techniques need to be assessed in large registry 
data to establish how tools can impact survival.   
  









History CAD History of HTN History of Type 2 
diabetes 
History Dyslipidaemia 
  Std β (95%CI) P 
value 
Std β (95%CI) P 
value 
Std β (95%CI) P 
value 





0.47(0.10;2.3) 0.36 0.95(0.32;2.8) 0.92  1.09(0.13;8.8) 0.94  0.46(0.13;1.6) 0.23 





2.1(0.20;22.4) 0.54 1.2(0.29;4.8) 0.83  0.44(0.03;6.9) 0.56  1.5(0.26;8.2) 0.67 
Peak LDF 0.44(0.009;23.1) 0.69 0.09(0.007;1.1) 0.06 0.01(0.001;1.3) 0.06  0.34(0.02;6.2) 0.34 
Baseline-
Peak LDF 
0.99(0.98;1.01) 0.42 0.99(0.98;0.998) 0.03  0.98(0.96;1.005) 0.12 1.0(0.99;1.01) 0.67 




This thesis aimed to determine the role of advanced imaging techniques in PAH 
follow-up.  From this thesis, I have been able to draw a number of conclusions about 
the use of speckle tracking in the assessment of the RV. Chapter 3 details the 
importance of baseline measures, specifically of the right ventricle using RV free wall 
strain. When correcting for changes over time, RVFWS was the only RV function 
measures which displayed superiority. Finding that changes over time do not predict 
outcome appears counterintuitive but provides practical advice for clinicians in the 
follow up of pulmonary hypertension. Limitations in techniques involved in this paper 
could have weakened the results. Our use of averaging changes over visits could lead 
to dilution of this effect. There is variability in technical factors of echocardiography 
such as imaging windows, and tracing of the myocardium. The optimal research 
protocol would use prospectively acquired data, with images capture on the same 
ultrasound machine. PAH is a rare disease with low incidence rates.  Therefore 
prospective recruitment of patients is time consuming and would require multiple sites. 
Disease registries are the most powerful tool available to detect predictors of outcome. 
Registries do not have access to the level of echocardiographic data which is available 
in our cohort.  Our paper also has strength in the use of a sole sonographer for 
echocardiographic measures decreasing inter-variability error.  Our use of the novel 
echocardiographic RVFWS has not been compared in great detail to traditional 
outcome markers. Comparison of traditional systolic markers is essential to understand 
the role which novel markers have in improving clinical follow up of PAH.  
CMR is the optimal scanning method, but its cost restricts wide spread use in clinical 
follow-up. Throughout follow up, patients treatment regimens were accelerated or 
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reduced in line with symptom statues. This was not accounted for over clinical follow-
up but has an impact on the magnitude of changes.  
Chapter 4 addresses the impact which RV afterload has on the measurement of RV 
systolic function. Animal studies and invasive pressure-volume loop work define how 
vital the afterload to systolic function relationship is. There is no ideal way to account 
for the relationship bedside. The study results show that RVFWS is robust in 
differentiating 10 and 15% changes in pressure over time. Measurement of invasive 
pressure at the time of echocardiographic study would be ideal, but difficult to achieve 
in practice. Work performed in this chapter is considered as a “proof of concept”, and 
highlights areas of interest in the clinical field which require more work. There are 
numerous concepts to considering when identifying the effect of afterload on RVFWS 
(pulsatile load, previous RV infarct or disease, pathophysiology flow through the 
ventricle), but concise measurement of these in a clinical cohort with non-invasive 
means would be complicated. A second validation cohort to test regression equation 
would increase the strength of this work.  
Clinical applicability of findings is an essential aspect of the thesis. The chapter on 
pulmonary embolism answers a crucial diagnostic dilemma encountered in clinical 
practice; the differentiation of RV failure cause. In this chapter, RV failure in cohorts 
was matched for pressure assessment. A secondary matching technique would be 
through the pulmonary vascular resistance which would take into account flow through 
the ventricle. Due to the acquisition of pulmonary embolism scans during a critical 
care period, scans did not have flow measured, physicians instead ask for a targeted 
study to assess the presence of embolism and comments on RV size and function.  
Unfortunately, this is a reality of using retrospective data from a clinical cohort. 
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Although the mean differences for the Bland-Altman analysis are small, there appears 
to be some bias present with higher values showing increased mean differences 
between reads. Clinical applicability is a strong focus of the work which I have 
performed. Work in the pulmonary embolism cohort shows work can be translated to 
the bedside during routine clinical practice.  
Two chapters in this thesis have presented work on the longitudinal follow up of the 
PAH cohort. In Australia, six monthly visits are mandated. Within our data, the timing 
of follow up was not six month for all patients. The reasons for this a multifaceted. 
Firstly, only two tests were required to be performed. Primarily, this was an 
echocardiogram or 6MWD. If patients had a RHC done, they are not required to have 
both non-invasive tests performed. Treating teams can apply for an exemption if one 
measure is not available (for example an injury means no 6MWD can be performed). 
There were also limitations with echocardiographic databases, or some studies  
performed off-site. These are limitations of the retrospective nature of this work, but 
we feel it does not limit the strength of our findings.  
Chapter 7 details differentiation of left versus right heart disease in the systemic 
sclerosis cohort. Again, the retrospective nature of the paper leads to issues in the 
collection of clinical data. An example of this is the lack of DLCO% available in this 
cohort. The DLCO is a robust outcome predictor. In this chapter, the focus was on the 
novel LV function markers of circumferential strain, which was not assessed in our 
other cohorts. Models showed a significant association between GCS and PASP but 
with a weak R squared value suggesting there may be limited applicability in an 
individual patient setting. The use of multivariable  
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The control cohort for this paper had high all-cause readmission or death occurred in 
38% of the matched patient which is high for a matched group. The control cohort had 
high readmission rates, associated with the high incidence of COPD. The high rates of 
readmission present also relate to patients being recruited Tasmanian 
echocardiography databases, thus had a select bias for having an echocardiographic 
study performed. In this sense, they are not a pure control cohort as they have a clinical 
indication for echocardiography. A more accurate control cohort would have been 
from a community subgroup. The SSC cohort constituted of those with treated 
pulmonary arterial hypertension hence TR Vmax levels would be lower than in a 
treatment naïve cohort. The levels of PAH in the SSC group also add bias, as patients 
have already been diagnosed. A subgroup analysis was performed on those without 
PAH treatment, and results still hold true. A limitation of this paper is the omission of 
RVFWS thus it could not be included analysis with the LV GCS. As RVFWS is a 
marker of early cardiac disease, this would have been a more appropriate comparison 
as opposed to RVS’ and TAPSE.  
The distinction between pre versus postcapillary pulmonary hypertension is addressed 
in chapter 8. The cohort consisted of a large percentage of diagnosed PAH. In the 
normal screening population, rates of increased TR V max would be significantly 
lower in a population-based cohort. Cause of pulmonary hypertension has a drastic 
impact on the follow up required for the presenting patient. If diastolic dysfunction 
cannot be measured and accurately assessed, the need for invasive measures of patient 
haemodynamics is required. Work in this chapter shows further work needs to be done 
in this area to improve the sensitivity and specificity of LV filling pressure assessment 
with echocardiography.  
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The utility of RA function for clinical decision making has not been previously 
assessed. Although normal ranges have are quoted, research translation into clinical 
practice has not occurred. Our work has attempted to bridge this gap and determine 
the use RA strain in improving the sensitivity of echocardiographic estimation of RAP. 
Other work has been performed using secondary markers to improve the sensitivity of 
echocardiography. Secondary markers include tricuspid E/e, hepatic vein and superior 
vena cava flow. These markers were not routinely collected in our cohort, and we were 
not able to include these into the sensitivity and specificity analysis. The study did not 
show any significant increase in sensitivity with RA strain. Reasons for this could be 
differentiated into two main categories, physiological reasons or errors with the 
calculation of right atrial strain. Our cohort is not equipped to fully delve into the 
differentiation of these reasons. The gold standard would involve sonomicrometry of 
the right atrium, with simultaneous measures of right atrial pressure. Errors seen in 
clinical practice relate to image quality (adequate visualisation of the right atrial 
border), heart rate and consistencies with region tracking.  
The fluid loading chapter presents a cohort of clinical interest in attempting to find 
early onset markers  of pulmonary hypertension. The majority of these patients had 
systemic sclerosis. As mentioned in previous chapters this cohort can present with 
pre or post capillary pulmonary hypertension. It is hard to differentiate the cause of 
the raised pressure hence this group have not been included in the WHO pulmonary 
hypertension guidelines as a PH subtype. To determine the natural history of patients 
who present with raise pressure with fluid, they would need to be tracked over time 
and monitored for invasive changes. A control group of age-matched patients 
without SSC undergoing fluid loading to show how changes compare against a 
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healthy cohort would have been an interesting addition to the thesis. Research work 
now shows exercise is the preferred method of stress for diagnosing early changes in 
the pulmonary vasculature.   
In the final chapter presented vascular function in systemic sclerosis.  
Dichotomization of normal versus abnormal was based on conservative values of 
decreased function. By using these ranges, it reflects the early stage of cardiac 
disease which is more applicable when assessing microvascular changes. Cardiac 
stroke volume was significantly reduced in a large percentage of patients. Invasive 
measures of cardiac output are the gold standard, once diagnosed with PAH, we did 
not have a significant number of sequential invasive studies performed to add values 
into our analysis. Instead, the echocardiographic calculation was used. Measures 
were calculated as LVEDV-LVESV. As mentioned in the introduction statements, 
changes in morphology during PAH significantly alter LV geometry, which would 
have significantly hampered the success SV in our analysis. Stroke volume ranges 
are from a composites of large data sets. Our paper has a high percentage of women 
and a mean age of 63. Both of these factors lead to a reduction in stroke volume and 
overestimation of patients with impaired function.  
An interesting study design would be to follow microvascular changes over time and 
determine what outcome this has on cardiac parameters. As mentioned previously in 
the thesis, the SSC cohort is highly heterogeneous thus determining casualty based 
on changes would require intense monitoring of changes in a variety of organs.  
In conclusion, RV strain imaging is predictive of outcome in PAH- importantly, this 
is incremental and independent of PASP.  
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1) The time course/chronicity of the disease seem to be a better clue to the 
underlying cause of RV dysfunction than afterload increase 
2) RV free wall strain appears to be robust in the face of standard minor clinical 
fluctuations in PASP, more so then traditional 2D systolic function markers.  
3) RV free wall strain was also independent of pulmonary pressure for prediction 
of 6MW distance. 
The use of strain in PH is not limited to the assessment of RV dysfunction but can be 
used in RA pressure estimation, LV function in SSC and in distinguishing pre from 
post-capillary pulmonary hypertension. We have found that in a group with a high rate 
of PAH, current guidelines do not offer strong guidance on the differentiation of LV 
and pulmonary vascular aetiologies for PH. Although RA speckle tracking was 
associated with RAP, it did not appear to add in the correction of pressure assessment. 
Speckle tracking imaging also shows potential in systemic CTD, exposing unique 
fibrosis patterns in the LV.  
I have examined three methods for the detection of early disease, including strain 
combined with volume loading of the LV and vascular function markers.  The vascular 
function had associations with echocardiographic LV and RV parameters, but 
heterogeneity in this population hinder its use as a strong discriminative marker.  
Speckle tracking echocardiography does not appear to detect elevations of invasive 
PCWP.  
Future studies to progress the understanding of echocardiographic follow up in PAH 
should include the use of 3D imaging to accurately measure volume and chamber size.  
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Echocardiographic measures of flow are viable, but within the data presented did not 
show significance to outcome of 6MWD.  
Assessment of PAH patients symptom status needs to go beyond the 6MWD. Exercise 
echocardiography, ideally with a supine bike using light exercise protocols, is well 
poised to assess haemodynamics simultaneously with exercise. A crucial aspect is if 
RVFW strain remains an accurate measure during exercise. Failure to augment RV 
function during exercise is an important predictor of status, titration of medications 
based on findings would add value to the clinical utility of RVFWS. From a technical 
standpoint, RVFWS currently is using the left ventricular strain package. Work from 
industry to determine if optimisation of algorithms for the RV should be made. Two 
concepts to work on are the thickness of the tracking segment and also the impact 
which the curvatures of the RV have on the algorithm.  
In conclusion, new echocardiographic markers of RV systolic function offer a 
significant increment of prognostic information in PAH. The measurement of RV free 
wall strain should be integrated into clinical decision-making.  
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